Company Stories A

Stories that earlier appeared in Nelson's News

1366 Technologies

Solar technology developer 1366 Technologies (Lexington, MA; no SBIR) announced it has received a $150 million loan commitment from the U.S. Department of Energy for the construction of a commercial production facility in Massachusetts along with a second larger plant in the U.S. [Mass High Tech, Jun 17, 11]

to its Series B round, solar-power technology developer 1366 Technologies has added another $2.4 million, bringing it to $28.4 million, according to a regulatory filing [Kyle Alspach, Mass High Tech, Jan 14, 11]

1366 Technologies boosted its Series B financing round by $6 million, bringing it to a total of $26 million, according to a regulatory filing. .... developing a process for creating low-cost solar wafers [Mass High Tech, Dec 16, 10]

1366 Technologies, (Lexington, MA; no SBIR) focused on solar manufacturing, announced the close of a $20 million Series B financing that brings the total amount that the company has raised to $37.55 million [Boston Globe, Oct 19, 10]

Solar-power technology developer 1366 Technologies has landed $5.1 million of a planned $6.2 million round of venture capital. [Craig Douglas, Mass High Tech, Feb 4, 10]

several Massachusetts projects will receive a total of $33.2 million in federal funding for energy research. 1366 Technologies (Lexington) $4 million; , Agrivida (Medford; $300K SBIR) $4.6 million for efforts to cut the costs of cellulosic biofuels and chemicals; MIT $7 million on all-liquid metal grid-scale batteries; FastCAP Systems (Cambridge) $5.3 million to reduce the cost of hybrid and electric vehicles and of grid-scale storage; FloDesign Wind Turbine (Wilbraham) on new high efficiency shrouded wind turbines that could reduce noise and safety concerns $8.3 million ; Sun Catalytix (Cambridge) $4 million for a novel catalyst to enhance the efficiency of splitting water into hydrogen and oxygen. [Boston Globe, Oct 27, 09]

Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M; A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.

1st Detect (Austin, TX)

1st Detect (Austin, TX, no SBIR) which is developing a portable chemical detection device, said that it has received a $1.8 million grant from the Texas Emerging Technology Fund. .... formed by Astrotech (Austin, TX; no SBIR) satellite and space research company. It is commercializing miniature mass spectrometer technology first developed for the International Space Station. [Austin American-Statesman, Mar 4, 10]

21st Century Systems (Omaha, NE)

Whom You Know. [Sen Ben] Nelson's current $7.5 million earmark for software helps 21st Century Systems Inc. (21CSI) (Omaha, NE; $3M+ SBIR), which employs the senator's son, Patrick Nelson, as its marketing director. The company gets 80% of its funds from federal grants, mostly through earmarks. With nine offices scattered among states represented by appropriators in Congress, the company has in recent years spent $1.1M to lobby Congress and $160K in congressional campaign contributions. "As of April," the Omaha World-Herald reported, "only one piece of [the company's] software has been used -- to help guard a single Marine camp in Iraq -- and it was no longer in use." [Robert Novak, Washington Post, Jul 23]

23andMe

Anne Wojcicki is a Stanford-educated geneticist is the founder of 23andMe (no SBIR) which develops tests to identify gene markers for susceptibility to particular diseases. After spending 10 years managing investments in biotech companies, Wojcicki founded 23andMe in 2006. She is also married to another global innovator, Google’s Sergey Brin. [cnbc.com, Aug 5, 10] One of CNBC's fifteen leading innovators for the next decade. Mr Brin can surely spare all the needed seed capital for such a company.

24M Technologies (Wellesley, MA)

Battery startup 24M Technologies (Wellesley, MA) has received $10 million in Series A financing and will share in $6 million of federal funding to develop its technology, the company announced today. The company’s technology is spun out of research at MIT and lithium ion battery company A123 Systems. [Kyle Alspach, Mass High Tech, Aug 16, 10]

30 Second Software

Two Austin startups, 30 Second Software Inc. and Phurnace Software Inc., have received venture capital infusions. 30 Second Software, founded by Austin entrepreneur Dave Sikora, has raised $2.9 million from two corporate investors, to develop mobile commerce technology and services. Phurnace, which won the 2006 University of Texas MOOT Corp business-plan competition, received $1.3 million [from] a Texas-based venture fund affiliated with Draper Fisher Jurvetson. [Austin American-Statesman, Sep 3, 07]

Austin software industry veteran Dave Sikora has launched a startup focused on mobile commerce technology and services. The company, 30 Second Software Inc., offers a free e-commerce service for making purchases using BlackBerry devices. ... Sikora was formerly CEO of Austin-based Pervasive Software Inc. Prior to that he led three Austin software startups: Ventix Systems Inc., Question.com Inc. and Powered Inc. [Austin American-Statesman, Jan 29, 07]

3C Semiconductor (Portland, OR)

New CEO at 3C
3C Semiconductor (Portland, OR) announced Don Hagge, a veteran founder of tech companies, as first President and CEO. 3C got a BMDO Phase 2 SBIR recently to pursue heat resistant contacts to 3C silicon carbide devices. Having an business scarred CEO comforts the VCs who don't particularly like a scientist trying to do both science and business. Founder-scientist Jim Parsons and his investors from an Oregon VC firm apparently agreed a solution.

3D Technology Laboratories(Mountain View, CA)

True 3D Display
(May 5) Elizabeth Downing had a continuous flow of lookers at Photonics West 97 at her 3D pictures in a cube. She should get a larger flow after the John Drake's friendly article in MIT Technology Review May/Jun97. The BMDO SBIR-supported idea makes an image in 3D, not a 2D representation of a 3D image as on Hollywood's best silver screen or even Reveo's Vrex projector. Downing has now attracted VC to build a 6-inch cube display at her 3D Technology Laboratories (Mountain View, CA).

3F (Raleigh, NC)

Thirteen NC companies will split $1 M from a new state fund intended to help businesses create environmentally friendly technologies. In the Triangle area: Ecocurrent of Raleigh received $100,000 to convert hog manure into electric power; Kyma Technologies of Raleigh received $60,000 to work with N.C. State University on a more efficient, cheaper electric switch.; 3F LLC of Raleigh received $100,000 to develop a natural fiber-reinforced concrete formula.; Piedmont Biofuels of Pittsboro received $75,000 to work on a reactor that more efficiently creates biodiesel.; Nextreme Thermal Solutions of Durham received $57,319 to manufacture a generator that converts waste heat into electricity.; Rain Water Solutions of Raleigh received $18,000 to develop a new rain barrel manufacturing process. [Raleigh News & Observer, Jul 1]

3PrimiR (Westport, CT)

Spawned by Yale University, 3PrimiR (Westport, CT; no SBIR), which is focused on applying microRNA discoveries to cancer diagnostics, has raised $2 million in a planned $4 million equity financing, according to federal documents. [Mass High Tech, Sep 16, 09]

3VR (San Francisco, CA)

Video analytics firm 3VR Security of San Francisco raised $15 million in a third round of venture led by DAG Ventures. Also participating with follow-on investments were In-Q-Tel, the strategic venture firm funded by the Central Intelligence Agency, VantagePoint Venture Partners, and Kleiner Perkins Caulfield & Buyers. [San Jose Mercury News, Oct 11]

A123Systems (Watertown, MA)

Global competition. Over the past few years, domestic companies have entered a global competition to supply the advanced batteries that power electric vehicles. The start-ups came into the game with big backers and high hopes behind them: Venture capitalists saw a booming market ahead, and Washington saw a chance to spur a domestic green-manufacturing industry. So far, the results have been disappointing. Some high-profile battery makers have stumbled, burdened by high manufacturing costs, strong competition from Asian rivals and a slower-than-expected rollout of electric vehicles. Now the companies are responding by cutting costs, scaling back production and trying to tap other markets, such as large-scale storage for the electricity grid. ... Another prominent U.S. battery maker, A123 Systems Inc., has had to scale back production plans because one of its biggest customers, Fisker Automotive Holdings Inc., delayed battery purchases. A123 also missed out on some big contracts. The company lost a bid to provide batteries for General Motors Corp.'s Chevrolet Volt plug-in electric vehicle to LG Chem Ltd. of South Korea. Meanwhile, a joint venture between South Korea's Samsung SDI Co., part of Samsung Group, and Germany's Robert Bosch GmbH pushed A123 out of the bidding for a Chrysler Group LLC vehicle program. [Wall Street Journal, Dec 5, 11]

A123 Systems up 14% [Nov 30, 11]

A123 Systems up 11% [Nov 9, 11] has formed a licensing partnership with Japanese industrial equipment manufacturer IHI Corp., which will make IHI the sole provider of A123 battery systems in Japan’s transportation market. The deal will bring a $25 million payment from IHI to A123, the companies reported in a news release [Michelle Lang, Mass High Tech, Nov 9, 11]

A123 Systems down 10% [Nov 4, 11]

A123 Systems up 11% [Oct 27, 11]

A123 Systems up 27% [Oct 12, 11] will supply battery packs for the Chevrolet Spark EV mini-car, which will be sold in limited quantities in select US and global markets starting in 2013, General Motors Corp. said. [Chris Reidy, Boston Globe, Oct 12]

A123 Systems up 16% [Oct 4, 11]

A123 Systems down 12% [Oct 3, 11]

A123 up 15% [Sep 7, 11]

A123 Systems down 10% [Aug 12, 11]

A123 Systems up 45% [Aug 11, 11] after a new contract with General Motors to supply battery technology for GM as it expands production of electric vehicles. [CNBC, Aug 11]

A123 Systems up 12% [Aug 9, 11]

A123 Systems down 23% [Aug 8, 11]

A123 Systems down 12% [Aug 4, 11]

A123 Systems up 11% [Jun 13, 11]

A123 Systems down 10% [Jun 8, 11] when the company announced it had received an order for 24,000 electric vehicles from Wuxi Hao Jie Vehicle. [Motley Fool.com, Jun 8]

A123 Systems up 11% [Apr 18, 11]

A123 down 13% [Mar 29, 11]

A123 down 11% [Mar 1, 11]

A123 Systems has been chosen to produce battery packs for a pure-electric vehicle by a “major” North American automaker, which is expected to hit the market in 2013, CEO David Vieau said ... said its annual net loss widened by 78 percent in 2010 as the company laid a foundation to support rapid growth in coming years. [Kyle Alspach, , Mass High Tech, Mar 1, 11]

A123 Systems said its energy storage technology will be used by a power grid facility in Northern Chile. [Boston Globe, Feb 7, 11]

A123 Systems said that its battery packs will be used in electric cars made by one of China’s largest automakers. The lithium-ion batteries will be used by Shanghai Automotive Industry Corp. in a new 2012 electric passenger car for the Chinese market [Mass High Tech, Nov 10, 10]

A123 Systems down 14% [Nov 10, 10]

A123 Systems that was awarded $249 million in federal stimulus funds a year ago, will not supply batteries for Chrysler’s electric Fiat 500. In an earnings call earlier this week, A123 chief executive David Vieau said his company had withdrawn from a Chrysler production program after a rival vendor said it could provide batteries at below market cost. [Boston Globe, Aug 12, 10] Can't compete with below-cost vendor. When does predatory pricing law take effect?

A123 Systems down 18% [Aug 11, 10] said its net loss widened, to $34.2 million, in the second quarter as the company invested ahead of major projects in the automotive and electric grid sectors [Mass High Tech, Aug 11, 10]

A123 Systems up 14% [Jul 26, 10]

A123 Systems up 11% [May 26, 10]

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners: Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary; OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems secondary, twice; Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

A123 Systems up 11% [May 14, 10]

A123 Systems down 11% [May 6, 10]

Subsidy. Massachusetts is giving A123 Systems a $5 million forgivable loan in return for creating 250 jobs and expanding operations for making large batteries that connect to the electricity grid. [Boston Globe, Apr 22, 10] Companies with jobs exploit inter-state competition to pull in government subsidies.

A123 Systems is still producing on a small scale but appears to be positioned well in both the U.S. and Asia. Although it has great potential, A123 has to wait for the production of electric cars and hybrids to really rev up in the next few years. And while it is one of the few U.S. battery companies already in Asia and vying for its vast market, it must battle regional heavyweights with years of experience in making batteries. [Cassandra Sweet, Wall Street Journal, Mar 24, 10]

Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon. Among the fifty most innovative: A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences. [MIT Tech Review, M/A10]

A123 Systems will be making its lithium ion battery systems for electric vehicles for truck company Navistar International Corp. under a new deal that will provide the batteries to a joint venture between Illinois-based Navistar and Japanese company Modec Inc. [Mass High Tech, Mar 11, 10]

A123 Systems said it is expanding capacity at its facility in Michigan and also announced a battery supply agreement with Fisker Automotive, a new American automaker building premium green vehicles. [Boston Globe, Jan 14, 10]

Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlington MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

A123 Systems and General Motors Co. partner SAIC Motor Corp. said yesterday that they plan a joint venture in China to supply batteries for electric and hybrid vehicles. [AP, Dec 17, 09]

A123 Systems up 18% [Nov 24, 09]

Factories Cost. Not even three months after it netted $249 million in stimulus dollars to build a manufacturing facility in Michigan, A123Systems is finalizing a deal with the U.S. Department of Energy for another $250 million, this time in loans for that facility’s construction, according to a report from Reuters. [Mass High Tech, Oct 22, 09]

A123 Systems down 10% [Oct 5, 09]

A123 Systems up 14% [Oct 2, 09]

A123Systems went public at $13.50 to collect $378 million; stock trades as AONE. [Mass High Tech, Sep 24, 09] First day trading ended up 50%.

A123 Systems hopes to raise some $225 million through an IPO the week of Sept. 21. The event, the first venture-backed cleantech company to go public this year [Mass High Tech, Sep 18, 09]

A123 Systems appears to be on its way to filing an [IPO], given the company’s move today to set terms of the offering. [Mass High Tech, Sep 9, 09]

Money Talks. A post on Scott Kirsner's Innovation Economy blog on Boston.com notes that A123Systems spent far more [$500K] on lobbying than Boston-Power did [$30K]. [Boston Globe, Aug, 7, 09] Boston-Power apparently still could win future federal funding. It is in the running for a $100 million grant from the Department of Defense, to be announced later this year. [Innovation Economy blog]

A123Systems yesterday was awarded $249 million in federal stimulus funds, which the company said will go to build factories to manufacture high-tech lithium-ion batteries. A123 previously received $100 million in economic incentives from the Michigan Economic Development Corporation to build a factory in Livonia, Mich [Boston Globe, Aug 6, 09]

The Obama administration plans to announce Wednesday the winners of $1.2 billion in federal stimulus funds for makers of advanced automotive batteries, part of an effort to make sure that electric cars sold in the U.S. run on American-made power sources. One of the winners in a competition that drew applications from more than 100 companies is A123 Systems [Wall Street Journal, Aug 5, 09]

In the interstate competition for federal battery money, Michigan is giving as much as $400 million in state support for four companies: Johnson Controls-Saft Advanced Power Solutions LLC, LG Chem-Compact Power Inc., KD Advanced Battery Group LLC and A123 Systems Inc. ... DOE said 122 companies submitted applications in May seeking to share $2 billion in stimulus funds that were earmarked for advanced-battery efforts. The DOE said it will divide $1.2 billion of that sum among seven or eight manufacturing companies, part of an effort to develop quickly a U.S. capability to produce millions of batteries for electric cars [Rebecca Smith, Wall Street Journal, Jul 9, 09]

A123Systems, that just yesterday said it had raised $69 million in its latest financing round, announced today that it has secured more than $100 million in refundable tax credits from the state of Michigan. [Boston Globe, Apr 14]

Chrysler chose A123 Systems [for batteries] in part because the company was looking for a supplier based in the United States, says Lou Rhodes, the vice president of advanced vehicle engineering at Chrysler. A123 is based in Watertown, MA, and is building factories in Michigan. The company's battery cells met Chrysler's performance and safety specifications, and the company was developing battery modules that could be easily adapted to fit different vehicles. This was important, Rhodes says, because the automaker plans to start selling several different electric vehicles at around the same time. [Kevin Bullis, MIT Tech Review, Apr 10]

Chrysler says A123Systems will supply the lithium-ion batteries for the company's extended-range gas-electric cars and its all-electric cars. [Boston Globe, Apr 7, 09]

A123 Systems announced a $15 million investment from GE Energy Financial Services and GE Capital Equity to expand the company’s lithium ion battery manufacturing and smart grid capabilities in the U.S. The investment brings GE’s total of seven funding events in A123 to about $70 million [Mass High Tech, Apr 13, 09]

A123Systems said it is seeking $1.84 billion in direct federal loans ... from DOE's Advanced Technology Vehicles Manufacturing Incentive Program (love those multi-syllables) ... to support the construction of new world-class lithium ion battery manufacturing facilities in the United States, with the first construction location in southeast Michigan, the company said in a press release. [Chris Reidy, Boston Globe, Jan 7, 09]

General Electric invested an additional $30 million in A123Systems, a maker of lithium-ion batteries that aims to power plug-in cars from General Motors and Chrysler. The investment raises GE's stake to 9 percent, making it the start-up's biggest cash investor. [Washington Post, Oct 23, 08]

A123 Systems (Watertown, MA; $750K SBIR) filed for IPO.

A radically modified version of the lithium-ion batteries used in portable electronics, the technology could jump-start the long-sputtering electric-vehicle market, which today represents a tiny fraction of 1 percent of vehicle sales in the United States. A123 Systems's batteries in particular have attracted the interest of General Motors, which is testing them as a way to power the Volt, an electric car with a gasoline generator; the vehicle is expected to go into mass production as early as 2010. [MIT Tech Review, Apr 30, 08]

A123 Systems publicly launched its Hymotion product line, which can convert Toyota Prius hybrid vehicles into 100 mpg, electric-powered plug-in hybrids to consumers. [Mass High Tech, Apr 29]

Of the 15 game-changing startups likely to upend existing industries - and spawn new entrepreneurial opportunities, two used SBIR - Cree and A123 Systems. Business 2.0 also named One Laptop Per Child, Desktop Factory, Renewable Energy Group, Zink, Vanu, Bloom Energy, PatientstLikeMe, Virgin Charter, MFG.com, Zipcar, Expensr, Raydiance, and Blinkx.

A123 Systems (Watertown, MA) Inc. has cut a new deal with a Norwegian electric car manufacturer that puts its nanophosphate power plants at the heart of a five-seat "crossover" style vehicle. [Mass High Tech, Mar 6, 08]

Nanotech battery maker A123Systems Inc. has been granted a new patent for its "nanophosphate" lithium ion batteries [Mass High Tech, Mar 4, 08]

A123Systems, which makes nanotechnology-based lithium-ion batteries, has completed a $30 million round of funding from GE Energy Financial Services, bringing the total raised by the company to $132 million. [Mass High Tech, Oct 24]

A123Systems has cut a new deal to supply nanophosphate lithium ion battery technology to Cessna Aircraft. [Mass High Tech, Sep 19, 07]

A123Systems (Watertown, MA) reports that, starting in early 2008, BAE Systems plans to offer A123Systems' lithium ion battery technology as part of its HybriDrive propulsion system, available on the DaimlerChrysler Orion VII hybrid transit bus. [Mass High Tech, May 17]

A123Systems (Watertown, MA; one Phase 2 SBIR) claims a powerful, safe, long-lived battery. “The problem came down to usability,” said Nick Zelenski, G.M.’s chief vehicle engineer. “You had to plan your life around when you were going to charge the EV1.” ... When Professor Chiang and two others founded the company in 2002, it was devoted to a radical business proposition: it hoped to develop a technique where component materials would “self assemble” into a practical lithium battery. ... Nice idea, too bad. By late 2003, the company had abandoned self-assembly for another, less alchemical but still dramatic technology. In place of cobalt oxide, it used a commonplace substance, iron phosphate, but assembled it in a novel, nano-structure .... [It] has raised more than $102 M from a variety of investors and a deal with GM to develop a battery for a new GM hybrid model. [Jason Pontin, New York Times, Mar 11]

Aastrom Biosciences

Aastrom Biosciences up 15% [Jan 10, 11]

Aastrom Biosciences down 23% [Dec 10, 10]

Aastrom Biosciences up 12% [Dec 6, 10]

Aastrom Biosciences down 16% [Nov 15, 10]

Aastrom Biosciences up 13% [Nov 9, 10]

Aastrom Bioscience, a quite volatile stock up 12% [Oct 30,06]

Abaxis

every commercial revolution is born out of pain and controversy. Abaxis (no SBIR) has often been a clumsy midwife to its own baby. For 18 months the company missed out on 100 to 200 unit sales per quarter because it couldn't fill orders; one-third of its machines had defective components and were returned. Salesmen had good leads but were distracted dealing with unhappy customers. ... Piling promise on top of unfulfilled promise, Abaxis has spent $100 million to develop its exceptional machine. Lawsuits, firings, cash shortages and operational mishaps ... founded in 1989 by a trio of ambitious scientists ... a machine that could take a drop of blood and within a few minutes give readings on 80 tests used by physicians. ... Entrepreneur of the Year CEO Severson thinks the worst is behind. His aim is to double earnings per share over the next couple of years and move closer to a 10% slice of the market for blood chemistry. [Forbes, Oct 29]

Abiomed

ABIOMED up 22% [Nov 3, 11]

ABIOMED up 10% [Oct 27, 11]

Abiomed up 10% [Oct 4, 11]

ABIOMED down 21% [Aug 4, 11]

Abiomed up 12% [Apr 15, 11]

The FDA has alerted health care providers to an ongoing recall launched by Abiomed for a device that supplies power to a blood pump used on failing hearts. [Mass High Tech, Mar 16, 10]

The man who underwent the first commercial implantation of a self-contained heart - a device made by a Danvers company - has died. Abiomed Inc. and Robert Wood Johnson University Hospital in Brunswick, N.J., yesterday acknowledged the death of the 76-year-old patient, who was not identified to protect his privacy. [Boston Globe, Sep 3, 09]

Abiomed up 11% [Apr 9, 09]

Abiomed up 10% [Mar 25, 09]

Abiomed down 11% [Mar 5, 09]

Abiomed down 12% [Mar 2, 09]

Abiomed down 23% [Feb 5, 09] biggest NASDAQ percentage decliner

Abiomed up 10% [Nov 24, 08]

Abiomed up 19% [Oct 30, 08]

Abiomed down 10% [Oct 27, 08]

Abiomed announced $20 million in shipments for fiscal year 2009 second-quarter shipments -- a record for the billed products and services. The amount signifies a 75 percent increase over fiscal year 2008’s second-quarter [Mass High Tech, Oct 17, 08]

Medical device maker Abiomed completed a public stock offering that raised nearly $42 million. [Boston Globe, Aug 22, 08]

Abiomed is expanding into Ireland, ... signed a long-term operating lease for a manufacturing facility in Athlone, Ireland, and expects its Impella blood pump production line to be operational there in about 18 months. [Elizabeth Campbell, Boston Globe, Jul 31, 08]

Abiomed reports it has agreed to convert a $5 million loan it received from World Heart Corp. into World Heart common stock -- part of World Heart’s plan to recapitalize itself for a total purchase price of at least $30 million. [Mass High Tech, Jun 24]

Abiomed jumped 16%, ...said the FDA approved its Impella 2.5 Cardiac Assist Device .... .threaded into the body through an artery to improve blood flow in the sickest of patients. ... about 150,000 patients in the U.S. each year are candidates for the pump, which will cost $20,000. [Wall Street Journal, Jun 3, 08]

Abiomed (Danvers, MA; much SBIR) said that it has gotten the approval of European Union regulators to market a power-pack (right) for one of its heart pumps in EU countries and countries that recognize EU approval. [Chris Reidy, Boston Globe, Mar 28]

Jewish Hospital in Louisville is citing the expense of the AbioCor implants as a reason for not partnering with the device's maker, Abiomed. [Boston Globe, Jan 25, 08]

FDA approved system upgrades for Abiomed’s AbioCor implantable replacement heart. The device replaces severely damaged hearts in patients who are not eligible for a transplant or other treatments. [AP, Jan 23] Abiomed wins FDA OK for iPulse system. [Mass High Tech, Dec 19, 07]

Abiomed (Danvers MA) agreed to invest in World Heart Corp. through $5M convertible loans. [Mass High Tech, Dec 12, 07]

Abiomed up 12% [Aug 16,07]

OK for Canada which approved Abiomed's Impella devices for heart failure patients. [Jul 18, 07] Not yet OK for USA.

Abiomed up 11% [Mar 20, 07]

Abiomed plans to raise $60M+ in a public stock sale. [Mar 07]

Abiomed signed a $16M five-year distribution agreement with a Japanese distributor of cardiac assist devices to sell Abiomed's AB5000 and Impella products. [AP, Nov 13, 06]

complicated Leon relationship concerns Abiomed, . In 2005, Leon's incubator, Accelerated Technologies, sold a small company called Impella to Abiomed for $42.2 M in stock. Impella had invented a tiny pump that helps the heart do its job and can be implanted in minutes. Three versions of it are on sale in Europe, and the company is conducting clinical trials in the U.S. Leon received stock then worth nearly $1 million, plus the opportunity to receive a small share of up to $16.75 million in milestone payments, based in part on Abiomed's regulatory approvals and units sold. Six months later, Impella was featured in two live cases at TCT. At the same conference, Abiomed co-sponsored an evening event featuring doctors talking about heart pumps. Leon, who was the keynote speaker, noted briefly in the disclosure booklet and on a slide that preceded the presentation that he was a "major shareholder" of Impella-Abiomed. He retains the opportunity to collect milestone payments from the company. Abiomed CEO Michael Minogue says Leon's involvement isn't problematic. "He doesn't own that high a percentage of the company, and he's not involved in the trials," Minogue says. "What he has brought to the company is that he helped make the product more user-friendly." This year's TCT promises the event's first-ever panel on conflicts of interest.

Abiomed gap-opened down 10% on projection of lower than expected revenues. [Oct 13, 06] It has had at least 15 Phase 2 SBIRs over the two decades of SBIR and a volatile stock price (between 3 and 60, now 13) over the last decade. Its cardiovascular business is medical products to assist or replace the pumping function of the failing heart.

Ablexis (San Francisco, CA)

biotech firm Ablexis LLC (San Francisco, CA; no SBIR) announced a $12 million round of Series A funding [San Francisco Business Times, Jun 3, 10] ... to advance AlivaMab, its transgenic mouse method for discovering human therapeutic antibodies....Ablexis was formed in December and is based on technology from Aliva Biopharmaceuticals (Pasadena, CA; $200K SBIR), which now is a subsidiary of Ablexis. [Ron Leuty, [San Francisco Business Times, Jun 2, 10]

Absorbent Materials (Wooster, OH)

Absorbent Materials (Wooster, OH; no SBIR; 7 people) is looking for $2.4 million in funding. ... using organically modified chemicals called silanes, resulting in reactive, swelling glass materials. The materials are hydrophobic — repelled by water — but can absorb nearly any volatile organic compound, according to the company. [Mass High Tech, Aug 28, 09]

Acadia Pharmeceuticals

Acadia Pharmaceuticals focused on central nervous system disorders. ... says it is selling nearly 12.6 million shares expected to generate gross proceeds of $15 million. [signonsandiego, Jan 10, 11]

Acadia Pharma down 66% [Sep 1, 09] after the company said its drug candidate pimavanserin failed to meet key treatment goals in a late-stage study focusing on patients with Parkinson's disease psychosis. [AP, Sep 1]

Acadia Pharma up 16% [Aug 13, 09]

Acadia Pharna up 16% [Aug 10, 09]

Acadia Pharma up 15% [Aug 3, 09]

Acadia Pharma up 29% [Jul 27, 09]

Acadia Pharma up 31% [Jul 24, 09]

Cash-strapped Acadia Pharmaceuticals said yesterday that it will receive $30 million in upfront cash in a deal with a Canadian company to commercialize its experimental drug to treat Parkinson's disease psychosis. [Penni Crabtree, San Diego Union Tribune, May 5, 09]

Acadia Pharma up 130% [May 4, 09]

Acadia Pharma up 61% [Oct 13, 08]

Acadia Pharma up 16% [Sep 18, 08 ]

Acadia Pharma down 14% [Sep 17, 08]

Acadia Pharma up 14% [Sep 16, 08]

Acadia Pharmaceuticals were beaten down 43% after the company reported a complete failure of its Phase II-b trial of a schizophrenia drug. The study didn't meet any of its primary or secondary goals at two separate doses. [Wall Street Journal, Jun 17, 08]

Acadia Pharmaceuticals down 43% [Jun 16, 08]

ACADIA Pharmaceuticals down 12% [Feb 5, 08]

Acadia Pharmaceuticals up 11% [Jan 31, 08]

Acadia Pharmaceuticals down 11% on downgrade to Sell. [Nov 6, 07]

Acadia Pharmaceuticals up 12% on news of selling another tranche of shares. [Apr 3, 07]

The Trials Giveth, ... Acadia Pharmaceuticals doubled on good news from the trials of its schizophrenia drug. [Mar 19, 07]

Acambis

Acambis (the two Cambridges; one Phase 1 SBIR) reports beginning clinical trials of its West Nile virus vaccine. [Mass High Tech, Mar 21]

Acceleron Pharma (Cambridge, MA)

Acceleron Pharma said it has launched a Phase 1 clinical trial of its ACE-536 anemia treatment candidate, which will trigger a $7.5 million milestone payment from collaborator Celgene Corp. of New Jersey. [Lori Valigra, Mass High Tech, Sep 14, 11]

Acceleron Pharma and Celgene Corp. said today that they have entered into a joint development and commercialization agreement for a potential anemia treatment called ACE-536. As part of the agreement, New Jersey-based Celgene will make an upfront payment of $25 million to Acceleron, which is headquartered in Cambridge. Acceleron is eligible to receive development, regulatory, and commercial milestones of up to $217 million for the ACE-536 program. [Boston Globe, Aug 3, 11]

Acceleron Pharma told the state it cut 57 employees, or roughly 40 percent of its workforce, late last month. [Boston Globe, Nov 2, 10]

Acceleron Pharma (Cambridge, MA; no SBIR, founded 2004) has raised $8.4 million of a planned $11.5 million securities offering, according to [SEC filing] ... develops novel therapeutics that modulate the growth of cells and tissues, including muscle, bone, fat, red blood cells and the vasculature. ... raised $11 million in equity financing in December. The financing was preceded by a $31 million Series C round in 2007. [Mass High Tech, Jun 25, 10]

Acceleron Pharma (Cambridge, MA; no SBIR) has raised $8.4 million of a planned $11.5 million securities offering, according to [SEC filing] .... develops novel therapeutics that modulate the growth of cells and tissues, including muscle, bone, fat, red blood cells and the vasculature.... raised $11 million in equity financing in December. The financing was preceded by a $31 million Series C round in 2007 [Mass High Tech, Jun 23, 10]

Acceleron Pharma (Cambridge, MA; no SBIR) landed $10.9 million in equity financing, ... develops preclinical protein treatments to combat bone loss, grow blood vessels and block fat growth. ... co-founded in 2004 [Mass High Tech, Dec 16, 09]

Alkermes said it will invest $10 million to license the rights to a drug technology developed by Acceleron Pharma (Cambridge, MA; no SBIR), and also take an equity stake. [Boston Globe, Dec 4, 09]

Acceleron Pharma (Cambridge, MA; no SBIR) said that preliminary test results were encouraging for its drug candidate designed to help people with neuromuscular diseases such as muscular dystrophy and amyotrophic lateral sclerosis, or ALS. [Boston Globe, Sep 3, 09]

Acceleron Pharma (Cambridge, MA; no SBIR) said that it has signed a lease on a third facility in Cambridge, further expanding its laboratory and office space by an additional 19,700 square feet ... biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing biotherapeutics that modulate the growth of bone, muscle, red blood cells, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. ... "has grown by more than 50 percent in each year since the company was founded in 2004, and we expect this rate of growth to continue throughout 2009," company founder and chief executive John Knopf said in a statement. [Chris Reidy, Boston Globe, May 1, 09]

Accelrys (San Diego,CA)

Accelrys (San Diego,CA; no SBIR) life sciences software company, said that it has completed the purchase of Symyx Technologies in an all-stock deal valued at about $180 million. [signonsandiego.com, Jul 1, 10]

Accentia BioPharmaceuticals (Tampa, FL)

Biotechnology companies in the United States are raising less cash than they have in a decade, in part because of the global economic crisis. The reductions have led to bankruptcies and threaten development of drugs based on biomedical breakthroughs. ... Twenty-five percent of the 370 public U.S. biotechnology companies have less than six months of cash, according to data compiled by the Biotechnology Industry Organization, a trade group in Washington. .... Among others, Peptimmune (Cambridge, MA; one SBIR), a 6-year-old firm, said it is struggling to pay for clinical trials of its multiple sclerosis drug. ... cut its staff more than half, to 22 people; moved to smaller offices to conserve the $6.5 million it has on hand; and is delaying research on drugs for Alzheimer's disease and Parkinson's disease, chief executive Thomas Mathers said. .... On Nov. 10, MicroIslet (San Diego, CA; $1.8M SBIR) developer of diabetes treatments, and Accentia BioPharmaceuticals (Tampa, FL; no SBIR) sought bankruptcy protection to reorganize, each citing an inability to raise money. [David Olmos and Rob Waters, Bloomberg News, Dec 1, 08]

Access Pharmaceuticals

As major pharmaceuticals seek companies with a pipeline of promising drugs to augment their own depleting inventories, some pros bet that one target will be Access Pharmaceuticals ($200K SBIR), now at 2.85 a share. It hit a high of 17 in 2005. Its drug MuGard, approved by the FDA in 2007, treats oral mucositis, a debilitating side effect of chemotherapy and radiation treatment. It's now sold in Europe, with a global market potential of $5 billion, says Access. [Gene Marcial, Business Week, Oct 12, 09]

Access Scientific (San Diego, CA)

Access Scientific (San Diego, CA; no SBIR) which raised more than $2.6 million five months ago, has raised an additional $2 million, according to a regulatory filing yesterday. The company has begun the launch of its first new product, the “PICC Wand,” an all-in-one device intended to simplify the process of deploying a peripherally inserted central catheter line, a type of intravenous line that can remain in a patient for an extended period of time. [Bruce Bigelow, signonsandiego.com, Nov 24, 10]

Accumetrics (San Diego, CA)

Accumetrics (San Diego, CA; no SBIR) develops, manufactures, and markets the VerifyNow® System, a comprehensive suite of tests for the assessment of platelet response to antiplatelet therapies. ... signed an agreement with Portola Pharmaceuticals, (South San Francisco, CA; $500K SBIR) to develop and supply the VerifyNow System and VerifyNow Tests for use in clinical trials. [Accumetrics company press release] has raised $24 million from investors since 2009 .. employs 70 people [signonsandiego.com, Mar 2, 11]

Accurate Automation Inc (Chattanooga, TN)

Business Waverider
The LoFlyte Mach 5 Waverider of Accurate Automation Corp (Chattanooga, TN) got national business coverage in Business Week (Aug26). Now to see if AAC can make a business of it and not be swallowed by the aerospace giants if and when the idea proves itself. Founder Bob Pap may well have enough of his spirit committed to the dream to resist all but the sweetest offers.

Bird? UFO? Plane? Waverider?
The LoFlyte waverider aircraft of Accurate Automation Corp (Chattanooga, TN) made the front page (above the fold) of yesterday's Sunday Times (Aug 11) in London. The news angle is explaining UFO sightings (give people a reason to read your stuff) over Europe. But since AAC has just started serious building plans, the sightings will need a different explanation. Or maybe DOD has been doing waverider for years and using AAC as a convenient innocent distraction. On the other hand, UFO sightings do attract attention. (A neighbor once told the newspapers of one right over our block; I saw it too - a C-135 on final approach at night to a rarely used Army military airfield.) AACs' strengths, nurtured with lots of Navy SBIR money for neural nets, are the neural control system and the entrepreneurial spirit of founder and CEO Bob Pap

LoFLYTE Rollout 750,000 people in Oshkosh watched the rollout of the first neural network piloted , SBIR powered, jet, the pride of Accurate Automation Inc (Chattanooga, TN). LoFLYTE is a high-lift, low drag, Mach 5 autonomous aircraft that rides the hypersonic shock and thus earns its waverider nomenclature. The PR Newswire story said that the "program represents a coordinated approach to SBIR contracts attempted by NASA Langley Research Center and the US Air Force to realize a complex objective". Which raises a complex question for SBIR - "What is SBIR really for?". Why would agencies fund it exclusively with SBIR if it has such high value? Did Congress intend such concentration of funding? Are the agencies just thereby avoiding the normal appropriations oversight of large projects? Even though the company has some decent claim to be commercially minded, does such a project pass a competitive investment efficiency test of commercial impact per marginal dollar invested? Did, indeed, the agencies even consider the investment competitiveness as viewed from the market sector? Why would anyone rain on a small business victory parade? Now that SBIR has proven the principle, will the normal agency R&D assume responsibility for the development under competitive bidding practices? And if so, can the company compete well outside the SBIR shelter since the technology belongs to the government for government use? Will success in such a maneuver now embolden the agencies to abandon the infant, diversified, market-minded, investment approach to invest a lot more money in a lot fewer companies with the objective of "a coordinated approach to SBIR contracts"? Does DOD hereby announce that Fast Track will be Second Track?

Accuray

Accuray (Sunnyvale, CA; $1.2M SBIR) said it will buy TomoTherapy (Madison, WI; $1M SBIR) for $277 million ( a 30% premium) in a deal that unites two companies that make radiation therapy systems. [Marley Seaman, AP, Mar 7, 11] Tomo rose 25%; Accuray fell 10%

Accuray (one SBIR) shed 12.5% after the maker of robotic surgery systems projected sales for the first quarter and the fiscal 2010 below analysts' expectations. [Wall Street Journal, Aug 26, 09]

Since CyberKnife was first approved in 1999 for tumor treatment, it has been used in some 40,000 cases, and demand is growing. ... from Accuray (Sunnyvale CA; one SBIR) ... allows doctors to treat tumors using a noninvasive, outpatient procedure that helps patients avoid the side effects of surgery, chemotherapy or other forms of radiation. It uses software and robotics to home in on cancerous tissue and deliver large doses of radiation while sparing surrounding healthy tissue. [Time, Dec 17, 07]

Accuray (Sunnyvale CA; one SBIR) entered a partnership with Still River Systems which makes proton bean radiotherapy products. [Silicon Valley Business Journal, Oct 30]

Accuray (one SBIR a decade ago) was up 62% from its IPO price the day before. [Feb 9, 07]

Accuri Cytometers (Ann Arbor, MI)

Accuri Cytometers (Ann Arbor, MI; no SBIR) got $13 M Series C Financing ... Spun out of the University Of Michigan in 2002, ... developed revolutionary high performance cell analysis systems. .... "We are a state-supported start-up company," says CEO Jennifer Baird, "and we've been making decisions of how to manufacture our product. We've decided to do it in the state of Michigan." [MetroMode, Jul 9, 08]

AcelRx Pharmaceuticals (Redwood City, CA)

Pain management company AcelRx Pharmaceuticals (Redwood City, CA; no SBIR) has filed for an IPO that could raise up to $86 million. ... founded in 2005 and has not yet generated product revenue [Silicon Valley / San Jose Business Journal, Nov 15, 10]

Acetylon Pharmaceuticals (Cambridge, MA)

Acetylon Pharmaceuticals (Boston, MA; no SBIR) said today that it has completed a $27 million Series B preferred equity investment round of financing. ... has raised a total of $40 million, said Walter C. Ogier, a company co-founder as well as its president and chief executive. ... focused on developing small molecule drugs to treat cancer, auto-immune diseases, and other diseases. Much of the company’s work is based on technology initially developed at the Dana-Farber Cancer Institute and at Harvard University. The company’s lead drug candidate is a potential treatment for relapsed and relapsed-refractory multiple myeloma. [Chis Reidy, Boston Globe, Jum 29, 11]

Acetylon Pharmaceuticals (Boston, MA; no SBIR) has raised $12.4 million of a planned $30 million Series B financing round, according to a filing with the U.S. Securities and Exchange Commission. ....founded in 2008, is focused on commercializing Histone Deacetylase inhibitors and pharmaceutical technology coming out of Harvard University and Dana-Farber Cancer Institute. [Michelle Lang, Mass High Tech, Feb 23, 11]

Therapeutics startup Acetylon Pharmaceuticals (Boston, MA; no SBIR) has pulled in $2 million in funding, bringing the total investment in the company to $9.25 million. [Mass High Tech, Jan 8, 10] ... formed in late 2008 to commercialize promising pharmaceutical technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon is focused on development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic efficacy and tolerability versus current alternatives. [mattcenter.mediaroom.com]

A handful of local life sciences companies have sprung to life over the past several months, in spite of a venture capital landscape that has sometimes looked windswept and barren. ... Companies that have successfully launched in this environment have powerful allies and a frugal mindset. Several are going after a platform that could target several diseases. Analysts say this approach gives the company several shots at profitability, making them more attractive to investors. ... Last week, Acetylon Pharmaceuticals (Cambridge, MA; no SBIR) announced its official launch with $7.25 million from private investors ... One company that did raise money from a traditional venture firm is Targ-Anox (Boston, MA; no SBIR). The company coalesced around technology discovered by Brigham and Women’s Hospital chief of medicine Joseph Loscalzo. [Mass High Tech, Aug 14, 09]

HDAC therapeutics startup Acetylon Pharmaceuticals (Cambridge, MA; no SBIR) has pulled in $7.25 million in a Series A funding round [Mass High Tech, Aug 7, 09]

Achaogen (South San Francisco, CA)

Achaogen (South San Francisco, CA; no SBIR) won a federal government contract worth up to $64.5 million to develop an antibiotic to treat bubonic plague and other biologic threats. Four months after Achaogen raised a $56 million venture round, the Biomedical Advanced Research and Development Authority within the Department of Health and Human Services committed $27 million during the base two years of the contract. Options would bring the total to $64.5 million. [Ron Leuty, San Francisco Business Times, Aug 30, 10]

Achillion Pharmaceuticals

Achillion Pharma up 10% [Dec 9, 11]

Achillion Pharma up 18% [Oct 14, 11]

Achillion Pharma up 12% [Oct 10, 11]

Achillion Pharma down 15% [Oct 3, 11]

Achillion Pharma up 10% [Aug 15, 11]

Achillion Pharma down 13% [Aug 8, 11]

Achillion Pharma up 11% [Jul 21, 11]

Achillion Pharma up 14% [Jul 7, 11]

Achillion Pharma up 21% [Jun 22, 11]

Achillion Pharma up 11% [May 26, 11]

Achillion Pharma up 22% [May 6, 11]

Antiviral drug developer Achillion Pharmaceuticals said that it plans to raise $50 million by selling stock to four venture capital firms. [Mass High Tech, Aug 20, 10]

Achillion Pharmaceuticals up 14% [Mar 12, 10] focused on infectious disease, said preliminary data on its early-stage clinical trial of a treatment for Hepatitis-C showed "meaningful reductions" in patients' viral load and demonstrated it could be effective at a lower dosing level and in once-a-day doses. [Wall Street Journal, May 13]

Achillion Pharmaceuticals said it entered a partnership to develop and sell its hepatitis B and HIV drug candidate elvucitabine in China and other territories. [AP, Feb 2, 10]

Achillion Pharma down 12% [Jan 22, 10]

Achillion Pharma down 10% [Jan 11, 10]

Achillion Pharma up 10% [Dec 17, 09]

Achillion Pharma up 48% [Dec 16, 09] after the company said its hepatitis C drug candidate showed positive "proof-of-concept" results, while meeting safety and tolerability goals in an early-stage study. [AP, Dec 16]

The $27 million cash stash at Achillion Pharmaceuticals is a needed cushion for its development of treatments for HIV and hepatitis C. ... elvucitabine for HIV has finished phase II clinical trials. Achillion hopes to team up with a big drugmaker to develop the drug further, says Nash. Its hepatitis drug ACH-1625 is set for its first human clinical trials. [Gene Marcial, Business Week, Dec 7, 09]

Achillion Pharmaceuticals up 12% [Jul 31, 08]

Achillion Pharmaceuticals up 39% [Jul 23, 08]

Achillion Pharmaceuticals is the type of biotech that Big Pharma looks for to find new drugs. Achillion develops small-molecule drugs to fight infectious diseases like Hepatitis C and HIV. Gilead Sciences has partnered with Achillion and signed a worldwide exclusive license for a compound aimed at stopping the Hepatitis C virus from replicating. The drug has an estimated $1 billion market, says Alfred Mansour, CEO of Biotech Watch [Gene Marcial, Business Week, Jun 23, 08]

Achillion Pharmaceuticals up 13% [Jun 13, 08]

Achillion Pharmaceuticals up 19% [Apr 29,08]

Achillion Pharmaceuticals down 10% [Apr 1, 08]

Achillion Pharmaceuticals down 11% [Mar 5, 08]

Achillion Pharmaceuticals up 10% [Feb 25, 08]

Achillion Pharmaceuticals down 10% [Feb 20, 08]

Achillion Pharmaceuticals up another 23% [Feb 4, 08]

Achillion Pharmaceuticals up 41% [Feb 1, 08]

Achillion Pharmaceuticals down 10% [Jan 30, 08]

Achillion Pharmaceuticals up 12% [Jan 14, 08]

Achillion Pharmaceuticals down 16% [Jan 2, 08]

Achillion Pharmaceuticals up 16%. [Dec 31, 07]

Achillion Pharmaceuticals up 10% [Nov 20, 07]

Achillion Pharmaceuticals down 12% [Nov 2, 07]

Lost a big bet. Achillion Pharmaceuticals shares dropped in half [Feb 9, 07] as it and its partner Gilead Sciences gave up on their hepatitis C drug when it showed abnormal liver problems.

Achillion Pharmaceuticals was up 22% for its first week of public trading. One Phase 2 SBIR.

Aciex Therapeutics (Westborough, MA)

Aciex Therapeutics (Westborough, MA; no SBIR) developer of eye-focused treatments, has raised $8 million in an equity offering ... gained a worldwide licensing deal for an Aciex over-the-counter eye care product and a manufacturing deal for another of Aciex’s ophthalmic products. .... seeking partners to co-develop, in-license and out-license treatments for dry eye, allergies, inflammation, glaucoma, infectious diseases and ocular pain [Michelle Lang, Mass High Tech, Aug 12, 11]

Acorda Therapeutics

Accorda Thera up 13% [Nov 4, 11]

Acorda Thera up 14% [May 20, 11]

Acorda Thera down 12% [May 5, 11]

Acorda Thera up 26% [Apr 14, 11] on a report that it may receive additional patent protection for its top- selling drug, an RBC Capital Markets analyst said. [Bloomberg, Apr 14]

Acorda Thera down 14% [Jan 21, 11]

Acorda Thera up 10% [Jan 22, 10]

Acorda Therapeutics up 47% after the company got a positive FDA panel vote Wednesday for fampridine-SR to improve walking in multiple-sclerosis patients. The FDA is set to decide on the drug's approval next week. [Wall Street Journal, Oct 16, 09]

Acorda Thera down 21% [Oct 9, 09]

Acorda Thera down 15% [Jul 1, 09] after the biotechnology company announced a licensing and collaboration agreement with Biogen Idec -- a deal analysts said will make Acorda a less attractive takeover target. [Wall Street Journal, Jul 2]

Acorda Therapeutics up 17% [May 6, 09] after the FDA assigned the company's multiple-sclerosis drug priority review and an October approval decision date. [Wall Street Journal, May 7]

Acorda Thera up 19% [Apr 23, 09]

Acorda Thera down 20%% [Mar 31, 09]

Acorda Thera up 11% [Mar 6, 09]

Acorda Thera up 19% [Feb 24, 09]

Acorda Thera up 13% [Dec 18, 08]

Acorda Thera down 15% [Dec 1, 08] On a stock bloodbath day

Acorda Thera up 12% [Oct 28, 08]

Acorda Thera down 10% [Oct 6, 08]

Acorda Therapeutics (Hawthorne, NY; $1.8M SBIR) rose 31% [Jun 2, 08] ... company said a second late-stage trial showed that its multiple-sclerosis drug improved mobility in some patients with the debilitating disease. Acorda plans to file for licensing to market the drug, being developed with Elan, in the first quarter [WSJ]

Acorda Therapeutics up 15% [Feb 13, 08]

Acorda Therapeutics down 11% [Feb 6, 08] on announcing higher R&D spending.

Acorda Therapeutics (Hawthorne, NY; $1.6M SBIR) up 25% [Jan 28, 08] after it said its multiple sclerosis drug Fampridine-SR does not raise the risk of heart-related side effects anymore than a placebo in a so-called QT cardiac safety study required by the FDA [Forbes.com]

Acorda Therapeutics up 12%[Jan 10, 08]

Acorda Therapeutics up 10% on no news. [Nov 20, 06]

Acorn Cardiovascular

Start-up Acorn Cardiovascular (no SBIR) went out of business late last year after spending $50 million on the main trial for its heart device and then conducted two more studies the FDA requested, former president Steve Anderson says. The FDA kept changing the terms of a third extra trial it sought, he says. The FDA says Acorn repeatedly ignored its advice and failed to address the problems it raised. "We can't be responsible for bad decisions by a company," a spokeswoman says. [Jonathan Rockoff, Wall Street Journal, Feb 18, 11]

AcroMetrix (Benicia, CA)

Life Technologies said it acquired the Bay Area company AcroMetrix (Benicia, CA; one SBIR) for an undisclosed amount. AcroMetrix makes diagnostic quality control products for laboratories, blood screening centers and diagnostic manufacturers. [Thomas Kupper, San Diego Union Tribune, Jan 13, 10]

AcryMed (Beaverton, OR)

I-Flow Corp. of Lake Forest, Calif., agreed to pay $25M in cash to acquire AcryMed (Beaverton, OR; $1.5M SBIR) ... focused on wound dressings since its beginning in 1993. [The Oregonian, Jan 3, 08]

ActaCell (Austin, TX)

ActaCell (Austin, TX; no SBIR) . has been awarded a $6.2 million research grant from the U.S. Commerce Department's National Institute of Standards and Technology. ... plans to use the grant to develop technology to increase production of the company's nanocomposite material for lithium batteries, a news release said. ... founded in 2007, licenses lithium-ion battery technologies that were developed at the University of Texas, according to the company's website. [Austin American Statesman, Dec 28, 10]

ActaCell (Austin, TX; no SBIR) won a grant from a national battery consortium to evaluate its high-powered lithium-ion cells. The $179,015 grant is from the United States Advanced Battery Coalition, a collaboration of the three major U.S.-based automakers. .... to evaluate its cells against the coalition's goals for cycle and storage life in hybrid-electric vehicles. Two weeks ago, ActaCell won a $3 million grant from the federal National Institute of Standards and Technology. That money will be used to advance the development of ActaCell's technology. [Austin American Statesman, Dec 23, 10]

NIST TIP winners $22 million in funding for nine research projects targeting innovative manufacturing technologies in fields ranging from biopharmaceuticals and electronics to renewable energy sources and energy storage: Isogenis (Aurora, CO; $4.8M SBIR); ActaCell, (Austin, TX; no SBIR); Engineered BioPharmaceuticals (Manchester, CT; no SBIR); Arsenal Medical (Watertown, MA; no SBIR); Kent Displays (Kent, OH; $2.6M SBIR); Precision BioSciences (Research Triangle Park, NC; $340K SBIR); Ginkgo BioWorks (Boston, MA; one SBIR); Sinmat (Gainesville, FL; $4.4M SBIR); Polyera (Skokie, IL; no SBIR). http://www.nist.gov/tip/tip_121510.cfm

ActaCell (Austin, TX; no SBIR) which is developing advanced battery cells, has received a grant worth as much as $1 million from the Texas Emerging Technology Fund. The company, which was founded in 2007 to commercialize some of the University of Texas' lithium-ion battery research, will get an initial $250,000, with more money to follow as the company meets certain benchmarks. .. previously raised $5.8 million from investors including Google.org, [Lori Hawkins, Austin American Statesman, Nov 11, 09]

ActaCell (Austin, TX; no SBIR) is hardly alone. [CEO] Ott estimates that a dozen companies, many of them startups, are chasing the same goal. Most them are trying to modify the lithium-ion technology now used in many laptop computers and cell phones. One Austin company, Valence Technology Inc., already is making batteries for a variety of vehicles, including the Segway Personal Transporter. ... and $2 billion in federal funds for advanced battery development just passed by Congress — has sparked a rush of investment in startup battery companies and a surge of interest in promoting more manufacturing of advanced batteries in the U.S. [Kirk Ladendorf, Austin American-Statesman, Mar 9, 08]

ActaCell (Austin, TX; no SBIR), A small battery company spun out of the University of Texas and nurtured by the Austin Technology Incubator has raised $5.8 million in a first round of venture capital, including a grant from the philanthropic arm of Google. ... formed to commercialize some of UT's lithium-ion battery research [Austin American Statesman, Jul 23, 08]

ACT Biotech (San Francisco, CA)

ACT Biotech (San Francisco, CA; no SBIR), a tiny 7-person operation led by executives from Onyx Pharmaceuticals ($800K SBIR) and Proteolix (no SBIR), showed off the data for its lead drug against stomach cancer. When given in combination with standard chemotherapy, the ACT Biotech drug was able to shrink tumors by at least 30 percent or more in about two-thirds of all patients (25 of 39) in a mid-stage clinical trial. [Luke Timmerman, m.xconomy.com, Jun 6, 11]

ActivBiotics (Lexington, MA)

ActivBiotics (Lexington, MA; no SBIR) developer of antibiotics, reports plans to liquidate all of its assets following the failure of its lead drug in clinical trials. [Mass High Tech, Dec 19, 07]

ActivMedia Robotics (Peterborough NH)

Smart new wheels. The government giveth to technology companies, and the government maketh life really difficult for them. Last week, I had the chance to ride in a souped-up, artificially intelligent motorized wheelchair. It was developed by ActivMedia Robotics of Peterborough NH., under a $100K NIH grant, and was shown publicly for the first time ... The chair uses a digital map of the room it is in to navigate autonomously. Click a point on the map and it will take you there, avoiding obstacles and people along the way. Eventually, it could be driven by touching icons on the screen or by speaking voice commands, like ''Go to the dining room.'' ... If not for the NIH grant, the chair wouldn't exist, and it won't have much hope of making it to the market without a further $750K NIH infusion. After that, there's the FDA approval process [who] must certify that the chair won't endanger the lives of its users by, for example, autonomously pitching them down a flight of stairs.... How large is the market for an intelligent wheelchair? And will prospective users and their caretakers trust the chair's driving ability enough to buy it? No one knows. Dietsch estimates that the chair, if made in small quantities, would cost about $30,000. If manufactured in large volume, $20,000. That's about the same price at which Johnson & Johnson is expected to sell its Independence 3000 Ibot Transporter, the robotic wheelchair developed by Dean Kamen that climbs stairs, handles all kinds of rough terrain, and balances on two wheels. ... Both the Ibot and ActivMedia's Independence-Enhancing Wheelchair are entirely new kinds of products, and they both will require that new tests be developed before they can be deemed safe for use. But how safe is safe enough? A human wheelchair operator is responsible if she drives the chair into a wall, and that happens often enough: Dietsch says that wheelchair accidents send 35,000 people to the hospital each year. Should ActivMedia's artificially intelligent chair be required to perform more reliably than a human and prevent 100 percent of all possible wheelchair accidents? The FDA's guidelines say that the benefits of a new medical device must outweigh the risks. But the agency can be slow in figuring that out. Clinical trials for the Ibot began in mid-1999. Kamen initially thought it would be on the market by early 2001, but the revised projection is later this year. [ Red glare, black ink. [Scott Kirsner, Boston Globe, July 1,02]

Active Power

Power system manufacturer Active Power (Austin, TX; no SBIR) has priced a 13.2 million common stock offering at 75 cents per share that could raise an expected $9 million for the company. ... founded 1997, 150 employees [Austin Business Journal, Feb 22, 10]

Active Power (Austin, TX; no SBIR), which makes battery-free, flywheel-based backup power systems, agreed to a $3 million private placement of its shares. [Austin American-Statesman, Jun 2, 09]

Shares of Austin-based Active Power shot up 40.5 percent after the company reported a 58.7 percent increase in fourth-quarter revenue and a dramatically smaller loss. [Austin American-Statesman, Jan 31]

Active Power (Austin, TX) received two multimillion-dollar orders from Caterpillar. [Austin Business Journal, Nov 24, 08]

Active Power (Austin, TX; no SBIR) said sales grew 34% in 2007, and the company narrowed its full-year ...makes battery-free backup power systems for facilities that need uninterrupted power. [Austin American-Statesman, Feb 2]

Active Power (Austin, TX; no SBIR), inventor and manufacturer of the most energy-efficient critical power systems in the world, announced today it completed a private placement of approximately $14 M of common stock to institutional investors. .. flywheel-based UPS systems protect critical operations in data centers, healthcare facilities, manufacturing plants, broadcast stations and governmental agencies in more than 40 countries. [company news release, Aug 16]

Backup power systems company Active Power reported a 27% gain in revenue ... specializes in battery-free, flywheel-based power systems ...still it lost $4.9M [Austin American-Statesman, Oct 27, 06]

Acton Pharmaceuticals (Marlborough, MA)

Drug developer Acton Pharmaceuticals (Marlborough, MA; founded 2008) has closed a $500,000 tranche in a planned $10 million preferred-stock sale, according to a regulatory filing.... engaged in the acquisition, development and commercialization of potential therapies to treat respiratory illnesses, according to the company’s website. [Mass High Tech, Dec 16, 09]

Actuality Systems

Actuality Systems Founded in 1997, Actuality Systems develops the world's first Spatial 3D visualization systems, which have been proven to provide faster and more accurate outcomes in critical defense, medical, and security operations. Organizations evaluating Perspecta include the National Institutes of Health, Centacor (J&J), Kyoto University, Nissho International, Purdue University, the US Army, University of Toronto $1.7 million grant from ATP for work to commercialize low-cost scalable 3D holographic video.sale of its PerspectaTM 3D system to the NASA Ames Research Center in California. The unique 360-degree display will be used as part of the center's work in 3D imaging of scientific data in the fields of earth science and astronomy. .. Apache Corp. has invested $1.2 million in the company. Houston-based Apache's investment is part of $6.5 million raised to expand business development, and add engineering staff.

Acucela

things are looking better: the research-oriented startups seem poised to survive the downturn, and long-awaited clinical results could propel larger companies like Dendreon to stardom. ... despite the financial crisis, the Accelerator, a local incubator based in Seattle's Eastlake neighborhood, created three firms last year - Recodagen, GPC-Rx and Mirina (none had SBIR) ... "Seattle is really a town of development-stage biotechs," Miller said. ... Light Sciences Oncology (no SBIR), a firm that canceled its initial public offering last February, managed to raise $10 million from venture capitalists in July. Private investors provided Redmond-based Healionics (no SBIR) — which manufactures material for implants — with a $2.6 million boost in December. In a deal that could yield big results, Bothell-based Acucela (no SBIR), which is developing therapies to treat blindness, signed a partnership deal in September with Japanese firm Otsuka Pharmaceutical that could potentially bring it $258 million. [Angel Gonzalez, Seattle Times, Jan 25, 09]

Aculight (Bothell, WA)

Laser technology company Aculight (Bothell, WA; $22M SBIR, 90 employees) is being purchased by Lockheed Martin for an undisclosed sum. [Puget Sound Business Journal, Jul 28, 08] Thanks to Duane Zieg, MDA Tech Applications group; MDA furnished a small fragment of the SBIR haul.

Acumentrics (Westwood MA)

Acumentrics (Westwood, MA; one SBIR) has developed and introduced a rugged uninterruptible power supply system able to provide simultaneous DC and AC outputs ... for solid oxide fuel cells. [Boston Globe, Sep 11]

Acumentrics (Westwood, MA; one SBIR) got a 3 1/2-year, $15.6 M grant to continue the development of the company's tubular solid oxide fuel cell technology, courtesy of the DOE's Office of Energy Efficiency and Renewable Energy [Mass High Tech, Jun 5, 08]

Acumentrics (Westwood MA) got its first recorded SBIR Phase 2 from DOE to develop optimized manufacturing techniques and to build pre-commercial prototypes of a hybrid ceramic-metallic heat exchanger for solid oxide fuel cells (SOFCs) [press release Oct 11, 07]

Adamis Pharmaceuticals (DelMar, CA)

La Jolla Pharmaceutical (LaJolla, CA; no SBIR) announced a merger deal with another small biotechnology company. The deal between La Jolla Pharmaceutical and Adamis Pharmaceuticals (DelMar, CA; no SBIR) will give La Jolla shareholders as much as 30 percent ownership of the combined company, while Adamis gets $2.5 million to $3 million in cash expected to be left over from La Jolla’s operations. [Thomas Kupper, San Diego Union Tribune, Dec 8, 09]

Adaptive Computing (Provo, UT)

Intel Capital said it's investing more than $30 million in four technology startups... Adaptive Computing (Provo, UT) developer of software for data centers and cloud computing; Ciranova, (Santa Clara, CA) maker of chip design software; Joyent, (San Francisco, CA) provider of cloud-computing infrastructure; Nexant a (San Francisco, CA) developer of energy-efficiency software and clean-energy services. [FM Russell, San Jose Mercury News, Sep 15, 10] None had SBIR.

Adaptive TCR

Adaptive TCR (Seattle, WA; no SBIR), a startup that grew out of immune-system profiling work at the Fred Hutchinson Cancer Research Center, has raised $5.8 million in an equity investment round that could be worth as much as $7.5 million over time. [Luke Timmerman, m.xconomy.com, Jun 6, 11]

In Washington state’s biotech cluster, 83 local biotech companies were awarded grants worth a combined $34 million, Adaptive TCR, AVI Biopharma, Omeros, Proteotech, and Trubion Pharmaceuticals and 78 others. [Luke Timmerman, Seattle Times, Nov 3] Most were $245K, a little money for almost everyone. Too little money to make a big swing in effect. Just politics.

Addiction Therapeutix (Wauwatosa, WI)

Addiction Therapeutix (Wauwatosa, WI; no SBIR) start-up that is developing therapies for people who can't kick alcohol, painkiller and nicotine habits, has licensed several compounds from the University of Wisconsin-Milwaukee. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 20]

Addrenex Pharmaceuticals (Durham, NC)

Addrenex Pharmaceuticals (Durham, NC; no SBIR) has been acquired for $29 million by Sciele Pharma , an Atlanta pharmaceutical company that has already licensed three of Addrenex’s products and is one of its current investors. [Triangle Business Journal, Nov 16, 09]

Adenosine Therapeutics (Charlottesville VA)

Adenosine Therapeutics (Charlottesville VA; $7.5M SBIR) got $14M financings from Novartis Option Fund [company press release, Jun 27, 07]

Adeza Technologies (Durham, NC)

Adeza Biomedical shot up by half on news that it was being bought by Cytyc rose 2%. [Feb 12, 07]

Adherex Technologies (Durham, NC)

Adherex Technologies (Durham, NC) has a deal with a Canadian investment bank for $25M in stock to work on new cancer therapies. Adherex recently regained the rights to develop its most advanced cancer therapy when GlaxoSmithKline decided not to continue assisting in its development., [Raleigh News and Observer, Jan 23] No SBIRs yet.

AdiMab (Lebanon, NH)

Adimab (Lebanon, NH; no SBIR) has raised $4 million, reports in a regulatory filing. ... [founder] Gerngross, an engineering professor at Dartmouth College, previously founded the biotech company GlycoFi ($2.2m SBIR)., which he sold to Merck & Co. Inc. for over $400 million. [Mass High Tech, Dec 1, 10]

AdiMab (Lebanon, NH; no SBIR) a biotech focused on antibody discovery technology, has closed a Series B round of venture capital to fuel growth and hire more workers, company officials said. ... $6.2 million Series A round last summer. Gerngross said the value of his biotech has increased by 300 percent from the time of the Series A to the Series B, based on investor valuations [Mass High Tech, Mar 26]

ADispell (Rochester, NY)

Most Promising Technology ... at the 10th Annual SmartStart UNYTECH Venture Forum– ADispell (Rochester, NY; no SBIR) biotech that develops new treatments for Alzheimer’s patients [Business Review (Albany), May 19, 10]

Adnexus Therapeutics (Waltham,MA)

Bristol-Myers Squibb said yesterday that it would pay $430M for Adnexus Therapeutics (Waltham, MA; no SBIR), a privately held biotechnology company whose lead product is a cancer drug in the earliest stages of human trials. ... is owned by a handful of venture capital companies [Reuters, Sep 25]

Adolor

Adolor up 143% [Oct 24, 11] Cubist Pharmaceuticals agreed to buy all outstanding shares of Adolor Corp. with an up-front payment of $190 million. Adolor can qualify for additional payments if its drugs achieve regulatory and commercialization milestones; the total transaction is valued at up to $415 million,... Adolor markets a drug designed to accelerate recovery time for patients who have had bowel resection surgery, and it has another promising drug candidate in its pipeline. [Chris Reidy, Boston Globe, Ocr 25, 11]

Adolor said it is laying off 30 workers, or nearly 30 percent of its work force. [Philadelphia Business Journal, Jul 15, 10]

Adolor fell 8.7% after the company's Phase II trials of two possible treatments for osteoarthritis failed to meet the goals of the study. [Wall Street Journal, Jun 19, 10]

Adolor said it is eliminating 45 jobs, or 285 of its work force, and implementing other cost-saving moves to reduce its operating cash burn rate. [Philadelphia Business Journal, Jun 3, 09]

Adolor up 17% [Feb 3, 09]

Adolor up 10% [Oct 20, 08]

Adolor up 18% [Oct 16, 08]

Adolor down 12% [Sep 17, 08]

Adolor down 11% [Jul 7, 08]

Adelor down 10% [Mar 14, 08]

Adelor up 19% [Dec 5, 07] after a deal with Pfizer.

Adolor up 13% [AP, Nov 28, 07] after it and GlaxoSmithKline PLC said that a U.S. Food and Drug Administration committee will review Adolor's application for experimental drug Entereg, which treats stomach-related side effects after surgery.

Adolor up 12% [Aug 7, 07]

Adolor's stock free-fell 60% after the company announced it had suspended for safety reasons clinical testing of its lead new drug candidate as a potential treatment for opioid-induced bowel dysfunction. [bizjournals.com] [Apr 10, 07]

Adelor up 26% [Mar 12, 07] on news that Glaxo will expand the testing of Adelor's bowel drug.

ADS Biotechnology (Toledo, OH)

Rocket Ventures, a pre-seed, early-stage venture fund for technology-based [Ohio] companies, has awarded Ignite! grants to three Toledo firms - ADS Biotechnology, TechTol Imaging, and DoX Systems. These grants are given to help the companies develop and use technology to create new products or improve processes that have an impact on jobs and revenues in Northwest Ohio. [Toledo Free Press, Jun 13, 08] No SBIR.

Advanced BioHealing (Westport, CT)

Advanced BioHealing (Westport, CT; no SBIR), a developer of cell-based regenerative skin therapy, has filed terms of an initial public offering, for which it plans to raise about $200 million. ... makes and sells its Dermagraft product, an FDA-approved skin substitute developed to treat diabetic foot ulcers. ... employs about 150 people and maintains a manufacturing facility in La Jolla , CA [Michelle Lang, Mass High Tech, May 6, 11] founded in 2003 to develop and commercialize bioengineered tissue products. By 2005, two rounds of venture financing totaling $10.4 million had been raised [company website]

Advanced Bionics

Back to SBIR. Advanced Bionics ($500K SBIR) will become an independent company again, with businesses in cochlear implants and its development program in drug pumps as Boston Scientific unwinds its 2004 acquisition ... Boston Scientific will be left with Advanced Bionics' pain-management business, including a spinal-cord stimulator for chronic pain, and the Bion, which is in development to treat migraine headaches. [Keith Winstein, Wall Street Journal, Aug 10]

Advanced Cell Diagnostics Fremont, CA)

Advanced Cell Diagnostics (Fremont, CA;$1.2M SBIR) has been awarded a three-year, $3 million grant from the National Cancer Institute ... developing its tumor-detection system for circulating tumor cells [San Francisco Business Times, Oct 8, 10]

Advanced Cell Technology (Worcester, MA)

Advanced Cell Technology (Worcester, MA; $400K SBIR) has landed a $25 million financing and been cleared by the U.S. Food and Drug Administration for its Investigational New Drug application to use human embryonic stem cells (hESC) in treating Dry Age-Related Macular Degeneration. [Mass High Tech, Jan 3, 11]

Advanced Cell Technology said that its is closing its research facility and Charlestown and won’t be renewing its lease on its headquarters in Alameda. Calif., in an effort to cut operating expenses. [Mass High Tech, Sep 9]

Advanced Cell Technology ($200K SBIR), the biotechnology company that recently announced it was having financial troubles, may find relief from its latest accomplishment. The firm announced that its scientists have used human embryonic stem cells to generate billions of blood cells. Though the technique is still preliminary and has not been proven safe in animals, the hope is that it could eventually lead to a new supply of blood for patients. The research appears online (pre-published ahead of print) in the journal Blood. [AAAS, Aug 27, 08]

Advanced Cell Technology a developer of stem cell treatments, has granted an exclusive license, potentially worth up to $1.25 million, to Embryome Sciences Inc. [Mass High Tech, Aug 11, 08]

For the past decade, Advanced Cell Technology (Worcester, MA; $300K SBIR) has claimed one spectacular success after another. ... the first to clone an endangered species ... cloned the first human embryo ... Now, ACT could be on the verge of shutting down. ... the company warned that it doesn't have cash to continue operating after July 31 without raising additional money or drastically slashing operations. [Todd Wallack, Boston Globe, Jul 17, 08]

Advanced Cell Technology (one SBIR) reports that, along with colleagues from the University of California, San Francisco and embryo bank StemLifeLine, the company has developed five human embryonic stem cell lines without having to destroy any embryos. [Mass High Tech, Jan 11, 08]

A Los Angeles-based developer of stem cell treatments with research facilities in Worcester [MA] is on the hunt for corporate partners to develop recently acquired products and therapies. Advanced Cell Technology (one SBIR) took ownership of a stem cell treatment for heart failure through a $5M acquisition of Boston's Mytogen (no SBIR), completed in September. [Mass High Tech, Dec 7]

Advanced Ceramics Research (Tucson, AZ)

Eyes Are Watching. Advanced Ceramics Research got some notoriety from the investigation of Congressman Curt Weldon (a huge friend of Defense) for its payments to lobbyists: paid Grimes $60,000 as its registered lobbyist in 2003 and 2004. An affiliate of Advanced Ceramics paid her an additional $40,000 during that time, according to her lobbying registration documents. Weldon gave testimonials on behalf of Advanced Ceramics Research in two separate hearings of the House Armed Services subcommittee on tactical air and land forces, which he chairs. Weldon had invited the Arizona company's CEO to testify in 2004 and 2005 about what he characterized as its "very interesting work in developing state of the art composites that have increased performance while significantly reducing component cost." ... Some watchdog organizations [like Taxpayers for Common Sense] previously noted Weldon's support for companies that had little to do with his constituents in Delaware County and that paid fees to the firm operated by his daughter and Sexton, or to a close friend of Weldon's, lobbyist Cecilia Grimes. [Jeffery Smith and Carol Loennig, Washington Post, Oct 18] Advanced Ceramics, and its apparent manufacturing spinoff (same address), have had $20M of SBIR.

Business Week (June 23) reports that Advanced Ceramics Research (Tucson) makes plastic bones that can be tailored to the exact shape needed for compound fractures. It says that ONR "pioneered" such rapid prototyping and indeed ONR gave ACR two Phase 2 SBIRs for such osteoinductive material work. ACR has been blessed with many SBIRs (29 DOD Phase 1s since 1992 leading to five Phase 2s so far, and three NASA Phase 2s). FDA approval could come in 3-4 years.

Advanced Diamond Technologies (Romeoville, IL)

Wisconsin investors also participated in a $3.5 million funding round for an Illinois company, Advanced Diamond Technologies (Romeoville, IL; $700K SBIR) firm turns natural gas into diamond for a variety of industrial, electronic and medical applications. [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 30, 09]

Advanced Electron Beams (Wilmington, MA)

Advanced Electron Beams (Wilmington, MA; no SBIR) said it has closed a $14.2 million Series C financing, bringing its total amount raised to more than $50 million since October 2005. [Boston Globe, Aug 4, 09]

Advanced Fuel Research (East Hartford, CT)

A Party, A Party
(Apr 21) On-Line Technologies is having a grand opening party for its manufacturing line. The Governor will remark. On-Line is a spin-off of Advanced Fuel Research (East Hartford, CT) which has consumed tons of SBIR money (and recently ATP $2.8M) for its FT-IR technology. AFR's WebPage on SBIR is still under construction (it takes a long time to make a credible rationale for so much investment). Because AFR and On-Line are private companies, they don't have to tell the public nuttin'; only the federal agencies who have supplied all the money can demand an accounting and they don't seem so inclined. The agencies don't mind the ton of kerosene to light a fire in whose glow they (and the local politicians) would then bask. They believe you can do great things as long as you don't mind how much money it takes. And On-Line's Website pretty much adopts that strategy with the usual stuff about our wonderful products. Nevertheless, a manufacturing line merits a some celebration in SBIR companies. Is there any harm in pouring all that kerosene into AFR? Depends on your view. If you're a federal agency who has committed itself to a technology, more money is good, not bad, and the competent R&D companies feed well on that. If you are a startup or an existing commercializer with a new idea, you often get shut out as the money goes to the established SBIR companies. Never-had-SBIR companies like startup Actify (San Francisco) and commercializer TM Electronics (Worcester) get not even a Phase 1 to even show their new technologies. Consider the calculus: every Phase 2 to an established company for struggling technology cuts out ten Phase 1 awards to new ideas (whenever the agency caps its SBIR).

So, you have an interesting concept for an instrument that you think industry will want because it lets them monitor gas temperatures at a distance? You soon find that industry is not as enthusiastic as you are and so you try the government to get R&D money to develop something that industry will surely buy. You tell that story to government, who really doesn't know all that much about industry economics. Lo, and behold, government gives you a cool half-million to develop it. But industry still won't buy it. Maybe you, too, don't understand the industry economics. Why not try government again with the same story? Nah, they can't be that dumb! Oh, really? Consider the case of FT-IR technology at Advanced Fuel Research (East Hartford, CT).

Advanced Fuel Research Phase II SBIRs for FT-IR

NASA 85 In-Situ Characterization of the Size and Composition of Atmospheric Aerosols by FT-IR

Energy 86 Measurement and Observation of Combustion Performance and Coal Water Fuels

USAF 88 Materials High Temperature Measuring Instr Emissivity Spectral Emissometers

SDIO 90 In Situ Diagnostics for deposition of High T Superconducting Films

NSF 91 Temperature Modulation Method for In-Situ Measurement of Surface Treatment & Emissivity

NSF 92 Temperature Modulation Instrument for Glass Manufacturing

USAF 92 Novel Test Method for Fuel Thermal Stability

Army 92 High Temperature Oxygen Index Apparatus Stability

NSF 92 A New Method of Time-Temperature Modeling of Sedimentary Basins

NSF 92 Measurements and Modeling of the Behavior of Charring Polymers in Fires

USAF 93 Process Monitoring and Control During Plasma Processing of Semiconductors

BMDO 93 Miniaturized FT-IR Sensor for Infrared Measurement

NSF 93 In-Situ Measurement of Sub-Micron Particles during Synthesis from Gaseous Pre-Cursors

NASA 94 Blackbody reference for Infrared Imaging Systems

Energy 94 On-Chip IR Spectral Sensors by Superconducting Detector Arrays

Energy 94 An In-Situ Particle Sensor for Metal Forming Processes

USAF 95 Real-Time FT-IR Diagnostics and Control of Semiconductor Fabrication

NSF 95 Fourier Transform Infrared Diagnostics

NASA 95 Process Control for Plasma Spray Coating

DARPA 96 Rapid Thermal Annealing Process with Real-Time Monitoring for SiO2 Layer

Army 96 Fiber Optic Raman Probe for Real-Time Monitoring of Composite Viscosity and Intelligent Process Control of Autoclave Cure

NSF 96 On-Line Control of Particulate and Volatile Air Toxic Emissions from Thermal Treatment Systems

NSF 96 NonIntrusive Diagnostics for Sooting Combustion Systems

Energy 97 Sensors for Performance Monitoring of Advanced Gas Turbines

NSF 97 In-Line Process Monitoring & Control for Poly-Silicon Formation Inside Cluster Tools

If there's a problem, who's responsible and what's the solution? Whatever, don't blame AFR which merely proposed what it would like to do. The government apparently accepted the promise of a bright future over and over. Could these proposals simply have been the best of a bad lot? Who would believe that with all the government and small firm blather about "a highly competitive" program? 'Nuf Said? Now, if you want the Complete History, dig into what was funded before 1993 by all the agencies whose Websites don't report earlier SBIRs (wonder why?). But then you don't need a longer history to get the message that government's view of history circumnavigates the present.

Advanced Life Sciences

Advanced Life Sciences led all downers 19% [Jul 2, 07] after bad news on the trials for its pneumonia drug.

Advanced Life Sciences down 10%. [Jun 25, 07]

Investors who stuck with Advanced Life Sciences even after it delayed completion of Phase 3 clinical trials on cethromycin felt rewarded when the Food & Drug Administration granted it "Orphan Drug" designation. ... The U.S. Army Medical Research Institute of Infectious Diseases is collaborating with Advanced Life on cethromycin [Gene Marcial, Business Week, Apr 2, 07]

Advanced Liquid Logic (RTP, NC)

Advanced Liquid Logic (RTP, NC: three Phase 1 SBIRs) won a runner-up award in the Semiconductor field for Technology Innovation 2007 by the Wall Street Journal.

Advanced Magnetics

Advanced Magnetics says it will sell common stock in a public offering to raise $130-150M. [May 07]

Advanced Magnetics settled its suit with Cytogen by paying $4M cash and releasing 50,000 shares of Cytogen stock to regain rights to two experimental products for use in detecting cancer. [Mass High Tech, Feb 16]

Revenue has dwindled, down nearly 80 percent from 16 years ago, and losses have gotten steeper. But then there is this: Advanced Magnetics shares have soared 430 percent, from $11.08 to $59.54 so far this year, making it the most successful Massachusetts stock of 2006. [Steven Syre, Boston Globe, Dec 28, 06]

Advanced Magnetics will sell another piece of itself for $132M which will more than cover the $25M loss in 2006 by its 36 workers. [facts from Mass High Tech, Dec 8, 06].

It Works! The Phase III clinical trial of Advanced Magnetics's ferumoxytol for blood iron was so good that the stock jumped 30%. Or as a sciencecrat said demonstrated a statistically significant achievement of all the primary and secondary endpoints. [Nov 17, 06]

Advanced Photonix

Advanced Photonix up 10% [Oct 23, 07] after announcing that its subsidiary, Picometrix, has received a follow-on $750K AF Phase II SBIR for further non-destructive testing (NDT) application development involving the testing of radomes for defects such as delaminations and water intrusion utilizing the T-Ray 4000 terahertz system platform. [company press release] Picometrix started life in 1992 with an SDIO SBIR when Steve Williamson got fed up with his university's handling of patenting his work.

We own the night! Advanced Photonix jumped 26% when it said it had booked a $520K Army buy of its (LED) Arrays used for night vision displays in the Army that claims to own the night. API is most notably a vendor of avalanche photodiodes. It had one Phase 2 SBIR, from BMDO, in 1993 for single-chip photodetector arrays when it had 65 employees and a market cap around $50M. Now it has 50 employees and a market cap of only $16M.

Advanced Programming Concepts

Ultra Electronics Advanced Tactical Systems has been awarded a $14.3 million contract from the U.S. Navy as Advanced Programming Concepts (one SBIR in 1990), develops tactical command and control systems. [Christopher Calnan, Austin Business Journal, Dec 1, 10]

Advanced Targeting Systems (San Diego, CA)

National Cancer Institute awarded $3 million to Advanced Targeting Systems (San Diego, CA; $5.2M SBIR) ... develops and provides products for neuroscience researchers, and has developed technology for targeting specific types of cells [Bruce Bigelow, signonsandiego.com, Oct 13, 10]

AdvanDx (Woburn, MA)

AdvanDx (Woburn, MA; no SBIR) maker of medical diagnostics, has raised $8 million, part of a Series C funding round [Mass High Tech, Aug 18, 09]

Adventrx (San Diego, CA)

Federal regulators rejected a new formulation of a chemotherapy drug made by Adventrx Pharmaceuticals (San Diego, CA; no SBIR), saying they couldn’t be certain the experimental non-small cell lung cancer treatment is as safe and effective as the original therapy, the company said [Keith Darce, signonsandiego.com, Aug 10, 11]

Can't Afford Science. The staff cuts (at Adventrx (San Diego, CA; no SBIR)), including the chief scientific officer, vice president of medical affairs and vice president of research and development, are expected to reduce 2009 payroll expenses by $1.5 million. ... leave the company with enough cash to fund operations until mid-09. [San Diego Union Tribune, Oct 22, 08]

Advion BioSciences (Ithaca, NY)

In March, Advion BioServices (Ithaca, NY; no SBIR) announced plans to establish a $6.1 million laboratory at the Purdue Research Park at Ameriplex, likely adding 49 jobs immediately and up to 66 jobs by 2015. [Indianapolis Star, Apr 27, 11]

Advion BioSciences (Ithaca, NY; no SBIR, founded 1993) will open a new lab in an effort with Eli Lilly in a Purdue University park near Indianapolis International Airport.... will research how potential new medicines are absorbed and metabolized in experimental models, collecting data for the preparation of a molecule's entry into clinical testing. ... The Indiana Economic Development Corp., a state agency assisted Advion with its efforts. [Indianapolis Star, Mar 3, 11] A commenter says, Net gain of jobs in Indianapolis -0. Some of the Lilly employees laid off, will get these lower paying jobs. SBIR advocates who tout small biz as a job engine will conveniently ignore the better compensated job loss elsewhere.

Aegea Medical (Redwood City, CA)

Aegea Medical (Redwood City, CA; no SBIR) has raised $13.3 million private equity financing ... has developed a minimally invasive treatment for abnormal uterine bleeding. [San Francisco Business Times, Jun 30, 11]

Aerie Pharmaceuticals (Research Triangle Park, NC)

Aerie Pharmaceuticals (Research Triangle Park, NC; no SBIR) has netted $30 million in venture capital funds to continue developing treatments for glaucoma. ... co-founded in 2005 by Duke medical professor David Epstein and Duke chemistry professor Eric Toone, will use the money to test its lead drug on patients in this country and in Europe. ... has raised $51 million in several rounds of venture capital funding [Raleigh News & Observer, Mar 8, 11]

Aerius Photonics (Ventura, CA)

Flir said it has bought infrared and laser component maker Aerius Photonics (Ventura, CA; $14M SBIR) for $27 million. The seven-year-old company makes infrared detectors, lightweight laser rangefinders and infrared illuminators and pointers. [Brent Hunsberger, Oregonlive.com, Jul 22,11]

Aero Farms System (Ithaca, NY)

Aero Farms System (Ithaca, NY; no SBIR) a leader in aeroponic technology, received the prestigious Red Herring North America 100 Award, which recognizes North American startups for their technologies and innovation in their respective industries. [LARTA Vox, Jul 13, 10]

AeroVironment

AeroVironment (Monrovia, CA; $16M SBIR) produces 85 percent of the unmanned aerial systems used by U.S. forces in Iraq and Afghanistan, .... Measured by number of units deployed, America’s top maker of surveillance drones. The Army is also funding production of AeroVironment’s newest UAV, called Switchblade. Like the Raven-B and AeroVironment’s other systems, Switchblade, which is still in development, will fit in a soldier’s backpack. But rather than merely spy, this toy-size drone can kill: When its operator spots an enemy, Switchblade locks on, turns into a missile, and blows up the target. “I think Switchblade, like our other small UAVs, is going to plug a hole in [the military’s] arsenal,” says Tim Conver, chief executive of AeroVironment. founded in 1971 by Paul MacCready, a legend in aerospace engineering and meteorology, and a 1978 documentary about the project, Flight of the Gossamer Condor, snagged an Oscar. ... In the 1990s, AeroVironment was a major supplier of technology for General Motors’ electric vehicle program. During the recession of the early ’90s, when GM lost money and retrenched, MacCready and Conver had to offer their homes as collateral to preserve AeroVironment’s line of credit. .... in the years after 9/11. The Pentagon, embroiled in two wars, became much more interested in battlefield robotics. AeroVironment was ready. ... the company can produce 80 UAVs a day ... McCready died in 2007. [Brad Stone,Bloomberg Business Week, Dec 7, 11] Its SBIR started in 1991 and its first UAV SBIR in 1996 and USAF gave it $5M SBIR in 2007. Now it has annual revenue over $300M and a market cap over $600M, thanks to the fortunes of war for the makers of tools of war.

Another miniaturization era. big, well-known drones are already outnumbered by small, cheap and capable aircraft. One good example is the RQ-11B Raven, made by AeroVironment and widely used by America’s armed forces. ... Pilots might dismiss Ravens as radio-controlled toys, but they are popular with soldiers. More are being rushed to Afghanistan. ... The controlling hardware is a tablet computer with buttons on the side, rather like a portable games console, and most people can get the hang of it in a couple of days. Predators, by contrast, were originally flown by real, albeit ground-based, pilots [The Economist, Sep 3,11]

Aerovironment down 12% [Aug 8, 11]

Aerovironment up 21% [Jun 22, 11]

Aerovironment down 12% [Apr 1, 11] after a UAV crashed in test

Aerovironment up 14% [Mar 9, 11] the company's blowout earnings report [Motley Fool, Mar 9]

A pocket-size drone dubbed the Nano Hummingbird for the way it flaps its tiny robotic wings has been developed for [DARPA] as a mini-spy plane capable of maneuvering on the battlefield and in urban areas. The battery-powered drone was built by AeroVironment (Monrovia, CA) as part of a series of experiments in nanotechnology. The little flying machine is built to look like a bird for potential use in spy missions. The Pentagon has awarded about $4 million to AeroVironment since 2006 to develop the drone. [WJ Henningan, LA Times, Feb 18, 11] Although DARPA shows no SBIR for such work the AF shows a $4M SBIR in 2007 as an adoption of a SOCOM Phase 1. SOCOM hasn't got that scale of SBIR money.

Aerovironment up 15% [Dec 8, 10] after posting a tiny gain instead of a tiny loss. and getting a $4.9M contract from Norway.

Aerovironment down 12% [Feb 4, 10] after preliminary federal budget plans, Companies in FBR's coverage space that fared the worst because of the budget were industry leader Lockheed Martin and AeroVironment, the firm said [Reuters]

Aerovironment up 10% [Jan 14, 10]

Forbes's 2009 list of best 200 small companies includes Aerovironment, American Science and Engineering (paying a dividend and with nearly $600M market cap), Argon ST, Hittite Microwave, II-IV, Meridian Bioscience, Neogen, NVE, and Synaptics.

AeroVironment hoped to make its plane, called Helios, into a cheaper version of a telecom satellite. That hasn't panned out yet. So the company instead makes most of its money closer to the ground, selling planes with 4-foot wingspans that fly at 500 feet. Small enough to fit in a soldier's backpack and outfitted with cameras that feed real-time video in color or infrared to a handheld screen, these drones have quickly become cherished equipment to soldiers searching for terrorists in Iraq and Afghanistan. .... had been working on small unmanned planes for a decade, so it was able to offer the military a series of small planes that were quickly adopted by several services. [Jonathan Fahey, Forbes, Jul 13, 09]

coondoggie writes "Unmanned aircraft maker AeroVironment got an additional $5.4 million to further develop a diminutive aircraft that can fly into tight spaces undetected, perch and send live surveillance information to its handlers. Last Fall, AeroVironment, got $4.6 million initial funding from the Defense Advanced Research Projects Agency (DARPA) to develop the Stealthy, Persistent, Perch and Stare Air Vehicle System (SP2S), which is being built on the company's one-pound, 29-inch wingspan battery-powered Wasp unmanned system." [slashdot.org, Jun 4, 09]

Aerovironment up 18% [May 7, 09]

AeroVironment down 33% [Mar 10, 09] maker of unmanned aircraft for the military posted fiscal third-quarter net income that fell short of Wall Street's expectations. ... also cut its fiscal-year revenue projection. [Wall Street Journal, Mar 11]

AeroVironment's fiscal third-quarter net income dropped 24% on lower margins and higher research and development expense. Shares sank 27% to $22.25 in after-hours trading as the results fell far short of Wall Street's expectations, and the aircraft manufacturer cut its fiscal-year revenue guidance, citing economic conditions and the timing of the receipt and shipment of customer orders. [Wall Street Journal, Mar 9]

Aerovironment up 12% [Jan 15, 09]

Aerovironment up 11% [Nov 21, 08]

Aerovironment up 10% [Oct 28, 08]

Aerovironment up 13% [Oct 13, 08]

Aerovironment down 18% [Sep 10, 08] after its fiscal first-quarter net income beat analysts' expectations. [Wall Street Journal, Sep 11]

AeroVironment up 15% [Jun 25, 08] to an all-time high after it posted better-than-expected fiscal fourth-quarter earnings [also up 15%] and predicted next year's sales will rise more than Wall Street has anticipated [AP, Jun 25]

The top Street analyst for Aerospace & Defense says His top pick this year is unmanned-aircraft maker AeroVironment ($8M SBIR), which went public in January 2007. It's a "pure play" on the military's adoption of such systems and a "strong acquisition candidate" in the next few years, he says. The company's Raven aircraft are small enough to be launched by hand. [Wall Street Journal, May 19]

AeroVironment ($8M SBIR since 1991), a leader in unmanned aircraft systems and efficient electric energy systems, announced that the U.S. Marine Corps has ordered $19.3M in BATMAV (Battlefield Air Targeting Micro Air Vehicle) systems, each consisting of two Wasp III micro air vehicles plus ancillary pieces. [company press release, Nov 20, 07]

AeroVironment, a leader in unmanned aircraft systems and efficient electric energy systems, has installed its Architectural Wind system on the roof of the new Beloit, Wis., manufacturing facility of Kettle Foods, a Salem, Ore.-based producer of all-natural potato chips and other snack foods. The Beloit installation includes 18 wind turbines. [press release, Oct 25]

Spending on products suited for deployed troops in harm’s way remained the most dominant spending driver for the group. Companies such as FLIR and AeroVironment continued to see strong order flow, deliver strong results, and have exceptionally optimistic outlooks for 2008. [Jeff Saut, minyanville.com, Oct 22]

Unmanned-aircraft maker AeroVironment shot up 41% on its first day of trading after its IPO. Eight Phase 2 SBIRs since the early 1990s. The company had a funded backlog of government contracts totaling $64 million as of Oct. 28 and an unfunded backlog of about $492 million. [Wall Street Journal, Jan 24,07]

AesRX (Newton, MA)

AesRx (Newton, MA; no SBIR) has boosted its latest financing round by about $125,000 to $1.5 million, according to a federal document. [Mass High Tech, Jil 1, 11] one of Central Texas' least-known business success stories.Thermon (Austin, TX; no SBIR) — which creates, manufactures and services heat tracing technologies for some of the world's biggest oil and chemical companies ... for decades, Thermon has consistently churned out profits and has become one of the biggest players in the worldwide heat tracing market, ... a long way from Thermon's 1954 birth, when founder Richard Burdick created the company with a borrowed $40 ... "Thermon is a really interesting play or investment in a high-growth, niche industrial technology space," [Industry analyst Brian] Drab said. "I'm always looking for high-growth industrial technology companies [Barry Harrell, Austin American Statesman, Jul 4, 11]

The Massachusetts Life Sciences Center, a quasi-public agency, awarded $3.75 million in loans to five early-stage life sciences companies. AesRX (Newton, MA; no SBIR) biopharmaceutical company focused on the development of sickle cell disease and other orphan drugs; MoMelan Technologies (MA; no SBIR) medical device company; Myomo (Cambridge,MA; one SBIR) focused on helping people move again after a neuro-muscular impairment; ECI Biotech (Worcester, MA $1.6M SBIR) developer and manufacturer of affordable diagnostic sensors that can be incorporated into any consumer product or medical device; and Grove Instruments (Worcester, MA; $400K SBIR) developing a painless, noninvasive technology that accurately measures blood sugar. [Boston Globe, Mar 23, 11]

AETC (San Siego CA)

AETC (San Diego, CA), that provides remote sensing systems and related services for the DOD, is being bought by SAIC for an undisclosed sum. [San Diego Union Tribune, Nov 9]. AETC had about $2M in DOD SBIRs.

Aethlon Medical (San Siego CA)

Aethlon Medical, which has been developing therapeutic blood filtration devices for treating infectious disease and cancer, says the [FDA] has approved the company’s request to export its “Hemopurifier” device to India. [Bruce Bigelow, xconomy.com/sandiego, Mar 10, 11]

February under-the-radar deals. Catadon Systems (Carlsbad, CA; no SBIR) A maker of towers for elevating wind turbines Equity $689,500; Aethlon Medical (San Diego, CA; no SBIR) A developer of a medical device to treat infectious diseases Debt* $600,000 ; Ampla Pharmaceuticals (La Jolla, CA; no SBIR) A stealthy biotech company Equity $295,271; Cibus Global (San Diego, CA; no SBIR) A developer of environmentally friendly technology for producing crop traits Equity* $201,132 *includes some options and warrants [Erin Kutz, signonsandiego.com, Apr 6, 10]

Several life sciences startups in the San Diego area have received funding in recent weeks. Auspex Pharmaceuticals raised $3 million, Aethlon Medical raised $600,000, and Tocagen got $3 million. [Bruce Bigelow, signonsandiego.com, Mar 12, 10]

Affectiva (Waltham, MA)

Dr. Picard, is a pioneer in the field, especially in the use of computing to measure and communicate emotions. For years, she and a research scientist at the university, Rana el-Kaliouby, have applied facial-expression analysis software to help young people with autism better recognize the emotional signals from others that they have such a hard time understanding. The two women are the co-founders of Affectiva (Waltham, MA; no SBIR) that is beginning to market its facial-expression analysis software to manufacturers of consumer products, retailers, marketers and movie studios. Its mission is to mine consumers’ emotional responses to improve the designs and marketing campaigns of products. [Steve Lohr, New York Times, Jan 2]

Affinimark Technologies (New Haven, CT)

In all, 52 venture capital deals were struck in Connecticut in 2010, with more than $187 million invested, compared with 39 deals and $157.4 million invested in 2009. In the recent quarter, Helix Therapeutics (New Haven, CT; one SBIR) biopharmaceutical company, received $2.5 million; SeeClickFix (New Haven) firm that develops online and mobile platforms, received $1.3 million; and Affinimark Technologies (New Haven, CT; no SBIR) start-up that develops medical diagnostic products, received more than $1.2 million. A Guilford-based online advertising start-up, uKnow, received $453,000; Interactive Mobile @dvertising LLC in Norwalk received $275,000; Retail Optimization Inc., a New Haven firm that develops merchandising software, received $250,000; Twigtek Inc., a New Haven company that operates a website for selling or recycling used electronic equipment, also received $250,000. And Semantifi Inc., a Stamford software firm, received $50,000 from Connecticut Innovations Inc., the state's venture capital investing arm. [Janice Podsada, Hartford Courant, Jan 21, 11]

Affinimark Technologies (New Haven, CT; no SBIR) that develops point-of-care tests for cerebrospinal leaks has received a $1,359,394 investment by the quasi-public agency Connecticut Innovations and LaunchCapital. ... to complete the clinical and regulatory development of the test technology [James Connolly, Mass High Tech, Oct 13, 10]

Affinity BioReagents (Golden, CO)

Thermo Fisher Scientific reports it has bought Affinity BioReagents (Golden, CO; one SBIR) a provider of life sciences research materials. [Mass High Tech, Jul 17, 08]

Affomix (Branford, CT)

Affomix (Branford, CT; $200K SBIR) has entered into a development deal with Canada’s Kalgene Pharmaceuticals Inc. in which Kalgene will use Affomix’s technology to help identify possible diagnostics and therapies for breast cancer. [Mass High Tech, Dec 31, 09] $7 million Series A Financing in 2008

Affymax (Palo Alto, CA)

Affymax up 36% [Dec 8, 11] as dialysis treatment found favor with FDA

Affymax said it priced a public offering of 8.5 million shares [for] gross proceeds of $50 million.

Affymax up 12% [Mar 8, 11]

Affymax up 2% after the company said it received a $30 million milestone payment from a Japanese partner for an investigational drug that treats anemia. The stock had plunged 69% Monday on negative study results for its Hematide treatment of anemia. [Wall Street Journal, Jun 23, 10]

Affymax is looking to go head to head with biotech's biggest player in a multibillion-dollar anemia-treatment market that has proved to be troublesome in recent years. ... developing Hematide in partnership with Japan's Takeda Pharmaceutical Co. as a longer-lasting alternative to Amgen Inc.'s Epogen and Aranesp, which had combined U.S. sales of $3.8 billion last year. Although growth of those drugs has evaporated in recent years due to safety and regulatory issues, they had U.S. sales of $5.3 billion in 2006, and Affymax says an opportunity remains for a new option. [Thomas Gryta, Wall Street Journal, Mar 17]

Affymax said it received a $5 million development milestone payment from Takeda Pharmaceutical Co. ... said the payment is part of the companies’ exclusive global agreement to develop and commercialize Hematide, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. [Silicon Valley/ San Jose Business Journal, Mar 10, 10]

Affymax (Palo Alto CA) going public this week. One Phase 2 SBIR.

Affymetrix

Affymetrix up 10% [Oct 4, 11]

Affymetrix down 13% [Aug 8, 11]

Affymetrix down 18% [Jul 7, 11]

Affymetrix up 11% [Jun 2, 11]

Affymetrix up 10% [Mar 25, 11]

Affymetrix up 15% [Jan 12, 11]

Affymetrix down 10% [Aug 11, 10]

Affymetrix up 13% [Jul 28, 10]

Affymetrix down 27% [Jul 7, 10] said it now sees second-quarter revenue coming in at $71 million to $72 million, down from its previous forecast of $80 million to $82 million. [Val Kennedy, MarketWatch, Jul 7]

Affymetrix down 14% [Apr 22, 10]

Affymetrix up 29% [Feb 4, 10]posted a surprise quarterly profit and said it expects to be profitable in 2010 after almost two years. [Reuters]

Affymetrix up 10% [Jan 14, 10]

Affymetrix down 14% [Jan 13, 10] The technology that Affymetrix develops is quickly becoming obsolete, or so analysts believe. ... increased pricing pressures from competitors as its technology becomes quickly outdated by new genetic analysis technology such as Illumina’s sequencing technology. [Lisa LaMotta, Minyanville.com, Jan 13, 10]

Affymetrix up 10% [Jan 6, 10]

Affymetrix up 14% [Dec 9, 09]

Affymetrix down 10% [Oct 28, 09]

Affymetrix down 18% [Oct 22, 09] after it reported a wider-than-expected quarterly loss hurt by weak gross margins, and forecast fourth-quarter revenue below market estimates. [Reuters]

Affymetrix up 33% [Jul 23, 09] company's second-quarter earnings topped Wall Street's estimates. [Wall Street Journal, Jul 24]

Affymetrix up 17% [Jul 20, 09]

Affymetrix down 10% [May 13, 09]

Affymetrix up 11% [Apr 28, 09]

Affymetrix up 13% [Apr 24, 09]

Affymetrix down 17% [Apr 23, 09]

Affymetrix up 11% [Apr 16, 09]

Affymetrix up 14% [Mar 26, 09]

Affymetrix up 13% [Mar 23, 09]

Affymetrix down 12% [Feb 20, 09]

Affymetrix down 20% [Jan 29, 09]

Affymetrix up 20% [Jan 27, 09]

Affymetrix down 10% [Dec 1, 08] On a stock bloodbath day

Affymetrix agreed to buy Panomics (Fremont, CA; $2.3M SBIR) for $73 million in cash. -... Panomics makes products for genetic, protein and cellular analysis. [San Francisco Business Times, Nov 11, 08]

Affymetrix down 14% [Oct 23, 08]

Affymetrix up 11% [Oct 20, 08]

Against the surge, Affymetrix down 17%, [Oct 13, 08] projected lower-than-expected third-quarter sales amid increased competition for academic research and funding and softness in industrial spending. [Wall Street Journal, Oct 14]

The Wall Street Journal's Patent Scorecard in Biotechnology ranks Invitrogen and Maxygen #2 and 3 in Science Strength (13-week rolling average). Sequenom was #6; Affymetrix #11 of 28 listed. Only Sequenom had an impressive stock price record, up 170% over 52 weeks.

Affymetrix fell 27%a day after the company reported moving from a second-quarter profit to a loss and presented a discouraging forecast. [Sacramento Business Journal, Jul 25, 08]

Affymetrix dropped more than a third after the maker of tools to analyze genes cut its revenue forecast, dragging down the shares of equipment suppliers Illumina and Applied Biosystems Group. [San Jose Mercury News, Apr 15, 08]

Affymetrix will pay $75M cash for USB Corp. (Cleveland, OH; no SBIR), which calls itself a supplier of reliable biochemicals and molecular biology products. [Dec 08]

Affymetrix down 10% [Nov 13, 07] said it will offer $250 M of unsecured senior convertible notes, due 2038.

Santa Clara CA gene chip maker Affymetrix won a four-year, $10.2M million federal grant to delve deeper into the secrets of human heredity. The grant from the National Human Genome Research Institute was awarded to a team of Affymetrix scientists and will finance the identification of various functional regions found across the human genome. [San Jose Mercury News, Oct 9]

Affymetrix won a patent fight with Illumina over five patents held by Affymetrix and Illumina was ordered to pay Affymetrix $16.7M. [Mar 07]

Affymetrix soared 14% after predicting high fourth-quarter revenue. [Jan 8, 07]

aFraxis (San Diego, CA)

aFraxis, (San Diego, CA; no SBIR) which has completed pre-clinical testing of a promising compound for treating fragile X syndrome, the most common cause of inherited mental impairment, has raised $1.2 million in a venture round targeting $6 million, according to a recent regulatory finding [Bruce Bigelow, xconomy.com, May 22, 10]

AgeneBio (Indianapolis, IN)

AgeneBio (Indianapolis, IN; no SBIR, founded 2008) received a $240,000 grant from the Alzheimer's Drug Discovery Foundation to help develop a new class of compounds that have promise in treating a neurological condition that often progresses to Alzheimer's disease. ... has a therapy in midstage clinical trials for the condition known as amnestic mild cognitive impairment. [Indianapolis Star, Aug 27, 10]

Agennix (Houston, TX)

Agennix (Houston, TX; $2.5M SBIR) is banking on the idea that an ingredient in mother's milk can help treat lung cancer. ,,, could become the first federally approved cancer drug to come out of Houston. ... Lung cancer kills more Americans than breast, prostate and colorectal cancers combined [Lynn Cook, Houston Chronicle, Jan 17]

Agile Materials (Goleta, CA)

Agile Materials & Technologies (Goleta, CA) got a first VC round of $5.8M and looking for $2-3M by next month. Agile, a spinoff of the UCSB, has had $1M SBIR from the Army, [LARTA, Sept. 23]

From SBIR to Real Money
(Jul 30) Agile Materials (Goleta, CA) passed briefly through DARPA and SBIR (Army Phase 1) to VC funding. Prof Robert York and Dr. Chris Elsass spun the company out from UCSB where York did thin film ferroelectrics with BST. [story from LARTA July 29] Agile's website claims that ferro-electric materials can shrink capacitors by 99% (I guess that's what "100X smaller" means) from some baseline; cost reduction claims are more vague. Maybe they could shrink the website too, as it takes several screens to deliver a simple message of the BST material's claims.

Agilyx (Tigard, OR)

Agilyx (Tigard, OR; no SBIR) has secured a $22 million funding boost led by a group of investors that includes Waste Management, Inc., both companies announced today.
The investment aims to further expand a fast-growing venture that takes waste plastics and converts them into synthetic crude oil. ... founded in 2004, and operated under the name Plas2Fuel until last year [Eric Florip, The Oregonian, Mar 31, 11]

Agiltron (Woburn, MA)

Agiltron (Woburn, MA; $30M SBIR) reports it has landed a Phase 3 Small Business Innovation Research grant from the U.S. Navy for a fiber-optic repair system that would help Navy technicians repair aircraft. [Mass High Tech, Dec 16, 09] Technically Phase 3 is not SBIR, but mainline R&D money. Little matter, this company has a decade-old lifeline to the Navy's purse. Let's guess its strengths: good engineering and snappy salutes.

Agios Pharmaceuticals (Cambridge, MA)

Agios Pharmaceuticals (Cambridge, MA; no SBIR) has raised $8.8 million in venture capital, according to a regulatory filing. ... follows an April 15 announcement that the Cambridge-based biotech had signed a $130 million agreement to collaborate with New Jersey-based Celgene Corp. in the development of potential cancer-fighting therapies. [Julie Donnelly, Mass High Tech, Apr 26, 10]

Agios Pharmaceuticals, (Cambridge, MA; no SBIR) a biopharmaceutical company that is focused on discovering and developing novel drugs in the field of cancer metabolism, said today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. [Boston Globe, Dec 22, 09] the first biopharmaceutical company dedicated to drug discovery based on targeting cancer metabolism .. founded 2008 with $33 Million Series A Funding [company website]

Agios Pharmaceuticals (Cambridge, MA; no SBIR) says it has secured $33 M in first round financing, for development of cancer metabolism-regulating drugs. .... The field of cancer metabolism concentrates on cell growth within cancer cells, which rely on more nutrients than normal cells to survive, Agios reports. While the company’s initial plans draw on cell metabolism therapeutics related to cancer, it may also eventually apply to other fields, including diabetes, inflammatory, autoimmune and neurological diseases. .... Agios Pharmaceuticals was founded by cell metabolism leaders Lewis C. Cantley, director of the Cancer Center at Beth Israel Deaconess Medical Center and professor of systems biology at Harvard Medical School; Tak W. Mak, of The Campbell Family Institute for Cancer Research and The University of Toronto; and Craig B. Thompson, director of the Abramson Cancer Center, University of Pennsylvania. [Mass High Tech, Jul 7, 08]

Agritope (Medford,MA)

Exelixis (a public firm founded 1994; $200K SBIR to Exelixis Plant Sciences (Portland, OR) raised about $180 million on early data to support this idea back in March, and now more and more public data is rolling in to buttress the argument. ... has shown off results over the past several days from a trial that enrolled 490 patients with nine different tumor types, to see where cabozantinib (XL184) might work best. The latest batch of data for this drug, from 171 patients with prostate cancer, is being presented to doctors today at the American Society of Clinical Oncology (ASCO) meeting in Chicago. Exelixis formed Exelixis Plant Sciences in December 2000, after acquiring Agritope ($600K SBIR) in order to expand its access to plant model system technologies and product development. [Luke Timmerman, xconomy.com/san francisco, Jun 6, 11]

Agrivida (Medford,MA)

Agrivida (Medford, MA; $300K SBIR) has received a $2 million grant from the USDA to develop genetically engineered feedstocks for biofuels production. [Mass High Tech, Nov 20, 09]

Aguila Technologies (San Marcos, CA)

Allied Signal did an exclusive agreement with Ormet Corp (Carlsbad, CA) to produce fine-line, micro-via, high-density electronic interconnect products. ... Ormet Corporation is an innovator in leading edge technology produces fine-line interconnect products and engineered material products based on its unique electronic materials. With a strong and growing intellectual property portfolio, Ormet is leveraging (whatever that means) both internal and government-sponsored research to produce commercial fine-line products and to license partners in selected technology areas. Ormet designs, manufactures and markets products and solutions in the high-density electronic market. Ormet's products include semiconductor packaging products, fine line-microvia interconnect products, thermally enhanced wiring boards, active substrate products, and engineered material products (EMI shielding, jumper wire and embedded passives). . [May 7] The founder of Ormet, then called Toranaga Technologies, Al Capote, invented Ormet inks and got $750K from BMDO and about $4 M from Venture Capital. The Allied Signal deal, says Capote, resulted from his idea to incorporate the Ormet conductor in microvias for high density PWBs. Capote these days has a new start-up, Aguila Technologies.

Al Capote speaks on entrpreneuring

I spent the large majority of my time writing business plans to sell my company to new investors who would then provide the additional capital to perfect my product, a conductive ink, and not enough time solving the technical problems. Which, I think, delayed the improvements that would make the product viable. It wasn't until four or five years later that it was working well enough that people actually started using it in real products. One of the first end-users was Ford, for PC boards in Lincoln dash panels...then Apple Computer started using it to correct errors in boards, overlaying the corrected circuit on top of the existing solder mask, eliminating the need to scrap 10 to 20 thousand circuit boards. Intel also used it for the same purpose. ...[Then] my venture capital partners, who had been with me from the beginning and had been quite good to me, had grown tired with me still talking about the pot of gold at the end of the rainbow. I saw an opportunity I wanted to pursue, but they were tired. We shook hands, parted company. Toranaga still exists...doing quite well. They have a really nifty technology for using the ink to produce multi-chip modules, a technology that's just getting started, and when it does catch on, that's when I get my check, as I'm still a major stockholder. The story of Al Capote at Toranaga Technologies (Carlsbad, CA) [interview in Designfax, May 98] In the ten years I was President of Toranaga I raised upwards of 12 million dollars. So I had an opportunity to begin again, with all the things I had learned...they even provided me a bit of seed money, and with that I started Aguila in 1996, which has done very well in a very short amount of time. What I've learned is that one must focus on the immediate and urgent needs of real customers. We don't begin R&D in any area unless there is a specific customer with a specific and urgent need for a solution we can provide. The speculative R&D I did at Toranaga -- where you conceive of a product, then go out and try to sell it -- is much too difficult. A more effective approach is to identify a need. .. started this new company...very quickly convinced the Department of Defense that this was an urgent need, raising nearly a million dollars from the US government to get started. The government's an outstanding source for start-up money.

Al was one of the few SBIR proposers who smelled like an entrepreneur, the kind you bet government R&D money on. In a commercialized SBIR government must judge by smell. Science will not suffice; the better you can analyze the proposal, the less likely it will make any breakthrough innovation. The many agencies that play safe with their SBIR will get only incremental advances to their comfortable paradigm. Anti-missile defense couldn't afford slow, safe, and steady. A note to Congress: no legislation can instill entrepreneuring in a federal agency. They can kill it though. Al's live-to-work attitude fulfills economic historian Landes's advice that we are living in a dessert age. We want things to be sweet; too many of us work to live and live to be happy. Nothing wrong with that; it just does not promote high productivity. You want high productivity? Then you should live to work and get happiness as a by-product. [David Landes, The Wealth and Poverty of Nations, 1997]

What It Takes to Win

One California state awardee was Aguila Technologies (San Marcos).which had to get rated by a committee (ugh!)that weighed the business plan and the technology. In the proposal, Aguila teamed up with a large corporation that is putting up cash in exchange for rights to the technology. To get the state funds, Aguila and teammate had to: 1) provide a cost share contribution of at least the California amount, at least 20% in cash, and 2) at least double the amount in Federal contract money. With BMDO's 4:1 match (for a company's very first Phase 2 SBIR) in Fast Track and the teammate's cash, Aguila met the state's demand. The state money can be used to buy capital equipment, which federal funds cannot. So, $75K cash by Aguila's corporate partner (plus Aguila's $100K) won a $175K state grant which allowed a $1M federal contract. Not a bad deal for a year-old market-driven startup. Disregarding the public policy problem in federal matching of state money to private firms, both state and federal governments rewarded a market-driven company driven by high-risk private capital which is what SBIR is supposed to do. Aguila is still at risk of government's (state or federal) dawdling and thus collapsing the structure.
In addition, Aguila founder Capote says it has launched its first product developed under a government contract - a flip chip adhesive flux that "has everybody in our industry excited. I am swamped with calls from prospective licensees who want to manufacture and market it for us". Aguila has been working a year under a DARPA contract on the technology.
Aguila also just won a Phase 1 STTR from NASA to develop yet another aspect of the flip chip technology. (If NASA backed more entrepreneurs like Capote, instead of mining the moon for astronomically uncommercial materials, its SBIR and its technical products would do what Congress intended for SBIR.)

Capote's view of the key to Aguila's commercial success is his devotion to a principle - focus on the URGENT and SPECIFIC needs of REAL customers. His formula - get the customer to tell the government just how important it is to solve their problem, how many millions the solution is worth, and how much money they themselves are willing to risk to solve it. "I use Phase 1 money to prove the feasibility of the solution to the customer. Then getting Phase 2 matching funds is a shoo-in. I have never lost a proposal where I got the customer and the government talking to one another."

Note: Capote's formula works wonders for product innovation. Another innovator class, visionary pioneers, don't satisfy today's clients; they look to create a new world with discontinuous change where today's customers are irrelevant. That's usually long-term, astronomical risk with a history of the pioneer being eaten by more market-driven entrepreneurs. Visionary government (an oxymoron) will help such pioneers. The ones who don't fare well in government competition are those who come down in the muddled middle - neither credible pioneer nor market-driven entrepreneur - scientists wanting a paid hobby.

You, too, can follow Capote's formula, at least since DOD has made it easier for newbies to find the levers.

Start-up Starts Up
Aguila Technologies (San Marcos, CA), Al Capote's new start-up, won an open competition $855K DARPA contract to develop a new flip-chip encapsulant technology. Three other partner companies - Kester Solder Division of Litton, Avex Electronics, and a major chip manufacturer - are co-investing in parallel R&D efforts at their own expense. Al founded Toranaga Technologies (Carlsbad, CA) with the help of four VC outfits who stepped into direct company management after Al won an SBIR award over $1M from BMDO with escalating matching provisions. The flip-chip technology simplifies attaching chips to silicon in multi-chip modules with a technology spun out from Al's first BMDO SBIR. Al has also done what SBIR intended, get a seed stage SBIR and then combine with strategic partners for further investment for market development. (No, more SBIR is NOT strategic partnering.) Al and Toranaga struck me as the kind of entrepreneur and company that SBIR was meant for. Anti-immigrant shriekers take note: Al came from Cuba and has created 22 jobs so far in California.

One of the VCs who sponsored Toranaga Technologies (Carlsbad, CA) from which Al Capote decamped has also decamped. Jim Morgan or the eponymous Morgan Holland Ventures is now CEO of ADRA Systems. Jim served one term recently as President of the National Venture Capital Association. He also served one year as the elected student body Grand Marshal in the 50s at RPI. I don't remember whether I voted for him.

Ahura Scientific (Wilmington MA)

Thermo Fisher Scientific Inc. has agreed to buy Ahura Scientific (Wilmington, MA, founded 2002; no SBIR) maker of analytical instruments, for $145 million in cash. [Mass High Tech, Jan 19, 10]

Ahura Scientific reports it has partnered with QinetiQ North America’s Technology Solutions Group to add Ahura’s spectrometry technology to QinetiQ’s Talon robots. Under terms of the agreement, the companies will add a compact, laboratory-grade Raman spectrometer to Talon military robots. [Mass High Tech, Sep 29, 09]

a hand-held tool with an extremely sensitive laser that can help detect counterfeit drugs. TruScan, developed by Ahura Scientific (Wilmington, MA; no SBIR) can analyze the composition of raw materials or finished manufactured drugs, in about 30 seconds, and is now gaining interest in the market, company officials say. [Mass High Tech, Aug 21, 09]

The National Guard has ordered $2.6M worth of Ahura Scientific (Wilmington MA; three SBIRs) First Defender instruments and fiber-optic extension probes. Early this year, Ahura closed a $7M financing deal bringing its total funding to $29.5M. [Mass High Tech, Nov 15]

Aiko Biotechnology (Portland, ME)

Aiko Biotechnology (Portland, ME; one SBIR) plans to raise $400,000 from unnamed investors. None of the shares has been sold so far. ... an early stage drug discovery company with drug candidates targeting pain, addiction and adverse side effects resulting from prescription opioid pain reliever use. [Mass High Tech, Sep 30, 09]

Aileron Therapeutics

Protein-focused Aileron Therapeutics (Cambridge, MA; no SBIR) reports it has closed on $40 million in a fourth round of financing ... developing therapies using small pieces of a naturally occurring protein, called Stapled Peptides, that restore programmed cell death in multiple myeloma cells [Mass High Tech, Jun 8]

The Multiple Myeloma Research Foundation reports that it has awarded $500,000 each in grant funding to a pair of Cambridge-based companies, Aileron Therapeutics (no SBIR) and Astex Therapeutics (no SBIR), for cancer therapy research. [Mass High Tech, Mar 2, 09]

AirXpanders (Palo Alto, CA)

AirXpanders (Palo Alto, CA; no SBIR) developing technology for breast cancer patients who require tissue expansion for reconstructive surgery, said Wednesday it raised $8 million through two financings. (incl $3M from Australia) [Elizabeth Kim, Silicon Valley / San Jose Business Journal, Mar 2, 11]

Airtricity

Irish Wind. The wind energy company Wind Capital Group LLC is getting a $150 M investment from Ireland-based NTR PLC — a financial boost that [founder] Carnahan says will help transform NTR will provide cash and supply 150 megawatts of wind turbines for delivery in 2010. ... NTR has within the last year sold off its interest in Airtricity, a wind energy developer in the U.S. and Europe, and it has been reinvesting some of the proceeds in startup renewable energy firms. Last week, the company agreed to pay $100 M for a majority stake in Phoenix-based Stirling Energy Systems, which is developing solar power plants. [St Louis Post Dispatch, Apr 25]

Airtricity plans to build enough wind-powered electricity plants here to make Texas the No. 1 wind state next year. [Dallas Morning News, Apr 4] New, more efficient wind technology has a future.

AIT Laboratories (Indianapolis, IN)

AIT Laboratories (Indianapolis, In; no SBIR) has built a reputation as an independent lab for forensics, clinical and pharmaceutical testing. It has spun off AIT Biosciences. ... health and toxicology-testing company [Daniel Evans] founded in 1990, then turned over to ownership by the employees ... could be a poster child for a successful, futuristic client of financing and advice from the [SBA] ... nearly 500 employees nationwide. [Bruce Smith, Indianapolis Star, Aug 9, 11]

Akebia Therapeutics (Cincinnati, OH)

Biomedical firm Akebia Therapeutics (Cincinnati, OH; no SBIR) has raised $16 million in new funding ... develops small-molecule drugs for the treatment of anemia and vascular disorders. Its first drug, an anemia treatment called AKB-6548, is scheduled to start Phase 1 clinical trials later this year. [Business Courier (Cincinnati), Jul 30, 09]

Akermin (St Louis, MO)

Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlington MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

Alabama Cryogenics Engineering (Huntsville, AL)

A Cool and Cozy Business. The professor started his own company to feed on SBIR and government work outside the gates of a high-tech government complex. Since 1983 when he had 10 employees the company has grown to 9 employees in 1996. It has won SBIRs from DOE, DOD, HHS, and NASA, a total of about $7.5M. Now it has a 1998 cryocooler DOE Phase 1 for a project that sounds about like a 1988 project and a 1983 project. The technology plods on and the professor has a nice, not rich by any means, lifestyle company supported by the government nursery program. $7.5M into a 10 person firm over 15 years means most of the firm was supported by SBIR for the company's life. Is that an SBIR-mill? Because it's a private firm, only the government knows whether any other economic good was done by the technology. And the government won't tell. But apparently, neither will the government hold the company accountable for 15 yars of funded plodding. As long as the company offers a good cool technology, the government will go for yet another dose.

1998: Develop an innovative regenerator that will allow reliable, high efficiency, pulse tube cryocoolers to be used with high sensitivity detectors, high vacuum cryopumps, and superconducting filters. In Phase I, a perforated plate regenerator using neodymium metal will be fabricated. Phase I will also produce a design of a prototype cryocooler to be demonstrated in a Phase II follow-on. 1994: regenerator structures using fine wires of a metal having high specific heat at low temperatures. Neodymium (Nd)spheres have been used in two-stage cryocoolers that can operate below 4K. In a single-stage cryoccoler, the minimum temperature will be lowered below 20K, making the refrigerator very useful for devices using the new ceramic high temperature superconductors. 1983:CRYOCOOLER CAPABLE OF REACHING 20 K. THE FIRST STAGE FLUID IS NITROGEN, THE SECOND STAGE FLUID HYDROGEN. COOLDOWN TIME OF LESS THAN 2 SECONDS; RUN TIME OF 10 MINUTES. USES AN INNOVATIVE FABRICATION TECHNIQUE, THAT YIELDS A "MONOLITHIC" STRUCTURE. THE FABRICATION TECHNIQUE IS INTRINSICALLY HIGH VOLUME, AND SHOULD YIELD SUBSTANTIAL COST SAVINGS IN HIGH VOLUME PRODUCTION COMPARED TO THE CURRENT TECHNOLOGY.

Albany NanoTech (Albany, NY)

No story about Albany NanoTech (no SBIR) is without a mention of its leader, Alain Kaloyeros, the UAlbany physics professor who has built the $3.5 B facility on Fuller Road by pulling together hundreds of millions of dollars in funding from IBM, the state of New York, and other semiconductor companies. ... BusinessWeek magazine did an extremely flattering piece on how IBM Corp. drastically changed its semiconductor research and development methods to include a host of partners, including Albany NanoTech and Advanced Micro Devices Inc., to great acclaim. [Albany Times-Union, Sep 9,07]

Aldagen (Durham, NC)

Aldagen (Durham, NC, fomerly StemCo Biomedical; one SBIR) latest attempt at going public has failed once again. ... has withdrawn its plans to raise about $75 million via an initial public offering of common stock because of "market conditions." Founded in 2000, has been developing experimental drugs using stem cells. [David Ranii, Raleigh News & Observer, Apr 5, 11]

Aldagen (Durham, NC; one SBIR) appears to be pushing ahead with its IPO. ... developing drugs using stem cells, revived plans for an initial public offering of stock in late October. ... scrapped an IPO in the fall of 2008 when the stock market slumped. .. founded in 2000 as StemCo Biomedical, based on technology developed at Duke University. [Alan Wolf, Raleigh News & Observer, Dec 11, 09]

Aldagen (Durham, NC; one SBIR), which employs 18 and develops treatments based on adult stem cells, hopes to raise as much as $80M with an IPO. ... founded in 2000 as StemCo Biomedical, based on technology developed at Duke University. It has raised about $48M in VC since then. ... testing four products in humans. The most advanced would improve cord blood transplants used to treat metabolic diseases in pediatric patients. [Sabine Vollmer, Raleigh News & Observer, May 13, 08]

Aldagen (Durham, NC; ?? SBIR) developing treatments based on stem cells raised $18 M VC. ... founded in 2000 as StemCo Biomedical based on technology developed at Duke University. [Raleigh News& Observer, Apr 26]

Private investment continues to boost young Triangle companies. Biologics (Raleigh NC; no SBIR) oncology pharmacy, $20M; . Aldagen (Durham, NC; no SBIR) biotech company, $9 M; HyperBranch Medical Technologies (Durham NC; one SBIR) medical device startup, $1.5M. [Sabine Vollmer, Raleigh News & Observer, Sep 15] Those who can, do; those who can't or won't depend on government handouts.

Aldevon (Fargo, ND)

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] .... founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers. ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

Alexion Pharmaceuticals

Alexion Pharmaceuticals and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut (PEI), Germany’s healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab (Soliris) as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome (STEC-HUS), which has resulted from infections by Enterohemorrhagic Escherichia coli (EHEC) in an unusually wide outbreak in Germany that began in May. [company press release, Jun 20, 11]

Taligen Therapeutics (Cambridge, MA (formerly Greenwood Village, CO); $1M SBIR) has been acquired by Alexion Pharmaceuticals (Cheshire, CT; $1.6M SBIR) for $111 million in an up front cash payment. [Mass High Tech, Jan 31, 11]

Alexion Pharma up 12% [Mar 12, 09]

Alexion Pharmaceuticals has resolved an ongoing patent dispute with PDL BioPharma Inc. over Alexion’s Soliris antibody therapy. Alexion announced that it would pay $25 million to PDL BioPharma for rights to use some of PDL’s patent portfolio called the Queen in its Soliris drug. [Mass High Tech, Jan 5, 09]

Alexion Pharma up 14% [Oct 13, 08]

Alexion Pharma down 10% [Sep 17, 08]

Alexion Pharma up 16% [Aug 8, 08]

Alexion Pharmaceuticals (Cheshire, CT; $1.8M SBIR) agreed to pay $10M to the Oklahoma Medical Research Foundation for all rights to certain patents related to technology used to develop Alexion's blood-disorder drug Soliris, ending a legal dispute between the two operations [Mass High Tech, Feb 14,08]

Alexion Pharmaceuticals up 10% [Oct 25, 07]

Alexion Pharmaceuticals up 18% on news that it didn't lose as much as expected. [Jul 25, 07]

Alexion Pharmaceuticals raised $140M with a public stock offering. Alexion has a drug for a rare blood disorder on fast track for FDA approval. The stock has been rising for about three years on an apparent road to recover its high of five years ago at twice the present price. [Nov 22, 06]

Alexza Pharmaceuticals

Alexza Pharma down 54% [Oct 11, 10]

Alexza Pharmaceuticals has agreed to sell common stock and warrants worth $18 million to a group of institutional investors [San Francisco Business Times, Aug 5, 10]

Alexza Pharmaceuticals rose 8% after the FDA accepted the company's drug application for a treatment for agitation in patients with schizophrenia or bipolar disorder. [Wall Street Journal, Feb 12, 10]

Alexza Pharmaceuticals said it plans to raise $19.7 million in a private placement of its common stock. [Silicon Valley/San Jose Business Journal, Sep 30, 09]

Alexza Pharma down 12% [Sep 14, 09] as preliminary results from the company's midstage trial for a migraine treatment failed to meet a goal. [Wall Street Journal, Sep 15, 09]

Alexza Pharma down 13% [Jan 29, 09]

Alexza Pharma up 13% [Jan 21, 09]

Alexza Pharma down 10% [Jan 9, 09]

Alexza Pharma up 15% [Oct 16, 08]

Alexza Pharma down 11% [Aug 29, 08]

Alexza Pharma up 18% [Aug 28, 08]

Alexza Pharmaceuticals down 11% [Aug 21, 08]

Alexza Pharmaceuticals up 13% [Jul 30, 08]

Alexza Pharmaceuticals down 14% [Jun 10, 08] on news of disappointing clinical trials.

Alexza Pharma up 16% [Mar 11, 08]

Alexza Pharmaceuticals up 11% [Feb 26, 08]

Alexza Pharmaceuticals up 10% [Nov 28, 07]

Alexza Pharmaceuticals down 12% on lack of good news. [Aug 14,07]

Alexza Pharmaceuticals up 10%. [Aug 8, 07]

Alexza Pharmaceuticals down 10%. [Aug 3, 07]

Alexza Pharmaceuticals doubled after announcing encouraging results from two studies intended to develop new treatments for migraine victims and schizophrenic patients with acute agitation. [Businessweek.com, Mar 26, 07]

Alfalight (Madison WI)

Alfalight (Madison WI; no SBIR) got a $1.2M Army contract for development of stronger fiber lasers for industrial and defense applications. Alfalight's commitment to innovation is validated by funding from several government branches including DARPA, the Air Force Research Laboratory, and the Army Research Laboratory [company website]

AlgEternal Technologies (Austin, TX)

AlgEternal Technologies (Austin, TX; no SBIR) working with the University of Texas, has a technology that it hopes will make it possible to grow algae on a much larger scale and in a much smaller space. ... is near completion of a commercial facility at UT's J.J. Pickle Research Campus. ... The concept, in simplistic terms, is to grow algae vertically, instead of the traditional, horizontal way. That's being done with a proprietary process that uses tall glass tubes — called bioreactors — instead of the traditional open-pond method. [Austin American Statesman, Sep 12, 11]

Alien Technology

Optimism Not Enough. Wall Street just escaped an attempted alien abduction, spurning a wildly inappropriate initial public stock offering from Alien Technology of Morgan Hill. Alien, struggling to develop a new way of making low-cost radio identification tags for retailing and other applications, is in no way qualified to be a public company. Alien's losses are bigger than its sales, its technology is unproven and the company has missed self-imposed deadlines to make that technology work as claimed. [Mike Langberg, San Jose Mercury News, Aug 26]

Alimera Sciences (Alpharetta, GA)

pSividia (Watertown, MA; no SBIR) has taken a $15 million payment from Alimera Sciences (Alpharetta, GA; no SBIR) to cover licensing of its lead product Iluvien to treat diabetic macular edema (DME). ... pSivida was launched in Australia, and reincorporated as a U.S. company based in Watertown in April of 2008. [Mass High Tech, Apr 29, 10]

Aliva Biopharmaceuticals (Pasadena, CA)

Alkermes

Alkermes said it plans to acquire a division of Irish drug maker Elan Corp. plc in a cash and stock deal valued at $960 million. Elan will receive $500 million plus an equity stake of 25 percent in Alkermes, which will now be known as Alkermes plc, and will be incorporated in Ireland [Julie Donnelly, Dayton Business Journal, May 9, 11] Alkermes had $3M NIH SBIR in the 1990s.

Alkermes Pharma down 11% [Mar 3, 11] The diabetes drug being developed by Eli Lilly, Amylin Pharmaceuticals, and Alkermes didn't control the disease better than Novo Nordisk A/S' Victoza in a study, Bloomberg News reported [Indianapolis Star, Mar 3, 11]

Alkermes said today that a clinical trial shows one of its drug candidates can relieve constipation caused by use of opioid pain medications without reducing the effectiveness of the pain drugs. [AP, Feb 15, 11]

Alkermes up 10% [Feb 4, 11]

Analysts and company officials at Alkermes have been taken my surprise by [FDA] decision not to approve a drug candidate to treat type 2 diabetes, Bydureon. [Mass High Tech, Oct 20, 10]

Alkermes up 5% said a [FDA] advisory panel voted 12-to-1 that its drug Vivitrol should be approved for the treatment of opioid dependence. The FDA isn't bound by panel recommendations, but it usually follows them. [Wall Street Journal, Sep 18, 10]

Alkermes has launched an early stage drug trial for a potential treatment for side effects of opiod use for patients will chronic pain. [Mass High Tech, Mar 19, 10]

Amylin Pharmaceuticals rose 16% after the FDA issued a complete response letter that rejected immediate approval of a long-acting version of diabetes treatment Byetta, being developed with Eli Lilly and Alkermes. The FDA's response removed the worst-case scenario—the need for additional clinical trials. Alkermes advanced 15% [Wall Street Journal, Mar 16, 10]

Alkermes up 15% [Mar 15, 10]

Life science firms pitch optimism [CEO] of Alkermes stood before scores of potential investors yesterday and talked about two drugs - for diabetes and opiate dependency - that his Cambridge company expects to get approved in 2010. “This year is going to be a big year,’’ Pops said. ... Henri Termeer defending his leadership at Genzyme as it scrambles to fix production problems, Biogen Idec’s James C. Mullen avoiding any mention of his recent decision to step down from the company’s top post - the mood was generally upbeat. ... companies have been raising more money in follow-on offerings than any time in the past decade, about $6 billion in 2009 ... Another huge market opportunity lies in a drug being developed by Vertex Pharmaceuticals to treat hepatitis C, a largely untreated virus estimated to affect about 3 million Americans and 100 million people globally. “We’re doing a lot to raise awareness of this disease,’’ said new Vertex chief Matthew Emmens. [Robert Weisman, Boston Globe, Jan 14, 10] from the 28th annual J.P. Morgan Healthcare Conference in San Francisco

Alkermes up 14% [Nov 17, 09] said a late stage clinical trial shows its drug Vivitrol, which is used to help alcoholics quit drinking, also helped opioid addicts stay off drugs. [AP, Nov 16, 09]

Alkermes said that a drug for addiction and nervous system disorders met its goal in two early stage clinical trials. [Boston Globe, Oct 13, 09]

Alkermes up 11% [May 5, 09]

Alkermes up 13% [Mar 26, 09]

Alkermes up 12% [Mar 12, 09]

FDA is looking for more information about Cambridge-based biotech company Alkermes’s bipolar disorder treatment drug Risperdal Consta before it considers granting permission to expand its usage. [Mass High Tech, Feb 11, 09]

Alkermes up 14% [Dec 11, 08]

Alkermes down 10% [Dec 9, 08]

Alkermes up 22% [Dec 8, 08]

Alkermes said that it has regained from Cephalon full commercialization rights to Vivitrol, once-monthly, extended-release injectable medication for the treatment of alcohol dependence. [Boston Globe, Dec 1, 08]

Alkermes down 12% [Oct 27, 08]

Alkermes down 14% [Oct 15, 08]

Alkermes up 13% [Oct 13, 08]

Alkermes down 12% [Aug 27, 08]

Alkermes down 10% [Aug 18, 08]

Alkermes up 11% [Aug 8, 08]

more and more companies in the pharmaceutical game, including biotech firm Alkermes, think the way to kick that addiction is through a dose of their drugs. Millions of Americans are hooked on everything including booze, cigarettes, cocaine and even cheeseburgers — and drug-makers are filling their research and development pipelines with potential treatments for such addictions. With mixed results, Alkermes and several pharma companies have launched a handful of drugs to help patients quit drinking or smoking. [Mass High Tech, Jul 11]

Alkermes will expand its common stock repurchase program by an additional $40 M. According to biotech firm Alkermes, the $40 million boost in the buyback plan comes after the company received a $40 million payment from Eli Lilly after the drug giant canceled its inhaled insulin program with Alkermes in March.

More insulin innovation, please. Alkermes reports that it expects partner Eli Lilly and Co. to pull the plug on the AIR Inhaled Insulin product, which is being developed by the two companies [Mass High Tech, Mar 7, 08] Indeed, Eli Lilly joined the exodus: abandoned plans to develop inhalable insulin, joining other drug makers that have exited from the field. [Wall Street Journal, Mar 8]

Alkermes plans to continue working with partner Eli Lilly and Co. on an inhalable form of insulin for diabetes patients, even though two other drug makers scrapped work on competing products in the past few months. [Boston Globe, Jan 18]

Alkermes said a unit of Johnson & Johnson has agreed to sell its treatment for alcohol and opioid dependence in Russia and other countries of the Commonwealth of Independent States (CIS). [Mass High Tech, Jan 7, 08]

Alkermes reports it plans to sell its stake in New Jersey-based Reliant Pharmaceuticals Inc. to GlaxoSmithKline for up to $174 M cash. [Mass High Tech, Nov 23, 07]

Alkermes up 13% on good earnings and prospects [Aug 3, 07]

Alkermes gained 13% on reporting doubled profit and a brighter future. [Feb 8, 07]

Allegro Diagnostics (Boston, MA)

Allegro Diagnostics (Maynard, MA; $2.9M SBIR) developer of medical tests for cancer, has closed a $5.4 million Series A financing round, ... to move the company’s BronchoGen genomic test, used to detect potential lung cancer signs, into commercialization next year. [Michelle Lang, Mass High Tech, Jul 7, 11]

Allegro Diagnostics (Boston, MA; no SBIR) a diagnostics startup with ties to Boston University, has reeled in its first round of venture capital financing to develop its molecular tests, officials said [Mass High Tech, Mar 7, 08] announced the completion of $4M in Series A financing. [Boston Globe, Mar 7]

Allegro MicroSystems (Worcester,MA)

NIH gave Allegro Diagnostics, (Boston, MA; no SBIR) developer of medical tests for cancer, a $2.8 million Phase 1/2 Fast Track SBIR for a clinical study of its lung cancer diagnostic test, BronchoGen. ... Founded in 2006 by researchers from Boston University, ... received a $4 million Series A round in 2008. [Mass High Tech, Oct 22, 09]

Allegro MicroSystems (Worcester, MA; no SBIR) is pulling its planned IPO, citing negative market conditions.The company filed for its IPO, expecting to raise $115 million [Mass High Tech, Aug 22, 08]

Allegro MicroSystems (Worcester,MA) that makes semiconductors for the automotive industry and other markets, said today that it will not go through with its initial public offering of common stock due to current market conditions.

Allena Pharmaceuticals (Newton, MA)

Allena Pharmaceuticals (Newton, MA). is launching as a start-up after securing $15 million in Series A venture capital financing. The company is looking to develop and commercialize non-systemic protein therapeutics to treat metabolic and orphan diseases, with a focus on nephrologic and urologic conditions. The company’s founders are Alexey Margolin, founder and former chief executive of Alnara Pharmaceuticals Inc., and Robert Gallotto, former chief business officer of Alnara. [Chris Reidy, Boston Globe, Nov 16, 11]

AllerQuest (West Hartford, CT)

Six start-up technology firms have received grants as part of the state's small-business incubator program, ... administered by the Connecticut Center for Advanced Technology ... $32,000 to $50,000 went to: AllerQuest LLC of West Hartford, Catelectric Corp. of Storrs, Hydrogen Safety of East Hartford, Quadra-Aerrow International of Glastonbury, Revegen Inc. of Farmington and the Center for Network Centric Product Support Research of East Hartford. [Hartford Courant, Dec 12, 08] no SBIR for any

AlloCure

AlloCure (Burlington, MA) (Burlington, MA; no SBIR) startup developing cell therapy to treat kidney disease, has taken in $1.5 million in a debt and securities offering ... focuses its lead program, AC607, as a mesenchymal stem cell treatment for acute kidney injury. An alternative to dialysis, AC607 is designed to stimulate organ repair, the AlloCure website noted, and has been tested in a Phase 1 clinical trial. [Michelle Lang, Mass High Tech, Oct 14, 11]

Allos Therapeutics

Allos Thera up 16% [Nov 5, 10]

Allos Thera down 15% [Jul 28, 10]

Allos Thera down 11% [May 6, 10]

Allos Thera down 13% [Mar 2, 10]

Allos Thera down 11% [Dec 7, 09]

Allos Therapeutics (Westminster, CO; $400K SBIR a decade ago) finished selling 14 million shares of stock, raising $93 million the biotech drug maker plans to use to market its newly approved drug Folotyn and for general purposes. [Denver Business Journal, Oct 13, 09]

Allos Therapeutics ($0.4M SBIR) priced its underwritten public stock offering ... to raise about $99.4 million from the offering, before underwriting discounts and expenses, to help it commercialize its cancer drug Folotyn and for general corporate purposes. [Denver Business Journal, Oct 7, 09]

Allos Thera down 12%% [Mar 31, 09]

Allos Thera up 13% [Jan 21, 09]

Allos Thera up 11% [Dec 31, 08]

Allos Thera down 21% [Dec 8, 08]

Allos Thera up 15% [Dec 5, 08]

Allos Thera down 19% [Dec 1, 08] On a stock bloodbath day

Allos Thera down 13% [Oct 24, 08]

Allos Thera up 10% [Oct 20, 08]

Allos Thera up 11% [Oct 16, 08]

Allos Therapeutics down 14% [Oct 15, 08]

Allos Thera down 11% [Oct 14, 08]

Allos Thera up 30% [Oct 13, 08]

Allos Therapeutics down 14% [Oct 7, 08]

Allos Threapeutics down 10% [Oct 2, 08]

Allos Therapeutics down 14% [Oct 7, 08]

Allos Threapeutics down 10% [Oct 2, 08]

Allos Thera down 11% [Sep 17, 08]

Allos Thera up 11% [Sep 16, 08]

Allos Thera down 10% [Sep 8, 08]

Allos Therapeutics down 10% [Sep 4, 08]

Allos Therapeutics up 14% [May 22, 08]

Allos Therapeutics up 17% [Mar 24, 08]

Allos Therapeutics up 12% [Oct 26, 07]

Allos Therapeutics down 11% on soggy profits. [Oct 16, 07]

Allos Therapeutics down 15% [Aug 8, 07] on news of a growing loss.

Allos Therapeutics down 14% [Jun 22, 07]

Allos Therapeutics jumped another 11%. [Feb 6, 07]

Allos Therapeutics jumped 10% even after raising $50M in a stock sale a few days earlier. [Feb 2, 07]

Allos Therapeutics up 10% after being up 20% intra-day. [Nov 14, 06]

Alloy Polymers (East Texas)

Alloy Polymers (East Texas; no SBIR) a plastics compounding company recently canceled its state job creation contract, joining other businesses that have quit or changed their pacts under the Texas Enterprise Fund. ... citing "business reasons," said Lucy Nashed , a spokeswoman for Gov. Rick Perry. Nashed said the company paid back with interest the $100,000 in taxpayer money it had received so far under the $200,000 agreement.... was to have created 52 new jobs in Houston County as part of the 2006 agreement. [Kelly Shannon, AP, Sep 1, 10]

Alloy Surfaces (Aston, PA)

Alloy Surfaces (Aston, PA; two SBIRs twenty years ago) has been awarded a three-year contract worth $38.3 million to produce MJU-49/B decoy devices for the Navy, ... now a subsidiary of the Chemring Group PLC, which is based in Whiteley, England. [Philadelphia Business Journal, Jul 23, 10]

Alnara Pharmaceutical

Eli Lilly has completed the purchase of Alnara Pharmaceuticals, a Boston-area biotech startup whose promising lead drug could help people with cystic fibrosis. [Indianapolis Star, Jul 23, 10]

Alnara Pharmaceuticals (Cambridge, MA; no SBIR, founded 2008). has agreed to be acquired by Eli Lilly, bringing the Indianapolis pharmaceutical giant an inroad into enzyme replacement therapy, used to treat diseases such as cystic fibrosis. [Mass High Tech, Jul 2, 10]

Alnara Pharmaceuticals (no SBIR) stands ready to send its drug target to treat cystic fibrosis to the U.S. Food and Drug Administration, a mere 16 months after the company raised its first venture capital round of $20 million. [Julie Donnelly, Mass High Tech, Mar 5, 10]

Alnara Pharmaceuticals (Cambridge, MA; no SBIR) a developer of metabolic disease treatments, has raised $35 million in Series B funding. ... to file a new drug application for liprotamase, its pancreatic enzyme replacement therapy for patients with cystic fibrosis, which has gone through Phase 3 clinical trials with support from the Cystic Fibrosis Foundation Therapeutics Inc. [Mass High Tech, Jan 28, 10]

Alnara Pharmaceuticals, a pharmaceutical startup developing non-systemic protein therapeutics for the treatment of metabolic and inflammatory diseases, has secured $20 million in Series A funding [Mass High Tech, Oct 30]

Alnara Pharmaceuticals Inc., a newly formed life sciences company in Boston, announced today that it has secured $20 million in Series A venture capital financing. [Boston Globe, Oct 30,08]

Alnylam Pharmaceuticals

Alnylam Pharma up 10% [Sep 13, 11]

Alnylam Pharma down 11% [Aug 10, 11]

Alnylam Pharmaceuticals pulled in a $10 million tech transfer payment from Japanese drug maker Takeda Pharmaceutical Co. Ltd., related to a May 2008 deal between the two companies potentially worth up to $1 billion. [Mass High Tech, Mar 28, 11]

Alnylam Pharma up 15% [Feb 18, 11]

Alnylam Pharmaceuticals unveiled a goal to have five drug candidates in the late stages of clinical development by 2015. [Boston Globe, Jan 6, 11]

Alnylam Pharmaceuticals developing drugs based on RNA interference, said it intends to reduce its workforce by 25 percent to 30 percent as it looks to save about $25 million in 2011 cash operating expenses. [Boston Globe, Sep 24, 10]

Alnylam Pharmaceuticals said that three European countries have cleared it for early-stage clinical testing of a potential treatment for a hereditary disease caused by a genetic mutation. [Boston Globe, Jun 29, 10]

Alnylam Pharmaceuticals focused on using RNA interference technology to develop drugs, said it is in line to receive a $1.8 million payment from Regulus Therapeutics a California company it helped form with Isis Pharmaceuticals in 2007. [Boston Globe, Jun 22, 10]

Alnylam Pharmaceuticals said that the European Patent Office has issued a notification of an intent to grant for a patent series that includes 16 claims covering compositions and methods. [Boston Globe, May 4, 10]

Short Interest. Synaptics has shorts amounting to 43% of its float. Alnylam Pharma has short interest of 38 days of average volume. [Wall Street Journal, Mar 25]

Alnylam Pharma said it received $20 million from Takeda Pharmaceutical Co. Ltd. after transferring gene-silencing technology to the company. [AP, Mar 23, 10]

Shorts. Synaptics was eighth in rank of short interest as a percentage of float. Alnylam Pharma and Cepheid were seventh and eight in days of average trading volume to cover the short interest. [Wall Street Journal, Mar 10, 10]

Alnylam Pharmaceuticals said today that it received a milestone payment from its partner Roche AG after Roche started a study of a drug developed with Alnylam's gene-silencing technology. [Boston Globe, Jan 6, 10]

DIY Pharma. At a time when major drug makers are consolidating and may be less willing to buy fledgling companies, biotechs have to make it on their own and bring drugs to market themselves. Industry leaders warned that the old model of forming a biotech company, shepherding a drug through development and years of clinical trials, and then selling the company to a pharmaceutical buyer may be played out. Success will now require a survival mentality and a focus on remaining independent, said Barry Greene, president of Cambridge biotech Alnylam Pharmaceuticals Inc. [Robert Weisman, Boston Globe, Oct 7, 09]

Alnylam Pharmaceuticals and Regulus Therapeutics (no SBIR) said that they have been awarded a US patent that covers some of their intellectual property related to microRNAs, a field thought to be ripe for developing new drugs. [Boston Globe, Aug 11, 09]

Alnylam Pharma up 13% [Jul 23, 09]

Alnylam Pharmaceuticals said today it extended a long-standing contract with Novartis focusing on developing drugs using RNAi, or gene silencing, technology. This marks the second extension by Novartis, as well as the fifth and final year of the contract. [Boston Globe, Jul 17]

Alnylam Pharma up 11% [May 8, 09]

Alnylam Pharmaceuticals said that Novartis AG has elected to fully exercise its current right to purchase 65,922 unregistered shares of Alnylam's common stock in accordance with the terms of a 2005 investor rights agreement between the two companies. [Boston Globe, May 7, 09]

Alnylam Pharma and Isis Pharma said they have formed a new collaboration focused on the development of single-stranded RNAi (ssRNAi) technology. [Chris Reidy, Boston Globe, Apr 29, 09]

Alnylam Pharma up 11% [Mar 10, 09]

Alnylam Pharmaceuticals said it was one of two firms that invested a collective total of $20 million in Regulus Therapeutics (no SBIR) ... In 2007, Alnylam and Isis Pharmaceuticals established Regulus to "focus on the discovery, development, and commercialization of microRNA-based therapeutics," the two companies said in a press release. [Boston Globe, Mar 5, 09].

Alnylam Pharma down 12% [Mar 2, 09]

Alnylam Pharma down 11% [Jan 20, 09]

Two local life sciences companies are teaming up to work on a collaboration to commercialize some RNAi therapeutics that could potentially yield one of the companies just over $100 million in up-front and milestone payments. Cubist Pharmaceuticals and Alnylam Pharmaceuticals announced that they have formed a strategic collaboration to develop and commercialize Alnylam's ALN-RSV program; the RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus infection in adult lung transplant patients, the two companies said in a press release. [Boston Globe, Jan 9, 09]

Alnylam Pharmaceuticals has bought up a large portfolio of intellectual property from Nucleonics (one SBIR). [Mass High Tech, Dec 8, 08]

Alnylam Pharma up 11% [Dec 8, 08]

Alnylam Pharma down 11% [Nov 14, 08]

Alnylam Pharma down 11% [Nov 12, 08]

Alnynam Pharma up 11% [Nov 4, 08]

Alynlam Pharma up 11% [Oct 30, 08]

Alnylam Pharma down 13% [Oct 27, 08]

RNAi biotech company Alnylam Pharmaceuticals received a $20 million milestone payment from Takeda Pharmaceutical Company Ltd., adding to the $100 million the Cambridge-based biotech has earned already from Takeda. [Mass High Tech, Oct 7, 08]

Alnylam up 12% [Sep 18, 08]

Researchers have uncovered a new pathway to malaria infection, linking cholesterol metabolism to the disease, which could ultimately lead to new treatments using RNAi therapeutics. Scientists from Cambridge-based Alnylam Pharmaceuticals, Dresden, Germany-based Cenix BioScience GmbH and Lisbon-based Instituto de Medicina Molecular (IMM) published their findings in Cell Host & Microbe. [Mass High Tech, Sep 11]

Alnylam Pharmaceuticals said it has formed a collaboration with the Max Planck Institute in Germany. [Boston Globe, Aug 11, 08]

Alnylam Pharmaceuticals said that its second-quarter loss increased slightly, as rising expenses canceled out improved revenue from collaborations. [Boston Globe, Aug 7, 08]

Alnylam Pharmaceuticals signed its second collaborative deal in as many months, sending shares higher. [Boston Globe, Jun 19, 08]

Alnylam Pharmaceuticals says it has made a $5 million equity investment in Tekmira Pharmaceuticals Corp. as part of an expanded licensing deal [Mass High Tech, Jun 2, 08]

Takeda Pharmaceutical is betting big on U.S. biotechnology companies to reinvigorate Japan's No. 1 pharmaceutical company.... [After buying one company for nearly $9B], a technology alliance with biopharmaceuticals company Alnylam Pharmaceuticals (Cambridge, MA; $600K SBIR). Under the agreement, Takeda could pay as much as $1 billion if all development and sales targets are met. [Hiroko Tabuchi, Wall Street Journal, May 28, 08] includes a $100 million up-front payment, $50 million in near-term technology transfer payments, and more than $850 million in potential milestone payments and royalties, [Boston Globe, May 28]

Alnylam Pharmaceuticals reports that [Swiss giant] Novartis AG will pay $5.4 million to buy more shares in the Cambridge-based biopharmaceutical company that is focused on using RNA interference (RNAi) for developing therapies. [Mass High Tech, May 8]

Alnylam Pharmaceuticals (Cambridge, MA; $600K SBIR) granted Shanghai GenePharma a non-exclusive world-wide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family. [company website, Mar 20, 08] The nearly $1B market cap barely moved.

Alnylam Pharmaceuticals (Cambridge, MA; no SBIR) said it was part of a research team awarded a new $3.8 million grant from the Michael J. Fox Foundation to further develop an RNAi therapeutic for the treatment of Parkinson's disease.... seeks to develop novel technologies based on RNA interference, or RNAi, a naturally occurring mechanism within cells for selectively silencing and regulating specific genes; since many diseases are caused by the inappropriate activity of specific cells, the ability to silence genes selectively through RNAi has great potential, researchers think. [Chris Reidy, Boston Globe, Jan 7, 07]

AlphaMed (Acton, MA)

AlphaMed (Acton, MA; six Phase 1 SBIRs) reports it has received a $750,000 grant from the National Cancer Institute to advance its experimental treatment for deadly skin cancer. ... The two-person firm hopes to find development partners and raise $5 million to $10 million in a Series A round of venture capital this year .....the company's founders: Richard F. Testa, formerly of Thermo Electron Corp., Digital Equipment Corp., and General Electric Co.; Herbert A. Moore, formerly of DuPont Merck Pharmaceuticals Co., Hoffman la Roche Inc., and Tracerlab Inc. [Mass High Tech, May 7, 08]

AlphaVax (RTP, NC)

AlphaVax (RTP, NC; no SBIR) got three-year $3.6M NIH contract to advance its development of adjuvant technologies, which are agents used to enhance the effects of other agents used in vaccines. In February, the company raised $12.7M in a preferred stock offering to begin clinical trials relating to herpes and influenza. [Raleigh News & Observer, Jul 12]

Alseres Pharmaceuticals (Hopkinton, MA)

Alseres Pharmaceuticals (Hopkinton, MA; no SBIR) focused on the development of therapeutic and diagnostic products for disorders in the central nervous system, announced $1 million financing. [Boston Globe, Nov 20, 08]

Altair Therapeutics

Altair Therapeutics, a spinoff from Isis Pharmaceuticals, has shut down operations after the startup’s only drug candidate failed in a mid-stage clinical trial against asthma [signonsandiego.com, Feb 3, 11]

AltAir Fuels (Seattle, WA)

AltAir Fuels, (Seattle, WA startup), said it has entered into agreements with [14] airlines to negotiate the purchase of jet fuel and diesel derived from the camelina plant, a weed related to mustard that produces seeds with a high oil content. ... the company aims to build a new facility within the Tesoro refinery in Anacortes and begin operating in 2012. He said the company expects Tesoro to become an investor in AltAir. ... The camelina oil will be sourced from Montana-based Sustainable Oils, which has camelina-research expertise and production contracts with farmers. [Cristi Heim, Seattle Times, Dec 16, 09] SBIR history unknowable until SBA repairs its often crippled website.

AltaRock

Nature Prices Extraction. Startup AltaRock (Seattle, WA; no SBIR) stopped its California geothermal project after earthquakes in Switzerland from similar extraction of heat from geologically active rocks. In addition to a $6 million grant from the Energy Department, AltaRock had attracted some $30 million in venture capital from high-profile investors ... AltaRock has also received some $25 million in federal money for a project in Oregon [James Glanz, Wall Street Journal, Dec 11, 09]

Althea Technologies (San Diego,CA)

Hercules Technology Growth Capital Inc. has closed loan commitments of $52 million to three new portfolio companies -- Althea Technologies (San Diego, CA; $400K SBIR), Calera (no SBIR) (CEO Brent Constantz picked by CNBC as one of fifteen leading innovators), and an unnamed company. [San Francisco Business Times, Aug 5, 10]

Altor (Miramar FL)

Hing C. Wong founded Altor (Miramar FL; $1.5M SBIR) in 2002 as a spin-off from Sunol Molecular (Miramar FL; $0.5M SBIR) which seeded the company with $4M. Top venture funds then invested $6M. The company’s proprietary technology, which it calls its “STAR” platform, has been in development for a decade. [Allan Maurer, Tech Journal South, Nov 9]

Altra (Los Angeles, CA)

Altra (Los Angeles CA), a biofuel company, said it received $50 M from a group of private investors including venture capitalist Vinod Khosla, a founder of Sun Microsystems. Altra, founded in 2004 as Malibu Capital Partners Inc., acquires and develops projects using renewable energy, including ethanol and biodiesel. [LA Times, Apr 6]

Altus Pharmaceuticals

Altus Pharmaceuticals, the former Waltham drug maker that filed for Chapter 7 bankruptcy in November and has since ceased operations, has had its intellectual property portfolio and protein formulation assets picked up by San Diego biotech Althea Technologies Inc. [Mass High Tech, May 4, 10]

At least five Massachusetts biotechs — Dynogen Pharmaceuticals Inc., Epix Pharmaceuticals, Oscient Pharmaceuticals, Biopure Corp. and Altus — have more or less ceased operations since the stock market meltdown in September 2008. [Julie Donnelly, Mass High Tech, Mar 5, 10]

Nasdaq said it will delist Altus Pharmaceuticals [AP, Dec 16, 09]

Altus Pharmaceuticals (Waltham, MA; no SBIR) filed for bankruptcy. ... had been developing a human growth hormone that would have been injected to treat diseases [Boston Globe, Nov 12, 09]

Three years after Altus Pharmaceuticals went public and raised $105 million in a single day, the Cambridge biotechnology company is running out of money, and its stock, which once traded for more than $25 a share, closed at 40 cents yesterday. [Scott Kirsner, Boston Globe, May 9, 09]

Shares of Altus Pharmaceuticals plunged to an all-time low Tuesday as Wall Street reacted negatively to preliminary results from a late stage trial of its Trizytek enzymes. [Boston Globe, Aug 13,08]

Altus Pharmaceuticals up 11% after reporting top-line results from a Phase 1 clinical trial of ALTU-237 in healthy adult volunteers. [Jun 5, 08]

Altus Pharma up 11% [May 22, 08]

Altus Pharmaceuticals up 10% [Mar 18, 08]

Altus Pharmaceuticals up 15% [Feb 4, 08]

Altus Pharmaceuticals bought back a human growth hormone formulation it had licensed to a California biotech [Genentech] almost exactly one year ago ... reported a net loss of $55.7 M on $5.1 M in revenue for 2006. [Mass High Tech, Dec 20, 07] The return was disastrous news for the stock which tumbled 44%.

Altus Pharmaceuticals up 10% [Nov 13, 07]

Altus Pharmaceuticals up 10% [Aug 16,07]

ALung Technologies (Pittsburgh, PA)

ALung Technologies (Pittsburgh, PA; no SBIR) said it has raised $2.5 million from its investors. ... to fund clinical trials in India and Germany scheduled to begin in late 2009, and support working capital needs. The investors are private individuals or angels and were not identified. ... commercializing artificial lung devices for the treatment of acute and chronic respiratory disorders. [Pittsburgh Business Journal, Oct 6, 09]

AMAG Pharmaceuticals

Amag Pharmaceuticals is in line to receive a $3 million milestone payment under a licensing agreement for its iron-replacement drug. The drug is Feraheme, and it has been available in the United States for more than two years. [Chris Reidy, Boston Globe, Dec 12, 11]

AMAG Pharma up 18% [Nov 4, 11] said that president and chief executive has resigned, effective immediately. The company also unveiled a restructuring plan that includes a 25 percent reduction in positions. [Chris Reidy, Boston Globe, Nov 4, 11]

AMAG Pharma down 13% [Aug 8, 11]

a New York-based fund specializing in long-term strategic investments in health care and biotechnology, has made an unsolicited bid to acquire AMAG Pharmaceuticals for $378 million, to block the proposed merger between AMAG and Allos Therapeutics. [Julie Donnelly, Mass High Tech, Aug 5, 11]

AMAG Pharmaceuticals up 11% [Aug 3, 11]

Shares of Amag Pharmaceuticals jumped today in premarket trading, after the drugmaker said it received an unsolicited buyout offer worth $381 million from MSMB Capital Management. [Boston Globe, Aug 3, 11]

AMAG Pharma down 14% [Jul 20, 11] announced plans to merge with Colorado company Allos Therapeutics in a stock-for-stock deal worth approximately $686 million. [Mass High Tech, Jul 20, 11]

AMAG Pharma up 10% [May 31, 11]

AMAG Pharma up 11% [Apr 25, 11]

AMAG Pharmaceuticals said it has reached an agreement with the Food and Drug Administration regarding an update to the product label for Feraheme, an anemia drug..... said recently that it would slash 24 percent of its workforce due to declining sales and safety concerns tied to Feraheme [Boston Globe, Nov 30, 10]

AMAG Pharma up 13% [Nov 29, 10]

AMAG Pharmaceuticals has announced a plan to cut its workforce by 24 percent to lower operating expenses. [Mass High Tech, Nov 1, 10]

AMAG Pharma up 12% [Sep 30, 10]

AMAG Pharma down 15% [Sep 21, 10]

AMAG Pharma down 13% [Jul 29, 10]

AMAG Pharmaceuticals and Japan's Takeda Pharmaceutical Co. Ltd. today jointly announced that the companies have entered into a license, development, and commercialization agreement related to the drug Feraheme, which is approved in the United States for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. [Boston Globe, Apr 1, 10] ... will bring it $60 million in upfront payments and could yield up to $280 million total. [Mass High Tech, Apr 1]

AMAG Pharma down 16% [Feb 4, 10] after an analyst downgraded the stock on concerns that kidney disease patients treated with the company's intravenous iron replacement therapy Feraheme are ending up in the hospital with severe allergic reactions. [thestreet.com]

AMAG Pharma up 20% [Jan 11, 10] besting Wall Street expectations.

AMAG Pharma up 12% [Oct 29, 09] third-quarter loss narrowed on higher sales of the anemia drug Feraheme. [AP, Oct 29]

AMAG Pharma up 11% [Mar 23, 09]

AMAG Pharma down 12% [Mar 2, 09]

AMAG Pharma down 15% [Feb 26, 09] said that its fourth-quarter loss widened on higher costs as the company sets up operations for the eventual marketing of its anemia drug Feraheme. [Boston Globe, Feb 27]

AMAG Pharmaceuticals said the FDA asked for more information on the anemia drug candidate ferumoxytol before considering it for approval. [Boston Globe, Dec 23, 08]

AMAG Pharma down 11% [Dec 1, 08] On a stock bloodbath day

AMAG Pharma doubled [Nov 13, 08] after going one step closer to getting its anemia drug approved by the Food and Drug Administration. The agency declared a response for more information to be complete, allowing the biopharmaceutical company to recover some of the value that had been lost over the past three months amid concerns about the fate of its treatment for iron-deficiency anemia. [Wall Street Journal, Nov 14]

AMAG Pharma down 12% [Nov 12, 08]AMAG Pharma down 19% [Nov 10, 08]

AMAG Pharma down 14% [Nov 4, 08]

AMAG Pharma down 12% [Oct 20, 08] received a letter from the FDA asking for more information on its iron-replacement drug ferumoxytol. The company said it should be able to respond quickly to the request without conducting any more clinical trials. [Wall Street Journal, Oct 21]

AMAG Pharmaceuticals said the FDA granted Fast Track designation to a diagnostic agent that can be used during vascular-enhanced magnetic resonance imaging procedures. The agent, called ferumoxytol, improves the assessment of peripheral arterial disease in patients with known or suspected chronic kidney disease, or CKD, the company said. [Boston Globe, Aug 21, 08]

AMAG Pharmaceuticals fell 13% after [a broker] recommended investors sell shares of the Cambridge, Mass., biopharmaceutical company, saying it believes development of the company's drug to treat iron-deficiency anemia won't get FDA approval without an additional trial. [Wall Street Journal, Apr 10, 08]

AMAG Pharmaceuticals up 10% [Mar 24, 08]

AMAG Pharmaceuticals down 10% [Jan 30, 08] after reporting that mortality rates for patients taking the experimental iron deficiency treatment ferumoxytol were lower compared with those taking oral iron pills.

AmberWave Systems (Salem, NH)

AmberWave Systems (Salem, NH; one SBIR) is partnering with the University of New Hampshire after receiving a "Granite State Technology Innovation Grant" from the New Hampshire Innovation Research Center (NHIRC). Amount unstated founded in 1999, has raised more than $91M in private funding . ...The NHIRC grant combines funding from the state of New Hampshire with federal dollars from the National Science Foundation's Experimental Program to Stimulate Competitive Research - EPSCOR, a program designed to hand money to the "have-not" states. So, why does a company that attracts $91M private capital need, or accept, a tiny "have-not " grant? Any free dollar is a good dollar even if it diverts attention from the serious business of making a profit in the competitive markets?

Amber Wave (Salem, NH) settled all its strained silicon patent infringement lawsuits against Intel. [Mass High Tech, Mar 6]

AmberWave Systems (Salem, NH) raised another $21M in VC money to bring its total to $66M. If all goes as planned, Amber Wave will bring its strained silicon for semiconductors to a profitable market. Back in the late 90s, during the IT bubble, Amber Wave got one SBIR for $1M from BMDO (now MDA) although not for strained silicon. If any company, like Amber Wave, wanted similar SBIR money this summer, it would have a hard time finding any DOD topic open to broad impact technology like semiconductors. DOD wants ready-to-go projects that produce a hard product (or some vague math model) for a specific program. What happened to all the broad thinkers?

AMBP Technology (Buffalo, NY)

Ready for the Factory Floor. Another MBE SBIR, one of a gazillion in 15 years, says it is preparing for the factory floor. AMBP Technology (Buffalo, NY), a spin off from the University of Buffalo, got a BMDO Phase 2 SBIR to combine laser heating and MBE to deposit thin metal films at a market price. The Buffalo News story March 19 says the academic types will get financing from NJ businessman Gary Tompa (who has had SBIRs in at least two other companies), now company president. While the technology sounds wonderful, - as they all do - MBE has usually been too expensive for market-competitive cost chips. Says founder Jim Garvey, There's really no technology hurdles I anticipate. Tompa must have told the two academics that BMDO wasn't going to fund their nice research in their 1997 SBIR Phase 1. Either find a credible commercialization route, or apply to some other SBIR program. After a couple of years (BMDO gives the Phase 1s whatever time is needed) to round up a credible story, they got $900K Phase 2, no doubt with the usual contingency clauses about co-investment and continuing technical credibility. SBA will probably gnash its bureaucratic teeth at the co-investment clause that guarantees that SBIR money has market attention.

Ambrx (San Diego, CA)

Bristol-Myers Squibb will pay drug developer Ambrx (San Diego, CA; no SBIR) at least $24 million to develop and commercialize drugs derived from a protein targeting type 2 diabetes and a hormone that has shown promise for treating heart failure, the companies said. .... the fourth strategic partnership signed by Ambrx since 2007. It gives Bristol-Myers worldwide rights to research, develop and sell drugs that come out of the Ambrx programs. [Keith Darce, signonsandiego.com, Sep 22, 11]

American Science and Engineering

American Science and Engineering said that it has received a $17.5 million order for cargo X-ray inspection systems from a Middle East client. [Chris Reidy, Boston Globe, Nov 7, 11]

American Science & Engineering down 14% [Aug 5, 11]

American Science and Engineering said it has been awarded a contract with a potential value of up to $248.5 million to provide the US Department of Defense with inspection systems that can screen cargo and people. [Chis Reidy, Boston Globe, Jum 29, 11]

American Science and Engineering announced today the receipt of a $16.3 million order for Z Backscatter Vans that make use of the detection technology. [Boston Globe, Feb 22]

American Science and Engineering won a $14 million contract from the U.S. Department of Homeland Security [Mass High Tech, Jan 18, 11]

American Science and Engineering said it has received a $5.5 million order from Abu Dhabi Customs Administration for some of its products. [Boston Globe, Jan 12, 11]

American Superconductor said that it has received an order from a South Korean firm for more than $10 million in wind turbine electrical control systems. [Kyle Alspach, Mass High Tech, Jan 4, 11]

American Science and Engineering said it has received a $3.8 million government order for military trailers equipped with its detection gear. [Boston Globe, Dec 22]

American Science and Engineering has been awarded an additional order valued at $4.9 million under its US government contract for Z Portal vehicle screening systems. [Boston Globe, Dec 9, 10]

American Science and Engineering announced the receipt of a $10 million order from the US government for the service and maintenance of military trailers that use the company's screening technology. [Boston Globe, Sep 16, 10]

American Science and Engineering said it has received a $42.2 million service and maintenance renewal order from the US government to extend support of the screening systems that the company provides to the government. [Boston Globe, Sep 10, 10]

American Science and Engineering said it has landed a $5.3 million follow-on order for its X-ray-based Z Backscatter Vans for a customs agency in an unnamed Latin American country. [Mass High Tech, Jul 26, 10]

American Science and Engineering said it has received a $23 million order for a significant quantity of its SmartCheck Inspection Systems that will be used by an "undisclosed government agency." [Boston Globe, Jul 22, 10]

American Science and Engineering said it received a $7.3 million order from the US government for vans that provide mobile screening systems. [Boston Globe, Jul 16, 10]

American Science and Engineering said that it has received a $8.3 million award for its Z Backscatter Vans from a Latin American customs agency. [Boston Globe, Jul 8, 10]

American Science and Engineering received a $6.7 million order from the U.S. government for its ZBV military trailers. [Mass High Tech, Jun 28, 10]

American Science and Engineering said that US Customs and Border Protection has terminated a $11.8 million contract. [AP, May 21, 10]

American Science and Engineering announced the receipt of a $13.9 million order from the US government for its Z Backscatter Van X-ray screening systems. [Boston Globe, May 10, 10]

American Science and Engineering announced today the receipt of a federal order for its ZBV military trailers that could be worth up to $48.8 million. [Boston Globe, Apr 23, 10]

American Science and Engineering said it received a $2.5 million service and maintenance order for X-ray systems from the US government. ... to support the Z Backscatter Van (ZBV) X-ray inspection systems for "strategic missions in harsh environments." [Boston Globe, Mar 29, 10]

American Science & Engineering reports it has brought in $8.2 million for cargo inspection systems from an unnamed customer. [Mass High Tech, Mar 22, 10]

American Science and Engineering reports it has landed $5.8 million from an unnamed Middle Eastern customer for cargo inspection equipment. [Mass High Tech, Jan 5, 10]

American Science and Engineering rose 5.3% after an unnamed government agency placed a $39.7 million order for cargo X-ray inspection systems to screen cargo and vehicles for explosives at border crossings. [Wall Street Journal, Jan 5]

American Science & Engineering reports it has landed $7.3 million for its parcel inspection systems. Under the deal, AS&E will provide its Gemini parcel inspection systems to an unnamed Middle Eastern customer. [Mass High Tech, Dec 22, 09]

American Science and Engineering received a $9.1 million order from U.S. Customs and Border Protection to supply its cargo and vehicle inspection systems. [Mass High Tech, Oct 27, 09]

American Science and Engineering reports it has landed $18.2 million from a Saudi Arabian company for vehicle inspection systems to be used at customs stations in Saudi Arabia. [Mass High Tech, Oct 1, 09]

American Science and Engineering announced the receipt of a service contract award for up to $28.2 million from the US government to provide service and maintenance for the company's Z Backscatter Van X-ray inspection systems. [Boston Globe, Sep 16, 09]

American Science and Engineering won an $11.5 million renewal order from the U.S. government to handle service and maintenance on the company’s Z Backscatter Vans and ZBV Military Trailers — two systems used in counterterrorist measures. [Mass High Tech, Aug 20, 09]

American Science and Engineering landed an $8.6 million follow-on order of Z Portal X-ray screening systems for Abu Dhabi Customs Administration [Mass High Tech, Jul 9, 09]

American Science and Engineering reports it has won a patent infringement suit against three New Jersey companies. [Mass High Tech, Jun 15, 09]

American Science and Engineering which also declared a regular dividend landed $2.2 million from an unnamed European customs agency for service and maintenance on cargo X-ray inspection systems.. [Mass High Tech, May 14, 09]

American Science and Engineering reports it has landed $4.7 million from an unnamed law enforcement agency for its cargo screening vans. [Mass High Tech, May 4, 09]

American Science and Engineering reports it has landed $4.4 million from an unnamed U.S. government agency for maintenance on its cargo inspection vans. [Mass High Tech, Apr 27, 09]

American Science and Engineering won a $6.3 million follow-on order from an unnamed client in the Middle East for an unspecified number of its Z Portal cargo and vehicle screening systems. [Mass High Tech, Apr 2, 09]

American Science and Engineering said it has received a $2.9 million order for its Z Backscatter units. [Boston Globe, Feb 21, 09]

American Science and Engineering announced today the receipt of a $67.1 million order from the US government for ZBV military trailers. [Chris Reidy, Boston Globe, Jan 15]

American Science & Engr up 11% [Jan 8, 09]

American Science & Engineering up15% [Nov 11, 08] after the company reported a 63 percent rise in its fiscal second-quarter earnings. [Boston Globe, Nov 12]

American Science & Engineering said its profit climbed 63% in the fiscal second quarter. [Boston Globe, Nov 10, 08]

American Science and Engineering announced the receipt of a multi-year $12.5 million service order to provide service, maintenance, training, and spare parts for multiple cargo systems. [Boston Globe, Sep 17]

American Science and Engineering said that the company has received a $22M order from the USG. .... for 22 Z Backscatter Vans, or ZBVs, a mobile X-ray screening system, the company said. [Boston Globe, Aug 25, 08]

American Science and Engineering got a $2.6 million order for its mobile X-ray detection system from a Middle East government agency [Boston Globe, Jul 31]

American Science and Engineering reports it has landed a $15.5 million contract from the U.S. government for service on its x-ray systems. [Mass High Tech, Jul 28, 08]

American Science and Engineering reports it has won $55 M from a customs agency in the United Arab Emirates for its X-ray detection systems, including its OmniView, Z Portal and Z Backscatter Van detection systems. [Mass High Tech, Jul 2, 08]

The U.S. government has awarded American Science and Engineering a $3.4 million service, support and maintenance order for AS&E’s Z Backscatter Vans, completing the multi-year contract totalling $46.2 million . [Mass High Tech, Jun 24]

American Science and Engineering , a maker of X-ray inspection systems, said it received a $9.2 million contract to supply a Latin American customs agency. [Boston Globe, May 14]

American Science and Engineering got a $3.4M contract for X-ray technology from a unnamed Middle Eastern customer. [Mass High Tech, Oct 2, 07]

American Science and Engineering says it is developing X-ray systems for a secret undisclosed government agency in Africa, which if AS&E is lucky will pay its bills from the proceeds of its customs bribery.

American Science and Engineering won a $5.9 M contract with an undisclosed agency of the U.S. government for service and maintenance work on AS&E's mobile screening systems, known as Z Backscatter Vans. [Mass High Tech, Sep 12, 07]

American Science and Engineering got a $10.8M contract from the TSA for the lease of five of the company's SmartCheck screening systems, with an option to acquire an additional 75. [Boston Globe, Aug 9, 07]

American Science and Engineering got a $17M government order for detection systems [Mar 07]

the best chance for investors to cash in on the security trend is with the pure-play small fry (albeit ones with commercial applications, too). His favorites have market caps of $2 billion or less ... a lot of customers for American Science & Engineering Peters likes its X-ray technology, called the Z Backscatter, which goes beyond traditional security X rays because it can pick up nonmetallic objects. ... The company, which is profitable, has a large order backlog [Forbes, Mar 26, 07]

TSA has begun testing American Science and Engineering Inc.'s SmartCheck personal screening system at Sky Harbor International Airport in Phoenix, [Mass High Tech, Feb 23, 07]

American Science and Engineering got a $2.2M government contract to deliver a 'ruggedized' Z Backscatter Van X-ray-based explosive detection system. AS&E reported an annual net income of $30M. [Mass High Tech, Nov 6, 06]

American Science and Engineering got a $13M deal from NATO for x-ray inspection of cargo, parcel and personnel. [Nov 06]

Hate Nasty Surprises. American Science and Engineering said fiscal first-quarter earnings fell as expenses for stock options and a higher tax bill cut into the bottom line. The results badly missed Wall Street expectations, sending the company's shares tumbling. Down 17%. [AP, Aug 9, 06]

American Superconductor

American Superconductor said it has reduced its workforce by more than 20 percent in order to lower the company’s cash usage as it works toward a return to profitability. That amounts to more than 100 jobs. [Chris Reidy, Boston Globe, Nov 29, 11]

American Superconductor is seeking more than $1.2 billion in damages and payments for contracted shipments from its once-largest customer, a Chinese wind turbine maker accused of stealing the Devens firm’s technology. [Erin Ailworth, Boston Globe, Nov 10, 11]

American Superconductor down 10% [Nov 10, 11]

American Superconductor canceled a deal to buy Finland’s The Switch Engineering Oy, citing “adverse market conditions.” [Bloomberg News, Oct 31, 11]

American Superconductor renaming itself to AMSC. When it launched nearly 25 years ago [in the burst of HTSC start-ups], the company’s sole focus was superconductors. It has since branched out into other related fields, such as providing wind turbine designs and wind turbine components. Its footprint, once largely confined to the US, now has global reach. [Chris Reidy, Boston Globe, Oct 17, 11]

At the end of a week when American Superconductor reported annual and quarterly losses, the company’s largest investor bought up almost a million shares. ... [to] just over 23 percent of AMSC’s stock [James Connolly, Mass High Tech, Oct 5, 11]

American Superconductor down 13% [Oct 3, 11]

American Superconductor down 12% [Sep 30, 11]

American Superconductor up 15% [Sep 29, 11]

A second-generation superconductor wire made by American Superconductor has been switched on in Korea’s electricity grid. ... [AMSC] said that this is the longest second-generation superconductor cable to be in use in a grid anywhere in the world. According to AMSC, its superconductor power cable systems can conduct up to 10 times the amount of power of conventional cables made with copper wire. [Chris Reidy, Boston Globe, Sep 29, 11]

American Superconductor up 14% [Sep 23, 11]

A former employee of American Superconductor was convicted in Austria on criminal charges in a corporate espionage case linked to China's biggest manufacturer of wind turbines. .... had been selling Sinovel components and software that control the productivity and power quality of wind turbines, as well as licensing its turbine designs. It began to suspect something was awry when Sinovel earlier this year rejected a large shipment of control components, company officials said. [Rebecca Smith, Wall Street Journal, Sep 24, 11]

American Superconductor down 11% [Sep 16, 11]

American Superconductor down 15% [Sep 15, 11]

American Superconductor is filing both criminal charges and civil complaints against its one-time largest customer, China’s Sinovel Wind Group Co. Ltd. over alleged theft of AMSC’s intellectual property about its wind turbines, stemming from a corporate espionage case. [Rodney Brown, Mass High Tech, Sep 15, 11]

American Superconductor up 14% [Aug 23, 11]

American Superconductor received a notice from the Nasdaq stock exchange warning the company that it is in danger of being dropped from the exchange because it failed to file quarterly financial statements [ Mass High Tech, Aug 22, 11]

American Superconductor up 12% [Aug 12, 11]

American Superconductor said that it has reduced its global workforce by about 30 percent following issues with its largest customer. [Chris Reidy, Boston Globe, Aug 11, 11]

American Superconductor up 12% [Aug 9, 11]

American Superconductor down 10% [Aug 4, 11]

American Superconductor disclosed that it expects to restate its results for two recent quarters, reducing its expected revenue by 35 percent for the quarters. [Mass High Tech, Jul 12, 11]

American Superconductor said it has been granted more time to secure financing for the planned $265 million acquisition of a Finnish power technologies firm ..faced financial upheaval since its largest customer, Chinese wind power firm Sinovel Wind Group Co., refused to accept shipments of wind turbine components in April. [Mass High Tech, Jul 1, 11]

American Semiconductor down 24% [Jun 1, 11] after it disclosed late yesterday that it did not file its 10K for the fiscal year ended March 31 by the SEC-mandated May 31 deadline; it has filed with the SEC requesting an extension. American Superconductors said it needs more time due in part to “a review of certain revenues associated with shipments to customers in China” in Q2, Q3 and Q4. The company said it expects to reverse recognition of a “material amount of revenue” it had included when estimating in an April 5 press release that revenue would be less than $355 million. In other words, even $355 million now looks too high. [Eric Savitz, Forbes, Jun 1]

American Superconductor down 42% [Apr 6, 11] after its largest customer [Beijing-based manufacturer Sinovel Wind Group] refused to accept a shipment [Randall Hackley and Marc Roca, Bloomberg, Apr 6]

American Superconductor’s largest investor, a wealthy telecommunications businessman, continued his string of major buys in the company with a $5.2 million stock purchase this week. [Mass High Tech, Mar 25, 11]

American Superconductor said it plans to acquire The Switch Engineering Oy, a power technologies firm based in Finland, for 190 million Euros (about $265 million) in cash and stock [Gregory Huang, xconomy.com, Mar 14, 11]

American Superconductor said it has received initial orders for a wind turbine electrical control system from China’s third largest wind turbine manufacturer. [Mass High Tech, Mar 2, 11]

American Superconductor up 10% [Feb 1, 11]

Confidence and long-term view. Wealthy investor Kevin Douglas bought $8.5 million in shares of American Superconductor last week as he continued to add to his holdings [to 14%] [Wall Street Journal, Jam 26, 11] Also, American Superconductor said it has received a $9 million follow-up order for the supply of wind turbine electrical control systems from a customer in India. [Boston Globe, Jan 25]

American Superconductor said it has received orders from a British company building wind farms. [Boston Globe, Jan 18, 11]

American Superconductor said it licensed wind turbine designs to a new customer in China, marking the company’s sixth customer in the country. [Mass High Tech, Jan 11, 11]

American Superconductor expects to raise about $155.1 million for "general corporate purposes" through a public offering of common stock [Mass High Tech, Nov 11, 10]

American Superconductor up 12% [Nov 2, 10] on news of higher sales, profits, and future

One large insider of American Superconductor bought $38M in shares and the CEO sold $9M. [Wall Street Journal, Oct 16, 10]

American Superconductor said it has received the world’s largest order for high-temperature superconductor wire in a deal with a South Korean firm. ... the Amperium wire is the company’s second generation of superconductor wire, and can conduct more than 100 times the electrical current of copper wire of the same dimensions. [Kyle Alspach, Mass High Tech, Oct 6, 10]

American Superconductor is expanding deeper into India with an order from a new Indian firm for wind turbine electrical control systems. The order – for 17 systems that will be deployed in 2-megawatt, doubly-fed induction wind turbines [Mass High Tech, Aug 24, 10]

American Superconductor acquired a 25% stake in Blade Dynamics Ltd.,a U.K.-based designer and manufacturer of wind turbine blades, the company announced for $8 million in cash [Mass High Tech, Aug 17, 10]

American Superconductor said that first-quarter net income was $9.2 million compared with net income of $1.8 million for the same quarter a year ago. [Boston Globe, Jul 29, 10] Ultimately, subsidy programs like SBIR have to be judged on profits and taxes that result from government investment in untried technology. Yakking about jobs as a criterion gets enmeshed in counting jobs paid for by the subsidy. Most of the hype about SBIR, as practiced for nearly three decades, as a job engine is bunk.

American Superconductor issued a press release that claims that nearly 10 percent of the world's wind-generated electricity is "powered by AMSC." [Boston Globe, Jun 15, 10]

American Superconductor has expanded its alliance with a South Korea-based company to jointly develop a 5-megawatt turbine to be used primarily in offshore wind farms. [Mass High Tech, Jun 11, 10]

American Superconductor received a $445 million order for its turbine electrical systems from Sinovel Wind Group Co. Ltd. in China. [Erin Ailworth, Boston Globe, May 18, 10]

American Superconductor says it will develop the world’s highest-capacity wind turbines, hoping to capitalize on an expected boom in offshore wind farm construction. [its] SeaTitan turbine will use high-temperature superconductor wire manufactured at its plant in Devens, which employs 200 people. American Superconductor officials said they anticipate the offshore market for large-capacity wind turbines to reach $1 billion by 2016. [Boston Globe, May 5, 10]

American Superconductor furthers its reach into the Asian markets with a $20 million initial order for electrical control systems wind turbines from India’s Ghodawat Energy Pvt. Ltd. .... will start shipping parts under the deal in the middle of this year, officials said. [Mass High Tech, Apr 6, 10]

American Science and Engineering announced the receipt of a $11.8 million order from US Customs and Border Protection for cargo and vehicle inspection systems. [Boston Globe, Apr 2, 10]

American Superconductor said it has received an order from an Australian company for a large grid interconnection system. [Boston Globe, Apr 1, 10]

A director of American Superconductor bought $2.6M of stock which is down 32% for the YTD despite many reports of new sales. [Wall Street Journal, Mar 27, 10]

American Superconductor said it has received another order from China’s largest wind turbine manufacturer. .. To date, it said it has received more than $700 million in orders from Sinovel. [Boston Globe, Mar 22, 10] Wall Street's analysts also expect it to make big profits in the next few years. Also said it is expanding its alliance with LS Cable Ltd., a power cable manufacturer headquartered in South Korea. [Boston Globe, Mar 24, 10]

American Superconductor reports it has landed $10 million from a Chinese company for electrical components for wind turbines. [Mass High Tech, Mar 8, 10]

American Superconductor down 10% [Feb 2, 10]

American Superconductor won a $70 million initial order from China’s Shenyang Blower Works (Group) Co. Ltd. for full wind turbine electrical control systems, to be used in wind turbines that were co-developed with its subsidiary AMSC Windtec.[Mass High Tech, Feb 1, 10]

American Superconductor said that it has received a follow-on order for $10 million worth of wind turbine core electrical components from CSR Zhuzhou Electric Locomotive Research Institute Co. Ltd. in China. [Boston Globe, Nov 17, 09]

American Superconductor up 23% [Oct 29, 09] posted better-than-expected quarterly results, powered by a booming Chinese wind industry, a key growth driver for the company. [Reuters, Oct 29]

American Superconductor has been chosen to supply its superconducting powerline “pipeline” technology to the Tres Amigas Project, the first renewable energy market hub in the country that, for the first time, interconnects the three major U.S. power grids. The company has also take a minority stake in the entity that runs the hub, Tres Amigas LLC, for $1.75 million in cash and AMSC stock. [Mass High Tech, Oct 13, 09]

American Superconductor up 10% [Sep 30, 09]

American Superconductor said that it has signed a $100 million-plus contract with Beijing-based Sinovel Wind Corporation Limited. ... to supply core electrical components that the Chinese company will use for wind turbines. [Boston Globe, Sep 30, 09]

American Superconductor said in a press release that it has formed AMSC Korea to serve South Korea rapidly growing wind energy and power grid markets. [Boston Globe, Sep 24, 09]

American Superconductor down 12% [Sep 21, 09] after a broker cut its investment rating on the company's stock to "hold" from "buy." [Wall Street Journal, Sep 22]

American Superconductor said it has formed a unit called AMSC India to serve India’s rapidly growing wind energy and power grid markets. [Chris Reidy, Boston Globe, Sep 09, 09]

American Superconductor said that it has received its second order for a D-VAR system to meet dynamic reactive compensation requirements for a power grid in China. [Chris Reidy, Boston Globe, Aug 26, 09]

American Superconductor reports that Beijing-based Sinovel Wind Corp. Ltd. increased the size of its contract to more than $470 million to meet greater demand for its wind turbines in China. That and other deals pushed AMSC to its second profitable quarter in a row. [Mass High Tech, Jul 30]

American Superconductor said it has received $12 million in U.S. Department of Energy [so-called stimulus] funding for work on smart grid demonstration projects. ... to develop a 138 kilovolt fault current limiter using the company’s superconductor wires. ... also received $7.6 million to fund the second phase of its superconductor power cable project with the Long Island Power Authority. [Mass High Tech, Jul 21, 09] Whether it's stimulus or pork depends on whether you got the money.

American Superconductor said it reported its first quarterly profit in company history, [Boston Globe, May 15,09]

American Superconductor received an order worth more than $10 million from ACCIONA Energy, a division of Spanish wind developer ACCIONA SA, for its newly released Dynamic VAR Ride Through (D-VAR RT) product. [Mass High Tech, May 13]

American Superconductor down 14% [May 7, 09]

American Superconductor up 10% [May 4, 09]

American Superconductor up 10% [Apr 22, 09]

American Superconductor landed a new deal for its 344 Superconductor Wire from LS Cable Ltd. of South Korea. ..... ordered 80,000 meters (50 miles) of AMSC’s proprietary brand of second-generation (2G) high-temperature superconductor [Mass High Tech, Apr 20, 09]

American Superconductor said it received a new order from Shanghai Electric Cable Research Institute for its high temperature superconductor wire. [Boston Globe, Apr 1, 09]

American Superconductor up 12% [Mar 26, 09]

American Superconductor up 15% [Mar 10, 09]

American Superconductor up 13% [Mar 4, 09]

American Superconductor down 10% [Feb 27, 09]

American Superconductor down 11% [Feb 23, 09]

American Superconductor reported a loss for the latest quarter that was 6%greater than a year ago. ... reported a burgeoning backlog: $602 million, up from $168 million a year ago ... expects to post a net loss for the full fiscal year of $17 million [Boston Globe, Feb 3, 09] All those sales don't necessarily mean self-sustaining profits. Which is the problem with SBIR's trumpeting follow-on sales as a measure of economic success. You can sell a lot of stuff if you're willing to mark the price down to where you will eventually go bust.

Job Stimulus Beneficiaries? Asia. A recent study by the Renewable Energy Policy Project in Washington, D.C., found that each megawatt of wind capacity installed in the U.S. creates 4.85 full-time jobs, of which 3.4 come from making components -- which is done mostly outside the U.S .... The American Wind Energy Association said this past week that wind suppliers expanded or added 55 facilities last year. But that increase has been outstripped by growth abroad. American Superconductor designs wind turbines and licenses its designs to other companies, then helps them build manufacturing facilities. In recent years, it has inked deals with a dozen companies, none of them American. One customer, South Korea's Hyundai Heavy Industries Co., is "specifically targeting the U.S. market," said Greg Yurek, chief executive of American Semiconductor. Korea's government said last week it is investing $4.37 billion to help Korean companies close the technology gap in 15 energy-product areas including wind, solar and battery technology. [Rebecca Smith, Wall Street Journal, Jan 31]

American Superconductor has received a new order for 100 sets of its wind turbine core electrical components from China [Mass High Tech, Jan 22, 09]

American Superconductor up 11% [Jan 15, 09]

American Superconductor said the US Navy successfully tested a 49,000 horsepower ship propulsion motor that includes the company's technology. [Boston Globe, Jan 13, 09]

American Superconductor said that it has received its first order for a D-VAR system to meet dynamic reactive compensation requirements for a 220 kilovolt power transmission grid in Chifeng, Inner Mongolia, China. [Boston Globe, Jan 7, 09]

American Superconductor up 10% [Dec 16, 08]

American Superconductor down 10% [Dec 11, 08]

American Superconductor up 13% [Dec 8, 08]

American Superconductor up 13% [Dec 5, 08]

American Superconductor expects revenues will grow to a range of $175 million to $185 million in its fiscal 2008 from approximately $112 million in fiscal 2007. The company also maintained its net loss guidance of $13 million to $15 million ... For fiscal 2009, the company expects to grow revenues to more than $225 million with gross margin in the range of 28 to 30 percent. The company also expects to be profitable on a GAAP basis for full year fiscal 2009." [Boston Globe, Dec 4, 08]

American Superconductor up 13% [Dec 2, 08]

American Superconductor down 16% [Dec 1, 08] On a stock bloodbath day

American Superconductor up 20% [Nov 26, 08]

American Superconductor up 21% [Nov 24, 08]

American Superconductor up 13% [Nov 21, 08]

American Superconductor said it has agreed to help a Chinese manufacturer become a wind-turbine supplier. ... has signed an agreement with Shenyang Blower Works Co. Ltd., a Chinese industrial equipment manufacturer with about $1 billion in annual sales. [Boston Globe, Nov 18]

American Superconductor down 12% [Nov 14, 08]

American Superconductor up 10% [Nov 13, 08]

American Superconductor down 14% [Nov 12, 08]

American Superconductor down 10% [Nov 6, 08]

American Superconductor up 17% [Nov 4, 08]

American Superconductor up 13% [Oct 30, 08]

American Superconductor said that it has received an order for four systems that will be used to improve pumping-station performance for a major crude-oil pipeline. [Boston Globe, Oct 30]

American Superconductor down 11% [Oct 27, 08]

American Superconductor down 12% [Oct 23, 08]

American Superconductor down 13% [Oct 22, 08]

American Superconductor up 15% [Oct 16, 08]

American Superconductor continues to make deals around its wind power technology, reporting that it has licensed a pair of its proprietary wind turbine designs to industrial giant Hyundai Heavy Industries Co. Ltd. of South Korea. [Mass High Tech, Oct 15, 08]

American Superconductor down 13% [Oct 15, 08]

American Superconductor up 24% [Oct 13, 08]

American Superconductor reports it has entered into a contract to design wind turbines for XJ Group Corp. of China. [Mass High Tech, Oct 8, 08]

American Superconductor down 12% [Oct 7, 08]

American Superconductor down 19% [Oct 6, 08]

American Superconductor down 12% [Oct 2, 08]

American Superconductor reports it has entered into a contract to design wind turbines for XJ Group Corp. of China. [Mass High Tech, Oct 8, 08]

American Superconductor down 12% [Oct 7, 08]

American Superconductor reports it has manufactured and shipped approximately 17,000 meters (56,000 feet) of its proprietary second-generation, high-temperature superconductor (HTS) wire for use in Project HYDRA, in New York. According to company statements, the shipment is the single largest shipment of 2G HTS wire by any company worldwide. [Mass High Tech, Oct 2, 08]

American Superconductor down 19% [Oct 6, 08]

American Superconductor down 12% [Oct 2, 08]

American Superconductor up 12% [Sep 29, 08]

American Superconductor up 13% [Sep 19, 08]

American Superconductor up 21% [Sep 18, 08]

American Superconductor doubled for the first half of 2008. The business is young and hasn't returned a profit yet, but Jesup & Lamont says sales from the wire could be profitable as early as 2010. [Roya Wolverson, Smart Money, Sep 08]

American Superconductor down 10% [Sep 9, 08]

American Superconductor down 10% [Jul 23, 08]

Twenty years later, the [superconducting] cables are snaking into commercial settings. ... American Superconductor supplied three to a Long Island Power Authority site in Hauppauge, N.Y. The lines are only about 600 meters long, but can move 50 times as much electricity as like-sized conventional cables. Expensive superconductors make the most sense in high-cost areas. Next up: New York City, where such cables may soon be used in Consolidated Edison's overstuffed manholes. [Adam Aston, Business Week, Jul 17, 08]

American Superconductor up 19% after it said it received a $450 million follow-on order to supply core electrical components for wind turbines from Beijing-based Sinovel Wind Corp, [Reuters, Jun 10]

American Superconductor licensed one of its proprietary wind turbine designs to TECO Electric & Machinery Co. Ltd. of Taiwan. [Boston Globe, Jun 6, 08]

American Superconductor up 10% [May 28, 08]

American Superconductor up 33% [May 8, 08] as its fourth-quarter loss narrowed 84 percent on wind power and electric utility sales. Net loss dropped to $1.8 million or 4 cents per share from $11.4 million in 2007. Sales more than doubled to $38.4 million from $19.1 million. [Boston Globe, May 8]

As part of an ongoing relationship with Beijing-based Sinovel Wind Corp. Ltd., power systems company American Superconductor received a new order from the wind developer worth more than $18 million, officials say. [Mass High Tech, Apr 2, 08]

American Superconductor got two new orders, one in Mississippi and one international, for its D-VAR voltage control products. Although revenues keep rolling in they can't keep up with expenses and the double-digit millions losses keep rolling also. [Feb 12,08]

American Superconductor claimed $3M in orders for its wind turbine components.

American Superconductor said it received a Department of Homeland Security contract for a project that aims to improve Manhattan's power delivery network. ... will provide up to $25 million in total funding for the $39 million project [Boston Globe, Jan 24, 08]

American Superconductor down 12% [Jan 17, 08] It was up 178% last year.

American Superconductor down 11% [Dec 17, 07]

American Superconductor is responding to growing demand in China with the formation of a new division known as "AMSC China" in Suzhou [Mass High Tech, Oct 30, 07]

American Superconductor is partnering with Texas-based TECO-Westinghouse Motor Co. to co-develop high-temperature superconductor (HTS) wire and related technologies for high-power wind generators for offshore wind farms. The 30-month research partnership is being funded in part with $3.4 in tandem funding from the National Institute of Science and Technology's Advanced Technology Program, which represents approximately half an estimated $6.8 million project price tag, according to the companies. [Mass High Tech, Oct 3, 07]

Congressional investigators have asked American Superconductor. to hand over documents and communications as part of their probe into one of the firm's government contracts [Wall Street Journal, Aug 28]

American Superconductor up 17% after getting a BUY rating. [Aug 8, 07] Meanwhile, Motley Fool is projecting a 24% stock dilution soon.

Windborne. American Superconductor got a follow-on $70M order for wind turbine electrical systems from Beijing-based Sinovel Wind Corp.

On the eve of tapping the public markets for as much as $100M , American Superconductor disclosed that one of its key government contracts is under investigation for potential violation of government contract-award rules. ... Shares have soared more than 55% since the May 21 announcement that it had been awarded the contract to develop technology for structurally secure power grids in New York in partnership with ConEd. [Karen Richardson, Wall Street Journal, Jul 23]

American Superconductor filed to raise $100M by selling stock. [Jun 07]

American Superconductor to be buried in New York, as ConEd installs superconducting electrical cable in midtown Manhattan largely funded by the DHS to harden the electrical infrastructure of critical national assets. Regardless of how many red states vote against evolution, the sine qua non assets are in the coastal metropoli. AMSC CEO said "We hope this breaks the logjam," as he smiled over the federal funding that he doesn't have to find the money for since everything is free from the government. Isn't it? Of course, ConEd will be raising its rates to pay for its share of the project. AMSC stock jumped 18%.

American Superconductor's Austrian subsidiary made an $8M wind power deal with China. [Mar 07]

Investors go hot and cold on alternative energy. But the wind isn't going away, nor is the emerging world's booming growth. Steven Syre [Boston Globe, Mar 8] has a friendly piece on prospects for American Superconductor after years of steady losses.

American Superconductor down 11% [Mar 5, 07]

American Superconductor got enough new orders from wind farm operators to boost its stock 16% [Feb 28, 07]

American Superconductor up 10% [Feb 26, 07]

South China Wind. American Superconductor made a $30M deal with a South China utility for a wind energy system made by AMSC's new formerly Austrian subsidiary. Last week it made a deal with a Korean maker of electric drive systems. [Mass High Tech, Jan 23]

American Superconductor signed a strategic business alliance with China's Shanghai Electric Cable Research Institute (SECRI) aimed at developing and promoting the use of its high temperature superconductor (HTS) power cables in China [Mass High Tech, Oct 31]

Not surprisingly the Navy is giving American Superconductor $5M to help get it AMSC's just produced super-duper HTSC propulsion motor into the fleet. The contract is the first in what AMSC expects to be a series of contracts from the U.S. Navy aimed at optimizing the motors and power electric drives for use in future surface combatants and other classes of naval ships, according to Greg Yurek, chief executive officer and founder of AMSC. [Mass High Tech, Oct 25]. SOP for new high tech stuff.

American Superconductor reports $4.6 million in new orders for voltage regulation systems at English-speaking wind farms in Australia, Canada, New Zealand, and the United Kingdom.

American Superconductor jumped 25% when it announced a nearly Holy Grail - commercial levels of electric current for the first time in long lengths of second generation (2G) high temperature superconductor (HTS) wire.

American Superconductor jumped 13% on news of booking orders for more than a mile of HTS wire. [Jan 06]

American Superconductor got a $10M add-on to its original $70M Navy contract for a 36.5 megawatt high temperature superconductor propulsion motor for electric warships to be delivered to the Navy in Philadelphia in September 2006. The USAF also chipped in $13M for costs associated with a high-temperature superconducting factory planned for Devens. AMSC is not a life-style company. American Superconductor got a $5.35 M DOD Title III contract to scale-up of its manufacturing of second generation high temperature superconductor wire [Dec 05]

American Superconductor lost $4M even though backlog grew superbly.

Growing: Sales, Technology, Shares, Losses. American Superconductor lost another $5.6M in the quarter and saw shares increase 20%, which drives (earnings) per share in the wrong direction.The shrinking number of Wall Street analysts don't see any profits next year either. The company's press release said, Prospects for new orders for industrial and wind farm D- VAR® systems and the substantial likelihood of one or more new U.S. Navy contracts for HTS rotating machines, in addition to our current revenue visibility, continue to point to a stronger second half than first half. We are also encouraged by the imminent signing of the Energy Bill into law, which should give rise to additional orders and contracts. When your biggest customer is wind farms, you hope fervently that government subsidies to those farms will continue.

Madden: American Superconductor is a pioneer in HTS technology, with 395 patents to its credit. HTS is potentially disruptive in nature for applications that currently use copper wires such as power cables, generators, you name it. A long-term chart shows that AMSC is trading at the same levels it did at its inception in 1991. ... The [in-process energy bill] bill provides for $100M for each HTS-grid solution, or high-temperature-superconductivity solutions, which American Superconductor provides. As the only HTS play, AMSC is positioned to capture the lion's share, which is meaningful, given that last year its sales were $58 million. Also, the bill stipulates for the enforcement of higher reliability standards that were absent during recent blackouts in our country. The change in regulation bodes wells for American Superconductor, as they have established products that allow utilities to be compliant. [Barron's, Jul 25]American Superconductor fired its president after an employee complaint. But Monday it led the percentage gainers at 23%. [Jun 05]

Power from Wind and Cold. American Superconductor got an order for two voltage regulation systems for a 150-megawatt wind farm in Saskatchewan that will blow enough zero-emission energy to serve 64,000 homes. [Nov 04]

American Superconductor says it will start prep to scale-up to full pilot production after satisfying its benchmarks for a second-generation HTS wire. It says its wire reached 330 amps, 10% over DOE (the government)'s specs for 2G HTS wires. [Mass High Tech, Jul 27] DOE chimed in with happy words in the administration's efforts to promote US manufacturing (especially in the swing states of the fall election)

American Superconductor's projected loss for the first quarter offset any glee from a doubled revenue for the fourth quarter, and the stock took a 24% dive.

American Superconductor got a sub-contract of unstated value to develop an ignition system for electro-thermal chemical (ETC) guns, an advanced weapon technology for future artillery, battle tank and infantry fighting vehicle (a dream machine for DOD weaponeers) The firing system uses pulsed power to ignite the propellant used by an ETC gun. [Mass High Tech, Nov 24] The big problem is that the Army has a huge capital investment in solid propellant guns and is unlikely to abandon it in favor of a completely new type with a marginal advantage and a huge logistcal problem.

American Superconductor will raise $50M in a public offering this week [Nov 03]

American Superconductor got a $400K award from DOD and Energy (DOE) for the first phase of a cost-sharing program of manufacturing scale-up for second generation (2G) high temperature superconductor (HTS) wire. If all goes well, Congress would pony up $10M for three year main course of a manufacturing plant. [facts from Mass High Tech, Oct 1] Why would an anti-industrial policy government build a commercial plant? There's a big election coming next year. That award is on top of a potential $2.5M award last week from DOE for the same wire.

American Superconductor won a contract to support remote power - voltage support to the electric power grid for Scotlands Orkney Islands. The idea is to protect the Orkney Islands' power supply from disasters like the loss of underwater power cables to the islands or too much variation in the wind power generation. [Mass High Tech, Sep 22] The Orkneys are a windswept group of islands an hour-plus ferry ride off Scotland's north coast. They Orkneys were the source of a lot of the workers for the Hudson Bay Company in the 19th century and a haven for gazillions of nesting seabirds (puffins, etc) in the spring and summer. Remote they are, although a mere stepping stone to their cousins the Shetlands even farther out, about half-way to Norway.

American Superconductor signed non-binding letters of intent to raise$50M including a five-year loan of up to $30M provided by a corporate finance company and several institutional investors. AS says it will use the money for working capital, general corporate purposes and scale-up of pilot manufacturing for the company's second generation (coated conductor composite) high temperature superconductor (HTS) wire.

Shares of American Superconductor jumped 20% yesterday when the company said it got a $70M Navy contract, its largest contract ever, for a prototype electric ship motor.

Not so Super Conductor Yet. American Superconductor sprang a leak in its plan to demonstrate HTSC cable in Detroit. Leaks in the thermal insulation system in the HTS cables point up a downside of the marvel of HTSC - an expensive maintanance system for cable temperature, especially 70K. CEO Greg Yurek put the best face on it, While a lot has been learned during the course of this project ... So goes high promise high tech in getting to actual profitable business.

Steady As She Goes. American Superconductor won a contract to supply electrical line stability with its D-VAR gizmo at a town in mid British Columbia. Start small, succeed, and maybe the world will copy. Says the company, The D-VAR system maintains steady-state voltage levels on transmission and distribution lines and also protects against other externally caused voltage disturbances -- such as those caused by large motors in manufacturing facilities. The D-VAR system is a mobile power reliability resource that utilizes AMSC's proprietary PowerModule(TM) power electronic converters to inject precise amounts of continuous and instantaneous reactive power (measured in VARs) into transmission grids to solve voltage regulation and dynamic voltage stability problems that otherwise may result in blackouts and brownouts. The traders were not impressed on the day Pres Bush said that he would frown on any company executive who does what he did on inside trading. AMSC still trades at a fourth of its 12-month high.

American Superconductor is laying off a fourth of its workforce, 100 workers as it combines Wisconsin units into one, which will make magnetic energy storage systems. Last month it won an $8M Navy contract for the first HTS motor for ship propulsion.

More Shipboard Power, Please
(Mar 7)American Superconductor says it got a $2.9M Navy (ONR) contract to develop architecture for onboard ship propulsion and other electrical components that will be required for the future all-electric Navy.CEO Greg Yurek said The Navy is looking for the fastest way to incorporate new technology into its next-generation ship propulsion and weapons systems, Of course, itf the Navy really wants it, why is the contract from ONR which is merely the research arm? Oh, never mind: money is money.

American Superconductor took a 13% hit on top of 11% the previous day as it reported larger losses than investors want to tolerate. Emcore dropped 17% in the soggy semiconductor industry. On the plus side, Embrex has held up well as better earnings are being reported in an industry not selling information technology.ViaSat got hit 17% despite a $2.5M DOD contract this month.

What's Uncool About the Money? After American Superconductor was listed as a participant in an $18M superconductor cable project from DOE, its stock plunged for two days. Down 16% the first day and 8% more the second day to a low price not seen since late 1998.

Revenues Hit, Stock Downgrade. American Superconductor reported halved revenues for the quarter and two brokers downgraded the stock. ``Our results for the first quarter were in line with our expectations,'' said Greg Yurek, chief executive officer. ``Taking into account the downturn in the economy and the regulatory confusion in the utility industry, we stated in April that we expected to achieve revenue in the range of $20 to $30M this fiscal year. We maintain that expectation.'' The temporary euphoria over HTS faded when California didn't run out of power this summer and energy prices tumbled.

Paul Grant, a superconductivity expert at the Electric Power Research Institute in Palo Alto, California points out that nobody in the superconductivity business is making money yet. Indeed, American Superconductor lost about $20M last year, and will probably not make a profit for at least another two years. Superconducting-wire technology has, though, made enormous progress. Manufacturers have increased the lengths of the wires they can produce many times over during the past few years, and have reduced the price considerably. Superconducting cable used to cost around $1,500 per kiloamp per metre, the standard industry measure of conducting capacity. Now, AMSC sells wire for $200 per kiloamp per metre, and expects to reduce the cost to about $50 per kiloamp per metre when it opens a new production plant next year. Reaching $25 per kiloamp per metre, the cost of copper cable, will take a little longer. The problem is no longer the cost of the ceramic itself, but of the metal casing. This is one cloud that is caused by its silver lining. [The Economist, Jul 14]

All is well, says American Superconductor,'s press release. American Superconductor is very well positioned with advanced, cost-effective solutions to meet critical power grid needs today. And we have a foundation in place to address significant growth in investment in the grid over the next 10 to 20 years. As the events of the last year have proven, the market is moving with greater speed in our direction. The solutions we offer - based on high temperature superconductor wire and solid-state power electronic switches - are timelier than ever. Alas, the market seems not to have understood as AMSC dove 5% after the release and remains about 60% below its last year's high.

Keeping Cool by Keeping Cold. American Superconductor got a 26% boost when it announced that Houston wants two more D-SMES units to keep cool in summer 2002. It already has two units for keeping cool in 2001. SMES is AMSC's patented means of storing prodigous amounts of electricity in a superconducting electromagnetic coil. California needn't pant after the stored electrons since Texas is pretty much an electric island outside any national scale grid. One Yahoo netster pooh-poohed, Face it folks, today's press relaease is not news but rather just another example of Yurek's spin machine. in that the two 2002 units had been announced earlier. Another wag notes, SMES would have a negligible effect on bulk transmission capability. It's just a little toy for low voltage transmission (115kv or less) or for distribution level stuff. Secondly, it will only help to increase power transfers for voltage (or angular) stability limited situations - which comprises a small fraction of existing limitations. With all that extra power, perhaps Houston can find a way to thin the traffic congestion on I-610.

American Superconductor cut its estimates of revenues and the traders cut their estimates of the stocks value. The company said it expected revenues for the fourth quarter of $2.5M, down from previous expectations of $5.5- 9M. For the fiscal year ended March 31, AMSC said it expected revenues of $16.8 million, and for fiscal 2002, it said it expected revenues of $20-30M.

American Superconductor keeps drifitng lower despite a recent apparent breakthrough in superconducting materials. Says AMSC, Superconducting magnesium diboride is a very brittle intermetallic compound. Thus, just as with HTS ceramic oxides, which are also inherently brittle materials, it will be a challenge to find ways to cost effectively manufacture flexible, durable wires from superconducting borides. ``American Superconductor is known for its world leadership in creating manufacturing methodologies to cost effectively produce usable wires out of inherently brittle materials - that is, to create ways to bend the unbendable, '' Yurek stated. ``Our scientists have been applying the company's knowledge base in HTS wire manufacturing - developed over 14 years - to the borides, and they are inventing new ways to manufacture boride-containing wires. We expect some of these manufacturing methodologies to be extensions of our existing, proprietary wire manufacturing techniques developed for HTS oxides, and we expect to protect the application of these and other wire-making methods with patents.'' AMSC is down to a fourth of its 12-month high and has had three broker downgrades in the last five weeks. The high promise of 1987 for HTSC is still high promise.

Ames Technology (Portland, OR)

Ames Technology (Portland, OR) a device to help stroke patients regain mobility by helping their brains form new neural connections. He had developed and tested the device for 10 years when the technology transfer office at OHSU helped persuade him to commercialize it. The money: $1 million in NIH grants before starting the company, then about $150,000 from Cordo's savings, and $2.2 million from a donor and three private investors. The plan: To have the first commercial product by 2011 and annual revenue of $60 million by 2016. His fear: That the recession will make it impossible to raise the money needed to bring the product to market. [The Oregonian, Dec 13]

Amgen

Amgen up 11% [Jun 2, 10]

Amgen up 14% [Jul 8, 09]

Amgen up 10% [Nov 21, 08]

Amgen up 12% [Oct 23, 08]

Amgen up 11% [Oct 13, 08]

Amnis (Seattle, WA)

EMD Millipore, which sells products such as lab filtration equipment to biotechs, pharmaceutical companies, and academic research labs, said that it has agreed to buy Amnis (Seattle, WA; $1.7M SBIR) as EMD Millipore looks to strengthen its bioscience business. [Chris Reidy, Bosotn Globe, Aug 30, 11]

Ampla Pharmaceuticals (La Jolla, CA)

Advent Healthcare Ventures, a Boston healthcare and life sciences investment firm, has funded and taken in another biotechnology firm – most recently, per federal documents, supporting the $1.5 million equity funding of stealthy firm Ampla Pharmaceuticals (LaJolla, CA; no SBIR)

AMRI (born Albany Molecular Research) (Albany, NY)

AMRI up 16% [Oct 27, 11]

AMRI down 15% [Oct 26, 11]

Albany Molecular Research won an NIH contract that could be worth up to $43 million over five years. ... will provide chemistry and other drug discovery technologies to support efforts by the National Institute of Neurological Disorders and Stroke (NINDS), an arm of the NIH, to develop pre-clincal drug candidates to treat diseases of the central nervous system. [Barbara Pinckney, The Business Review (Albany), Aug 19, 11]

AMRI down 14% [Aug 8, 11]

Albany Molecular Research has formed an alliance with a German company. Proteros Biostructures GmbH, a privately held company based in Martinsried, near Munich, offers structural biology services, such as protein crystallization and X-ray structural analysis. These services complement Albany, New York-based AMRI’s drug discovery capabilities. The two companies will now serve some biotechnology and pharmaceutical clients jointly. [Business Review (Albany), Jun 28, 11]

Drug-discovery firm Albany Molecular Research is laying off 20 local workers in response to dropping customer demand for some chemistry services. ... AMRI employs 640 workers in the Capital Region, about 45 percent of its global work force of 1,400 people. [The Business Review (Albany), Mar 25, 11]

The head of Albany Molecular Research said the drug-discovery company is “turning a corner” as it released mixed earnings results ... Net losses grew during the year and totaled $62.9 million [The Business Review (Albany), Feb 7, 11]

AMRI gave Genentech an exclusive license to commercialize potential products spawned from AMRI’s work to develop antibacterial compounds. AMRI will collaborate with Genentech in a new research program, and also receive royalties from worldwide sales of any compounds that Genentech commercializes. [Business Review (Albany), Jan 4, 11]

AMRI announced a plan to buy back up to $10 million of outstanding shares. [The Business Review (Albany), Jun 21, 10] graduated from SBIR in 2003. Recently bought Hyaluron (Burlington, MA; no SBIR) drug manufacturer for $27M - [The Business Review (Albany), Jun 15, 10]

Albany Molecular Research (a.k.a. AMRI) has bought a drug manufacturing company in Massachusetts for $27 million, ... acquired Hyaluron, (Burlington, MA; no SBIR) ... Last month, AMRI said it was closing a lab in Rensselaer and cutting 50 local jobs in response to slow domestic demand. Meanwhile, the company is spending $30 million to renovate overseas facilities, adding 180 foreign jobs. AMRI has about 650 employees in the Capital Region. Worldwide, employment is 1,350. [Adam Sichko, The Business Review (Albany), Jun 15, 10]

Albany Molecular Research has sued a consultant for at least $5 million, alleging the man gave away proprietary information to a competitor in the pharmaceutical industry. ... According to the lawsuit was [while consulting for AMRI] also employed as a consultant with [a foreign] company [that] AMRI beat in its bid for development work on the drug. [Adam Sichko, Business Review (Albany), Feb 25, 10]... AMRI also paid $19 million to acquire a chemical development company in Wales. [Business Review (Albany), Feb 18, 10]

AMRI down 13% [Aug 5, 09]

AMRI up 11% [Mar 23, 09]

AMRI down 10% [Mar 5, 09]

AMRI up 10% [Mar 4, 09]

AMRI down 10% [Mar 2, 09]

AMRI shot up 10% [Feb 9, 09] after it reported a 130 percent increase in net income for 2008, beating analyst estimates.

AMRI up 10% [Dec 16, 08]

AMRI up 10% [Dec 2, 08]

Albany Molecular Research has settled a patent dispute with two rivals regarding generic versions of the antihistamine Allegra. [Business Review (Albany), Nov 19, 08]

AMRI up 13% [Nov 13, 08]

Albany Molecular Research has expanded its manufacturing capacity in India. ... has had operations in Aurangabad, India, for about two years. It has expanded a manufacturing facility in that city to include a multipurpose pilot plant that can provide non-GMP manufacturing services up to a 1,000 liter scale. [The Business Review (Albany), Oct 29, 08]

AMRI up 20% [Oct 13, 08]

AMRI up 12% [Sep 16, 08]

Albany Molecular Research is in line to receive another $1.5 million milestone payment from Bristol-Myers Squibb .... because a second compound being developed under its research agreement with Bristol Myers will proceed into preclinical development. [The Business Review (Albany), Sep 8]

AMRI officials said Wednesday that revenue should top $200 million this year for the first time in the 17-year history of the contract drug discovery and development company. [Albany Times-Union, Jun 5, 08]

Albany Molecular Research up 15% after the company topped its own first-quarter profit outlook and raised full-year guidance. [AP, May 5, 08]

Federal regulations that limit the output of a controlled substance contributed to delays that crimped AMRI's fourth-quarter performance, company officials said [Albany Times-Union, Feb 12, 08]

AMRI down 11% on lower revenue forecast. [Jan 29, 08]

AMRI up 11% [Jan 23, 08]

Outsourcing Beneficiary. AMRI will expand its work force further this year as it projects significant growth, the company's chief executive said this week. ... formerly known as Albany Molecular Research ... The expansion comes as larger pharmaceutical companies, with fewer promising drugs in the pipeline, lay off chemists. [Eric Anderson, Albany Times-Union, Jan 11]

Albany Molecular Research took a 29% hit [Nov 6, 07] after reporting profits way below Street estimates.

Albany Molecular Research made a deal with Achaogen (no SBIR) to provide high throughput screening capability to test samples from its natural product libraries for activity against targets of interest in Achaogen's $25M DOD contract against anthrax and other baddies. [Jun 07]

Controlling expenses companywide, pursuing less expensive sources of raw materials overseas and emphasizing lean manufacturing techniques are among the steps Albany Molecular Research Inc. plans as it focuses on boosting profit margins. [Eric Anderson, Albany Times-Union, Jun 5, 07]

Albany Molecular Research will buy two drug manufacturing plants near the city of Mumbai (formerly called Bombay) in India for $11 million in cash. ... will buy more land in Aurangabad and will invest up to $15 million to expand capacity there in the next three years. ... also has operations in Hungary and Singapore. [Alan Wechsler, Albany Times-Union, May 22, 07]

Albany Molecular Research up 23% for the week ending May 10, 07.

Albany Molecular Research will shrink an unprofitable plant and the operation will be redesigned to be more "nimble and agile," Profit for the quarter also shrank thanks to shrunken royalty revenues. [Albany Times-Union, Nov 10,06]

Albany Molecular Research says it will start advanced preclinical testing for a compound that has been effective in killing cancer cells. The drug candidate is among a class of drugs that kill cancer cells by preventing them from dividing, and in preclinical tests it has performed better than those on the market. [Eric Anderson, Albany Times-Union, Oct 31, 06]

A generic competitor to Allegra cut royalty payments to Albany Molecular Research Inc. by more than $8M in the second quarter, and the drug discovery company posted a $353,000 loss. A year ago, it earned $7.3M. ... The company also took a $2.2M charge for the closing of its research center in Mount Prospect [IL]. [Albany Times-Union, Aug 3]

Albany Molecular Research will manufacture the active pharmaceutical ingredient in a promising new treatment for attention-deficit hyperactivity disorder in a multi-year contract with New River Pharmaceuticals (Radford, VA). The drug still needs FDA approval. [Albany Times-Union, Jul 25,06]

Albany Molecular Research led Tuesday in NASDAQ losing percentage with -23% after a broker downgraded its prospects. Is that fair? There is no "fair"; there is only the balance between buyers and sellers in an open marketplace. [Sep 05]

Albany Molecular took an 18% stock price hit when it reported less than expected profits. Note the difference between SBIR where doing good government work is sufficient, and the stock market where making profits matter and doing good work is merely a necessity. On the other hand, if you're one of the few SBIR entrepreneurs who can make growing profits, you can get seriously rich, whereas doing government work, you merely draw a decent salary. [Feb 05]

Albany Molecular Research will continue its seven-year deal with Eli Lilly to do fee-for-service chemistry research on projects in strategic therapeutic areas identified by Lilly. The company also is opening a wholly owned subsidiary in Singapore. [Jan 05]

Seventh Downgrade. Albany Molecular Research got hit with its seventh downgrade in two years when it reported less than stellar earnings. The stock price dropped 25% in two days from its 12-month high. To get back to its hey-day bubble high, it would have to quadruple from here. [2004]

Albany Molecular Research took a 20% stock hit when it lowered its estimates for profits by a third. AstroPower gets pounded.

Albany Molecular got a plaudit from USA Today's financial gurus as a good contrarian bet with a five-year record of 73% revenue growth rate, 80% profit growth rate, and 38% return on equity. Latest quarterly profits were up 18%.

Help Merck Discover (July 8)Albany Molecular Research got a three-year medicinal chemistry drug discovery research contract with Merck to identify and develop small molecule drug candidates for a proprietary Merck target. Albany gets milestone reward on top of the usual scientific labor for any great news discovered which could be multimillion-dollars per compound. Last year Albany made $34M profit on $98M revenue, 40% of which was royalties.

Albany Molecular Research announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to develop anti-cancer compounds.Under the terms of the five-year agreement, scientists from both AMRI and the National Cancer Institute (NCI) will select available, non-proprietary compounds for biocatalytic derivative synthesis from the NCI's repository.

A price dive also happened after good earnings hit Albany Molecular Research) after the chemistry outsourcing company cut its 2002 earnings forecast due to uncertainty about a contract with major customer DuPont Pharmaceuticals, which Bristol Myers Squibb recently acquired.

Amylin Pharmaceuticals (San Diego, CA)

Amylin Pharma up 13% [Oct 20, 11]

Amylin (San Diego, CA; $500K SBIR) was 198th on the new Deloitte Fast 500 list of fastest-growing technology companies [Mike Freeman, signonsandiego, Oct 21, 10]

Amylin Pharmaceuticals (San Diego, CA; $500K SBIR) has laid off about 60 employees, or 4 percent of its workforce, in recent weeks as part of an effort to make the company more efficient, ... has cut its global workforce by one-third in recent years through a series of layoffs. [Keith Darce, San Diego Union Tribune, Jun 18, 10]

Amylin Pharmaceuticals plunged 25% as the biotechnology concern reported four more deaths among users of its Byetta diabetes drug, which it markets with Eli Lilly. [Wall Street Journal, Aug 28, 08]

Amylin Pharmaceuticals fell 13% fter the FDA received reports of two deaths potentially related to pancreatic side effects of a diabetes drug. [Wall Street Journal, Aug 19, 08]

Amylin Pharmaceuticals (San Diego, CA; one Phase 2 SBIR) said yesterday that patients in a 24-week trial of its obesity therapy pramlintide lost an average of 25 pounds. [San Diego Union Tribune, Nov 16]

Amyris Biotechnologies (Emeryville, CA)

The U.S. Navy said that it will buy 450,000 gallons of advanced biofuels from two companies, including Solazyme (South San Francisco, CA; one SBIR). It's the government's largest biofuel purchase to date, and will allow the Navy to test how well bio-based versions of jet fuel and marine distillate fuel perform in a variety of ships and aircraft. .... Meanwhile, Amyris (Emeryville, CA; $700K SBIR) formed a joint venture with French oil giant Total to bring renewable diesel and jet fuel to the global market. [David Baker, San Francisco Chronicle, Dec 6, 11]

Sunlight companies. Joule Unlimited (formerly Joule Biotechnologies, Cambridge, MA; no SBIR) said it was the first company to patent an organism that secretes hydrocarbon fuel made continuously, directly from sunlight. Other companies, including Amyris Biotechnologies (Emeryville, CA; $700K SBIR), and LS9 (San Carlos, CA; no SBIR), are working on organisms that will make fuel if fed sugar from corn or cellulosic sources, but Joule’s bacterium does not require any sugar. Another company, Aurora Algae (Alameda, CA; no SBIR), said that it had developed an algae-based platform for production of fuel, pharmaceuticals and other valuable chemicals. [Matthew Wald, New York Times, Sep 14, 10]

Amyris Biotechnologies (Albany, CA; $700K SBIR) has raised $47.8 million from the Singapore government. Tamasek Holdings, which owns and manages direct investment by the Singapore government, made the investment into the Emeryville biofuels startup. Jeri Hilleman, chief financial officer of Amyris, said Tamasek has a strong interest in Brazil where Amyris is opening its first commercial plants that will turn sugarcane into renewable transportation fuels that can be used in today’s fueling infrastructure. [Lindsey Riddell, San Francisco Business Times, Apr 2, 10]

Amyris Biotechnologies (Albany CA; $700K SBIR) raised $70 M to produce bio-based fuels using genetic technology it used to make low-cost malaria drugs. [Wall Street Journal, Oct 29]

Anacor Pharmaceuticals (Palo Alto, CA)

GlaxoSmithKline paid Anacor Pharmaceuticals (Palo Alto, CA; no SBIR) $15 million to exercise an option to exclusively license to develop and commercialize an experimental antibiotic to fight gram-negative infections. [Ron Leuty, San Francisco Business Times, Aug 2, 10]

Anadigics

Anadigics down 13% [May 3, 11]

Anadigics up 10% [Mar 24, 11]

Anadigics up 10% [Oct 22, 10]

Anadigics up 21% [Jun 17, 10]

Anadigics up 11% [Dec 18, 09]

Anadigics up 13% [May 27, 09]

Anadigics down 31% [Oct 23, 08]

Anadigics up 10% [Oct 13, 08]

Anadigics down 38% [Aug 8, 08]

Anadigics down 32% [Jul 23, 08] on gloomy outlook. second-quarter net income more than tripled, but the company said it expects a decline in its wireless division on lower customer demand. [WSJ, Jul 24]

Anadigics up 13% [Jul 16, 08]

Anadigics down 16% [Jul 14, 08]

Anadigics up 30% [Apr 22, 08] after reporting a sweet profit.

Anadigics up 14% [Mar 18, 08]

Anadigics down 16% [Mar 3, 08]

Anadigics down 14% [Feb 13, 08]

Anadigics up 14% [Feb 11, 08]

Anadigics down 19% after the cell phone chip maker posted a third-quarter profit below its own forecast. [Oct 24, 07]

Anadigics up 17% as it made a surprise profit [Jul 25, 07]

Anadigics surged 17% after an investment fund manager, in an interview with Barron's magazine, said profit at the chip maker is poised to explode. [AP, Feb 5, 07] The manager owns 11% of the stock.

Anadys Pharmaceuticals

Anadys Pharmaceuticals raised $12.5 million through a registered stock offering [Luke Timmerman, signonsandiego,com, Jun 9, 10]

Anadys Pharmaceuticals ,developer of a treatment for hepatitis C, said today it has raised $12.5 million through a registered stock offering [Luke Timmerman, signonsandiago, Jun 3, 10]

Anadys Pharma down 12% [Dec 17, 09]

Anadys Pharma up 44% [Jul 31, 09] after the company said regulators approved the design of a study of a potential hepatitis C treatment

Anadys Pharma down 11% [May 14, 09]

Anadys Pharma down 12% [May 13, 09]

Anadys Pharma up 33% [May 11, 09]

Anadys Pharma down 17% [Apr 24, 09]

Anadys Pharma down 40% [Apr 23, 09] after it reported that three patients got rashes during a 14-day, 30-patient Phase I study of its hepatitis-C drug ANA598. [Wall Street Journal, Apr 24]

Anadys Pharma up 12% [Mar 17, 09]

Anadys Pharma up 14% [Feb 18, 09]

Anadys Pharma up 115% [Jan 8, 09]

Anadys Pharmaceuticals down 12% [Jun 24, 08]

Anadys Pharma up 18% [May 16, 08] and still down 29% over 52 weeks.

Anadys Pharmaceuticals up 11%. [Aug 7, 07]

Anadys Pharmaceuticals down 11% [Aug 1, 07] after saying it would it was cutting its workforce by a third and discontinuing further development of ANA380, its drug to treat hepatitis B virus infection.

Anadys Pharmaceuticals down 29% [Jul 27, 07] after ending development of a hepatitis C drug with Novartis, more than a year after the program was suspended over safety concerns.

Anadys Pharmaceuticals down 13% after doubling its quarterly loss. [Feb 23, 07]

Anadys Pharma up another 20%. [Nov 21, 06]

Anadys Pharmaceutica up 25%. [Nov 14, 06]

AnaptysBio (San Diego, CA)

AnaptysBio(San Diego, CA; no SBIR, founded 2005) could receive up to $1.5 million from [DARPA] to improve sensors the military would use to detect biological attack. ... creates heat-stable antibodies [Gary Robbins, San Diego Union Tribune, Jul 13, 10] the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. [company website]

Anchor Therapeutics (Cambridge, MA)

Anchor Therapeutics stands to receive up to $480 million from New Jersey-based Ortho-McNeil Janssen Pharmaceuticals Inc. (OMJPI), related to a collaborative research and licensing deal associated with Anchor’s pepducin technology. [Mass High Tech, Sep 9, 10]

Anchor Therapeutics (Cambridge, MA; no SBIR) (formerly Ascent Therapeutics) closed on $10 million in a Series B funding round ... focused on developing peptide drug candidates, called pepducins, that modulate G protein coupled receptors (GPCRs) [Mass High Tech, Aug 20, 10]

Ancora Pharmaceuticals (Medford, MA)

NIH awarded a $530,000 Phase 1 SBIR grant to Medford-based Ancora Pharmaceuticals (Medford, MA; $3.6M prior SBIR) to research a vaccine to prevent malaria anemia. [Mass High Tech, Jun 3, 09]

Anew Optics (Newton, MA)

Anew Optics (Newton, MA; no SBIR) has pulled in $952,000 of a planned $2 million equity offering, according to [SEC] filing ... does not yet have a website, appears to be involved in the development of an intraocular lens, made thin and lightweight to allow for more light transfer and greater comfort, according to a patent application [Michelle Lang, Mass High Tech, Aug 10, 10]

Anexon (Cambridge, MA)

Stealthy cardiovascular biotech Anexon (Cambridge, MA; no SBIR) reports it has raised $7 million in new venture financing, naming the prestigious Mayo Clinic as an investor. [Mass High Tech, Oct 20, 10]

AngioDynamics

AngioDynamics (Queensbury, NY; no SBIR) a medical device manufacturer paid $1.75 million for the assets of a similar, smaller company in California. ... the assets of FlowMedica (Fremont,CA; no SBIR), backed by venture capitalists. FlowMedica, founded in 2002, is developing ways to deliver drugs to kidneys to keep the organs functioning after certain medical procedures. [The Business review (Albany), Jan 13, 09]

If You Don't Own It, You Can't Sell It. AngioDynamics (no SBIR) paid $2M to the co-inventor of its recently introduced NeverTouch technology and will pay an additional $1 million after the product meets an unspecified milestone, the medical instruments manufacturer disclosed in a filing with regulators on Wednesday. AngioDynamics was forced to stop selling an earlier laser treatment for varicose veins after a federal court judge in Boston ruled it infringed on the patents of a competitor, Andover, Mass.-based Diomed Holdings (no SBIR).... The move comes as AngioDynamics appeals the decision in the Diomed case and defends itself in a patent-infringement case brought by VNUS Technologies Inc. of San Jose, Calif. [Eric Anderson, Albany Times Union, Jan 10]

AngioDynamics fell 21% as a jury found against it in a patent suit. [Wall Street Journal, Mar 29, 07]

Angiologix (Mountain View, CA)

Angiologix (Mountain View, CA; no SBIR) is a medical diagnostic device company whose products diagnose the first sign of cardiovascular disease — endothelial dysfunction. Angiologix says it has developed a diagnostic system that detects cardiovascular disease earlier than any other existing test. The diagnostic system has a cuff, which is placed on the patient’s arm, a hardware box and software with algorithms to detect the earliest sign of cardiovascular disease. [Mass High Tech, Aug 21, 09]

Angstrom Medica (Marquette, MI)

Pioneer Surgical Technology (PST) of Marquette, Mich., reports it has purchased Angstrom Medica (Woburn, MA; $1M SBIR) for an undisclosed amount. Angstrom is the first company to obtain U.S. Food and Drug Administration (FDA) approval for a nanotechnology device. [Mass High Tech, Oct 24]

Angstron Materials (Dayton, OH)

Angstron Materials (Dayton, OH; no SBIR) will get [cost-shared] $1.5M federal help [from NIST] to develop nanotechnology ... toward developing processes for mass-producing special nano materials, especially for the energy industries. [Dayton Business Journal, Dec 16, 09] creator of nano graphene platelets (NGPs), is the only company in the world now able to provide pristine graphite and single layer graphene. [company website]

Ansoft

Ansoft up 30% [Mar 31, 08] after large-cap Ansys agreed to buy the Pittsburgh electronic-design automation software producer for $832 million in cash and stock [Wall Street Journal, Apr 1]

Ansoft down 11% [Feb 15, 08]

Anthera Pharmaceuticals

Anthera Pharmaceuticals (no SBIR) hopes to net $47 million by selling more than 6.6 million shares ... developer of cardiovascular and autoimmune disease drugs [Ron Leuty, San Francisco Business Times, Jun 3, 11]

Anthera Pharmaceuticals (no SBIR), an unprofitable company that hasn't obtained regulatory approval for any of its treatments, rose one cent to $7.01 in their debut. ... restructured its offering after failing to debut last week;. [Wall Street Journal, Mar 2, 10]

Antigenics (NYC, NY)

Antigenics (Woburn, MA; $700K SBIR) has spent between $400 million and $500 million to conduct two Phase 3 trials on its potential cancer vaccine. But the Lexington-based company never plans to send it to the U.S. Food and Drug Administration for approval. “Not unless the agency significantly changes. The Western regulatory bureaucracies are too rigid to know how to deal with our product,” CEO Garo Armen said. [Julie Donnelly, Mass High Tech, Jan 22, 10]

Antigenics (Woburn, MA; $700K SBIR) said it will not seek approval for a potential kidney cancer treatment after a European advisory committee recommended against approving the drug candidate. [Boston Globe, Nov 20, 09]

In a tale of biotech snapback, Forbes [Matthew Herper, Oct 16, 09] notes that BioCryst Pharma is up 1014% from its 52-week low. Antigenics (Woburn, MA; $700K SBIR) is up 1032%.

Antigenics (Lexingtom, MA; $700K SBIR) sold 5 million shares for $10 million.... will use the proceeds from the sale to fund commercial and regulatory efforts, including sales of its cancer drug Oncophage in Russia, Europe, and elsewhere. [Boston Globe, Jul 31, 09]

Antigenics (New York City; $600K SBIR) up 23% after it said its treatment for kidney cancer received regulatory approval in Russia, the first authorization in any country for the cancer vaccine. [Wall Street Journal, Apr 9, 08]

Anue Systems

Hemi Thaker, age 43, has done this before ... he is back with another promising communications startup, Anue Systems (no SBIR) was among the 12 Austin firms that recently made Inc. magazine's annual list of the 500 fastest-growing companies in the country. ... "We can take our technology and apply it to different places, and all the sudden, the available market becomes much larger," he said. "We are going to morph into something that is no longer a niche company." [Kirk Ladendorf, Austin American-Statesman, Sep 11]

Anulex Technologies (Minneapolis, MN)

Anulex Technologies (Minneapolis, MN; no SBIR), a startup developing devices used to repair soft tissue in the spine, has closed on about $18 million in venture capital. [Katharine Grayson, Minneapolis/St Paul Business Journal, Jun 3, 10]

Anybots

damg writes "Anybots, which is three guys led by Trevor Blackwell, has developed the first robot that walks like we do, by dynamically balancing itself rather than being pre-programmed for walking like Asimo. The video shows the robot walking and being pushed by another 'bully' robot to demonstrate that it can't easily be pushed over." [slashdot.org, Feb 27]

AOptix Technologies (Campbell, CA)

AOptix Technologies (Campbell, CA; $1.6M SBIR) said that it has won an $11.4 million contract to deliver wireless air and ground optical terminals for [DARPA] [Silicon Valley / San Jose Business Journal, Dec 17, 10]

AOptix Technologies (Campbell, CA; $2M SBIR) raised $15M. It develops iris-recognition systems and ultra-high bandwidth laser communication technologies. [San Jose Mercury News, Jun 6]

APA Optics (Blaine, MN)

APA Enterprises (formerly APA Optics) broke the buck after falling 13%. [Nov 13, 07]

Changing of APA Guard. Founder Anil Jain has resigned from APA Enterprises as the company also made "additional staff reductions." APA lost $2.1M for the year and has had a continual struggle to turn the technology supported by SBIR in the 1980s into a profitable enterprise. Jain will buy the company's India operation for $500K. [story Minneapolis Star Tribune, Jun 29]

APA Enterprises lost 10% after reporting yet more loss. CEO Jain explained: We are very pleased with the increased revenues as well as substantial decrease in losses both for the 3rd quarter and the first 9 months of fiscal year 2007. Extrapolating these figures to an annualized basis, we believe that the yearly projected losses represent more that 50% improvement over the losses of the last several fiscal years dating back to fiscal year 2000. Clearly, the consolidation steps taken during the last two years are in the right direction. [MarketWire, Feb 13,07] APA is actually an SBIR success story in that after 16 Phase 2s for II-IV electronic materials 1986-1995 it struck out on its own and has survived, albeit struggling for profitability, for another decade. Jain has led it for the entire two decades. SBIR's goal should be more APAs wherein private capital picks up and runs with technology nurtured in its infancy by government. Whether the company ultimately survives or not, SBIR has done its job.

Watch That Sun. APA Optics says it is shipping sun monitors that sound an alarm when you have over-sunned. Betting on a fickle consumer product market, APA tries to make another profitable product from the GaN technology it developed with SBIR money in the mid 80s. Its last Phase 2 was 1996 as it shifted to making product especially in a new manufacturing plant in South Dakota. Whatever the outcome, APA clearly hopped off the SBIR pram to risk life as an adult. The other advertised optics products have apparently fizzled as losses continue. Making money is a lot harder than making commercialization strategies that the government will accept for SBIR awards. But then, the government doesn't have to make an ROI, only to pass out the money as directed by the SBIR law.

APA Doubles Loss
(Nov 2)APA Optics doubled its quarterly loss to $1.4M from higher cost of goods sold, reduced interest income, and the slowing economy. ``Our financial results reflect the impact of the current economic slowdown, particularly in fiber optic communications, and performance issues with our Dense Wavelength Divisional Multiplexers (DWDMs) related to environmental specifications, ... We continue to work toward automated production of DWDMs for increased production capacity, performance uniformity and lower production costs. said CEO Anil Jain. Too slow, too variable, and too costly; "performance issues" is a euphemism for the product didn't do what the customer wants. Lesson for SBIR companies: manufacturing only looks like a great way to build your business.

Customer Said, "Too Slow" (Aug 14) After a customer cancelled a half-million dollar order APA Optics stock tanked 15%. A lesson for wannabe commercializers: it is one thing to fluff your wonderful technology to the government SBIR folks; it is quite another to get customer spec hardware to the customer on the customer's schedule. For a company that has been making steady losses since switching from research to production in a remote spot (South Dakota), such a loss does not help stock valuation.

Expect Further Losses
(Aug 6) says APA Optics which is having a hard haul toward profitability after ditching SBIR as a way of life in the late 90s. Our net loss in fiscal 2001 was $2,9M compared to $3,8M in fiscal 2000. The decrease in the loss was primarily a result of increased revenues and significantly higher interest income from the investment of cash raised during the fiscal year. Further losses can be expected until revenues from production increase, or operating costs decrease, sufficiently to produce positive cash flow. Of course the swoosh from the info-tech bubble didn't help a company trying to sell new DWDM devices. Optimists are still hanging around; the company market cap is still $100M, off about 60% from a year ago's optimism.

APA Optics lost $3M for last year, less than the $3.8M in 1999, Revenues doubles for the year. CEO Anil K. Jain said he welcomed the continued progress in revenue growth.

APA Gets Hit Again
(Nov 28)APA Optics dropped another 16% yesterday which puts it down 90% from its spring high. Earlier in the month it reported yet another loss